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1.1. HUNTINGTON'S DISEASE 
Huntington's disease (HD) is an autosomal dominant neurodegenerative 
disorder characterised by involuntary choreatic and hypokinetic movements, 
and changes in mood and behaviour. The estimations of the mean age of 
onset range between 43.71 and 55.82 with standard deviations ranging from 
10.9 to 13.5 respectively. Affected individuals slowly loose control over 
physical and mental functions. The disorder affects behaviour, emotions, 
thinking, social abilities and the motor functions needed to perform the 
activities of daily living. The occurrence of HD is estimated at 5-10 per 
100.000 inhabitants.3 The burden of HD affects about everything in the 
families involved.4 
 In 1983, the HD community experienced the discovery of a genetic 
marker that localised the HD gene on the fourth chromosome as a great 
break through.5 A test was developed that provided information on the 
genetic status of many individuals at risk for HD. Depending on the 
informativeness of the DNA markers and the family structure of co-operating 
family members, the outcome of this test had a reliability of 90% to 99%. 
This finding gave a vista for a better future perspective and the hope 
became stronger that perhaps even a cure might become a reality. The 
discovery paved the way for predictive testing which was experienced by 
part of the HD community as a blessing, as a herald of better times in which 
the disease could be controlled, cured, and prevented. The test provided 
the opportunity to relieve the uncertainty, to have prenatal tests in order to 
have children free from the disorder, to make informed plans for the future 
regarding marriage, education, professional career, and finances. In 1993, 
the gene mutation for Huntington's Disease (HD) was identified.6 Testing 
became possible with a reliability of more than 99%, without the need for 
co-operation of relatives. Even testing embryos, prior to implantation, 
became possible, providing couples with the opportunity to have a 
pregnancy without the burden of termination after an unfavourable prenatal 
test result.7 In 2000 the first step towards cell therapy and neuronal 
transplantation was published.8 
 The spectacular advances in genetics also meant a novelty in medicine. 
The possibility of predictive testing for HD rang in a new era in which 
predictive testing for disorders with onset later in life would become 
available for many other -more or less rare- hereditary diseases with 
mendelian transmission. Moreover, increasing knowledge of the genetic 
factors in combination with environmental influences would inevitably open 
a new perspective for medicine. Individuals could get better information on 
their future health and the risk factors that might threaten a prosperous 
perspective. HD had the dubious honour to secede from the unknown rare 
diseases, and to become the paradigm that should provide the knowledge 
and experience to establish predictive testing programmes. This 
development has not only affected the medical field. The far-reaching 
consequences made predictive testing a matter of social, political and 
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economic forces9 and made HD an important model on which the 
establishment of many other testing programmes could be based. 
 The studies described in this thesis address psychological and 
methodological issues that were encountered in 20 years experience with 
predictive testing for Huntington's disease. 
1.2. PREDICTIVE GENETIC TESTING: HUNTINGTON'S DISEASE AS A 
MODEL 
1.2.1. Anticipating predictive testing 
In the mid-eighties of the previous century, the advent of predictive testing 
for HD was more or less a revolution in the world of science, health care, 
politics, insurance and companies. HD was regularly found at the front 
pages of prominent magazines and at prime time on television and radio. At 
the level of HD families, learning about the individuals' personal risk was 
expected to generate profound emotional responses that had to be 
acknowledged and dealt with. The risk of an adverse emotional response 
was considered the single greatest risk of predictive testing. Serious 
concerns were raised about the psychological consequences of results of 
predictive testing for HD, with the possibility of an increase in deaths by 
suicide among identified carriers of the gene. Suicide has long been 
recognized as a risk in families at risk for Huntington’s disease.10 In some 
instances, such as overt risk for suicide or other major depressive 
symptoms, it is appropriate to delay testing, initiate psychiatric treatment, 
and become emotionally stabilised before proceeding with the test. 
Although psychological evaluation of emotional stability became an 
important issue of the initial testing protocol, it should not be viewed as an 
obstacle to be jumped in order to get access to testing, but rather as a 
method of identifying persons likely to need greater emotional support after 
learning the test results. 
 This perspective highlighted the need for research to identify predictors 
of adjustment problems such as depression and suicidal intentions in those 
who would request for predictive testing. Previous studies of expectations of 
at-risk individuals had suggested that psychological effects of testing might 
include severe psychosocial problems such as overalertness for early 
symptoms, depression and suicidal behaviour in identified gene-carriers.11-13 
Between 40% and 79% of the individuals at risk reported their intention to 
take the test.14 Interest in testing was found to be negatively associated with 
being married, and positively correlated with the number of affected 
relatives and earlier parental age of onset of HD. The most commonly given 
reasons in these surveys were craving for certainty, relieving uncertainty, 
planning for the future, planning a family, and the need to inform the 
children.15-19 
 With the outlook on the availability of DNA analysis for the HD gene, the 
Committee of International Huntington Association and the Working Group 
on Huntington’s disease of the World Federation of Neurology gave 
consideration to the manner in which these tests should be carried out.20 
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The guidelines for protocols were first published in 1989 when the 
presymptomatic test made use of linkage analysis. After identification of the 
HD-gene in 1993, the guidelines were adjusted and published in 1994. In 
general the guidelines recommend that individuals at risk participating in 
presymptomatic testing programmes are seen for two to four counselling 
sessions, spread over a three month period before disclosure of the test 
results. Presymptomatic testing requires informed consent by the individual 
at risk, and the provision of psychological support. If the diagnosis is 
confirmed, counselling must be available for the family and others involved. 
The starting point is that presymptomatic tests should be offered only to 
individuals at risk who have had the appropriate counselling, are fully 
informed and wish to proceed.  
 Although HD can be considered as rare, the disease has proved to be a 
widely used model for research on psychological effects of genetic testing. 
1.2.2. Predictive testing for disorders with late onset 
After Huntington's disease, an increasing number of neurodegenerative 
diseases have been defined at the molecular level in the last decades, 
making it possible to determine precisely the genotype before the onset of 
symptoms. Predictive testing programmes are currently available for 
hereditary cerebral haemorrhage with amyloid-Dutch type (HCHWA-D),21 
myotonic dystrophy,22 frontotemporal dementia, early onset Alzheimer 
disease,23 spinocerebellar ataxia (SCA1-7),24 and cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leucoencephalopathy 
(CADASIL).25 No intervention is currently known to slow, stop, or reverse 
the progressive clinical deterioration or underlying neurodegeneration of 
these conditions. In contrast to these neurodegenerative diseases, several 
treatment or surveillance options are available for hereditary forms of 
cancer syndromes such breast/ovarian cancer and colon cancer. 
Susceptibility testing for several forms of cancer has been available since 
the early nineties. Women carrying a BRCA1/2 mutation, which causes 
breast and ovarian cancer, can opt for regular surveillance, prophylactic 
mastectomy, prophylactic bilateral salpingo-oophorectomy, and/or 
chemoprevention trials.26 Genetic testing for hereditary non-polyposis 
colorectal cancer (HNPCC) provides carriers of the mismatch repair genes 
(MSH2, MSH6, MLH or PMS) with the possibility of improving survival 
through intensive focus on early detection, such as colonoscopy, and 
preventive strategies.27 
 There are fundamental differences between conditions for which testing 
is possible. Hereditary breast cancer affects predominantly women, and the 
proven absence of a mutation in the BRCA-genes does not relinquish the 
need of regular mammographic screening for breast cancer in women over 
the age 50. Identified carriers of the neurodegenerative disorders have to 
face a lack of treatment options and can only await the onset of the first 
symptoms. HD affects both men and women, and only symptomatic 
treatment is available. There is neither a cure nor a way to delay the 
progression. The level of penetrance -the probability that the disease will 
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manifest during a normal lifetime- differs in the various hereditary 
conditions. The trinucleotide repeat that causes HD (>39 repeats) has a 
complete penetrance. Women identified with a BRCA1/2 mutation have a 
cumulative lifetime risk of 39-85% for breast cancer and a 11-63% risk for 
ovarian cancer at the age of 70.28-31 Furthermore, the life-time risk of 
contralateral breast cancer for genetically predisposed women after a 
history of breast cancer is 48-64%.32 
 Given the far-reaching psychosocial ramifications of test results, 
counselling and psychological follow-up studies have accompanied testing 
programmes to assess adjustment to genetic test outcomes and to identify 
factors that are associated with maladjustment. 
1.3. ADJUSTMENT TO TEST RESULTS 
It turned out that the actual uptake of the test for HD has been much lower 
than expected. The percentage of individuals at risk who requested testing 
when approached by registries or testing centres varied from 9% in Wales, 
10% in Indiana, 16% in the Manchester area, to 20% in the Vancouver 
area.14 In the Netherlands 752 out of 1032 individuals at risk, applying for 
predictive testing in the period 1987 to 1997, decided to be tested, which is 
24% of the of the persons at risk registered in the Leiden Roster for HD.33  
 An important part of genetic counselling is preparing test candidates for 
adverse responses and helping them to cope. This requires an estimation of 
the resources of test candidates. There was a strong urge to obtain 
experience with predictive testing for late onset disorders. Worldwide, a 
number of groups started a psychological follow-up programme that 
accompanied the testing protocol for individuals who decided to undergo the 
predictive test. 
 A total of 100 centres in 21 countries have conducted follow-up studies 
on the test results and the psychosocial effects.34 In general, the 
experiences are unambiguous over the years, and the studies published 
have shifted their attention. Understandably, the first concern was the newly 
identified mutation-carrier. However, a substantial minority of the non-
carriers proved to experience adjustment problems after the test result. 
Partners and children received initially little attention, although some groups 
have addressed them in a number of studies.35-37  
 The initially designed studies used a variety of standardised 
psychological instruments and self-developed questionnaires. There was 
close contact between the study groups from the very beginning with regard 
to the instruments to be used, to allow cross-cultural comparison. The 
studies aimed to describe experiences with test results, to follow the course 
of adjustment over time, and to find factors that could help to identify those 
test candidates who might be at risk for extreme adverse reactions and 
adjustment problems. Studied were the reasons that were given to apply for 
the test and what the expectations were.  
 Three reviews were published on the psychological effects of testing for 
hereditary diseases.14 38 39 The main cited reasons for taking a test were 
family planning, decrease uncertainty, and obtaining certainty. Partners 
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indicated that future planning was the most important reason. Test 
applicants expected generally few adverse psychological consequences of 
the test. No studies reported increased distress in mutation carriers or non-
carriers at any point during 12 months after testing.38 Both mutation carriers 
and non-carriers showed decreased distress after testing; this was greater 
and more rapid amongst non-carriers. Test result was rarely predictive of 
distress longer than one month after testing. Pre-test emotional state was 
predictive of subsequent distress in about half of the studies. Non-carriers 
and carriers differ significantly in their report of short term general 
psychological distress, but not in the long term.14 Adjustment to results was 
found to depend more on psychological adjustment before testing than the 
test result itself. Few adverse events have been described and no obvious 
contraindications for testing people at risk have been identified. It must be 
noted that the psychological follow-up studies are all based on self-selected 
populations who have agreed to participate in psychological studies. There 
is some evidence that test applicants are more resourceful and emotionally 
more robust than others, thus outcomes are not to be extended to the whole 
population of persons at risk for HD.40 
1.4. AIMS OF THE STUDY 
The first aim of this thesis is to describe the psychological issues related to 
genetic testing for HD. These issues cover: 
1. the psychological adaptation in the long term of individuals at risk for HD 
and their partners to the genetic test result (chapters 2, 3),  
2. the methodology that is used in research to adaptation to genetic test 
results in general (chapter 4), 
3. the characteristics of tested individuals who pursue a more accurate test 
(chapter 5), 
4. the calculation of the risk for HD of individuals who are not tested 
(chapter 6).  
The second aim is: 
5. to develop a tool for registration of the progression of HD that is easy 
and quick to administer by nursing personnel (chapter 7). 
1.4.1. Long term follow-up 
After the initial effects, many studies revealed stability in time course of the 
psychological measures studied. However, these studies were limited in 
time and covered, according the initial study designs, a period of a few 
years at most. Participants in the studies had not been asked their consent 
to be approached after the studies had finished. Moreover, the ethical 
question was raised whether it is acceptable to burden tested individuals 
and their families after the book of testing was closed. A new confrontation 
with the genetic centre might recall the stressful experience of testing, 
reactivate negative emotions, or disturb the psychological adjustment to the 
test results. However, we decided to extend our follow-up study. The results 
of the follow-up studies, 3 years and 7-10 years after disclosure of the test, 
are described in Chapter 2 and 3 respectively. 
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1.4.2. Methodology of psychological studies 
Psychological follow-up studies on the effects of predictive testing have 
provided important contributions to the improvement and refining of the 
testing programmes and counselling. The knowledge of the adjustments to 
test results and the insight into dynamics of families with a hereditary 
disease are based on reports of studies that have been published in peer-
reviewed journals. In general, studies to the psychological effects of genetic 
testing have a longitudinal design that can be compared to a randomised 
condition design. Before the test, at baseline, the applicant fills out a 
number of questionnaires, for example on depression, general well-being 
and future expectations. Then the test is performed and the outcome is 
disclosed. The test outcome is comparable to random admission to an 
experimental condition. Missing time points are not easy to prevent in 
longitudinal research. Moreover, follow-up research is vulnerable to the 
problem of selectivity; persons who do not return for later follow-ups -
dropouts- may have specific characteristics. As the analysis of findings of 
follow-up studies requires sound methodology and statistics, we reviewed 
all follow-up studies on effects of predictive testing for hereditary disorders 
with onset later in life that were carried out between 1988 and 2003 
(Chapter 4).  
1.4.3. Testing the test 
Localisation of the gene responsible for HD in 1983 allowed the 
development of a genetic test based on linkage analysis. A structured 
predictive testing procedure for HD was introduced in 1987 in Leiden. The 
testing protocol, following the international guidelines, included, at least, two 
pretest and one post-test counselling session. Reliability of test results 
depended on cooperation of multiple, specified family members. About 24% 
of persons estimated to be at risk for HD in the Netherlands have applied for 
the test.33 in this period, 245 individuals were tested with linkage analysis. 
Thirty-five did not receive an informative test outcome, 88 received an 
increased risk test outcome and 122 received a decreased outcome. 
 The detection in 1993 of the CAG repeat6 made direct or mutation 
testing possible with more than 99% accuracy. Standardized analysis 
makes accurate CAG repeat size measurement possible (Losekoot et al., 
1999). This new test could be performed without the need to test multiple 
family members. In the Netherlands, it was debated whether it was 
acceptable to inform linkage tested individuals that a more reliable test has 
become available and to offer them the accurate mutation test. The 
reluctance to inform them concerned the 'right not to know', and the risk that 
recalling the stressful events and reactivation of negative emotions would 
disturb the adjustments to the test results. The outcome of the debate, 
however, was that the tested individuals were informed on the mutation test 
and invited to discuss a re-test. This procedure allowed us to prolong the 
psychological follow-up study (Chapter 4). Furthermore, the psychological 
characteristics of individuals who were interested in the new test could be 
compared to individuals who were not (Chapter 5).  
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1.4.4. Risk refinement without a mutation test 
At birth, children of a Huntington patient have a risk of 50% to have 
inherited the disease. Without being tested and on the condition that there 
are no symptoms, the risk decreases gradually in course of time, in 
particular at older ages. When genetic counsellors inform older test 
applicants, they often make use of the tables provided by Newcombe, to 
estimate the residual risk.41 42 These tables were based on the age at onset 
or life-table analysis. Since the CAG repeat length is an important estimate 
for age at onset, we developed a model for an additional refinement of the 
residual risk, using information about the age at onset and test results of 
parents or other family members. The refined residual risk can contribute to 
the decision process of choosing to have the test performed, and to the 
process of adjusting to the test result. The systematic use of this calculation 
model can add to the quality of the information given by the genetic 
counsellor to the test applicants (Chapter 6). 
1.4.5. The Behaviour Observation Scale Huntington (BOSH) 
Preparing for the future is one of the main reasons to have a predictive test. 
Individuals, who received unfavourable test results, have to face new 
uncertainties with regard to the onset of the disease, and to the way the 
disease will manifest itself. The more specific information is available, the 
more identified carriers may be able to anticipate their future perspectives. 
HD is a disabling disease that progresses over time. Although no curative 
treatment is available yet, the increasing knowledge about HD has improved 
the caring and nursing considerably. The special wards for HD-patients in 
the Netherlands and Belgium (Katwijk aan Zee, Apeldoorn, Amsterdam, 
Geertruidenberg, Heist op den Berg) have much experience with HD-
patients in the later stages of the disease. The perspective of good care in 
the later stages may comfort people, and may help them to distract from the 
appalling experiences with caring and nursing of relatives in the past. 
However, to better tailor the care and nursing of HD-patients, more insight is 
needed into the course and progress of the disorder at different stages of 
the disease. Shoulson & Fahn43 made a categorisation of the progression 
on the basis of the capability to work, handle finances, domestic affairs, and 
activities of daily living. Patients are cared for at home until the care 
becomes too demanding or the patient becomes unmanageable. Admission 
to a nursing home is then inevitable. To monitor the disease progress, the 
Unified Huntington's Disease Rating Scale (UHDRS) was developed.44 The 
UHDRS assesses four domains of functioning: motor performance, 
cognitive performance, behavioural abnormalities, and functional capacity. 
However, due to ceiling effects the UHDRS is less sensitive in later stages 
of the disease. In chapter 7, we describe the development of the Behaviour 
Observation Scale Huntington (BOSH). The BOSH should provide insight 
into the specific behaviours in the later stages of HD. The development of 
the BOSH benefited from 5 special wards for HD-patients that have been 
established in the Netherlands and Belgium.  
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ABSTRACT 
The 3-year psychological effects of presymptomatic DNA diagnosis for 
Huntington’s disease are described in 20 identified carriers of the Hunting-
ton’s disease gene (mean age = 31 years), 29 noncarriers (mean age = 32 
years), and 37 partners. The Intrusion and Avoidance subscales of the 
Impact of Event Scale1 and the Beck Hopelessness Scale2 3 measured 
psychological distress at 4 time points: baseline (before disclosure of test 
results) and 1 week, 6 months, and 3 years after testing. Multivariate testing 
on course of distress revealed similar patterns of intrusive thoughts about 
Huntington’s disease over the 3-year follow-up in carriers and noncarriers 
but showed opposite patterns of avoidance at the 6-month assessment. 
One week after disclosure, carriers had increased and noncarriers had 
decreased levels of hopelessness. These effects disappeared after 6 
months and did not recur. Carrier partners followed the same course of 
distress as carriers. Carrier partners with children were significantly more 
distressed than those without offspring. Noncarrier partners were 
significantly less distressed than noncarriers after 3 years. 
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INTRODUCTION 
Huntington’s disease is a dominantly inherited, progressive 
neurodegenerative disorder, usually of adult onset, characterized by motor 
disability, often choreic in nature, a disturbance of affect, behavior and 
personality, and cognitive impairment.4 Children of an affected parent are at 
50% risk of being affected by Huntington’s disease in later life. Although the 
mean age of onset is 40 years, with a range of 2 to 75 years,5 at risk 
individuals will always remain at risk for Huntington’s disease. 
 Presymptomatic DNA testing using genetic linkage analysis has been 
available since 1986. After identification of the Huntington’s disease gene 
mutation in 1993, the laboratory aspect of testing was simplified.6 In the 
overwhelming majority of cases, the test result is unequivocal; the detection 
of the gene mutation indicates that the individual will develop Huntington’s 
disease at some time in the future, unless he or she dies of some other 
cause before the onset of early symptoms. 
 Previous studies of expectations of at risk individuals have suggested 
that psychological effects of testing might include severe psychosocial 
problems such as overalertness for early symptoms, depression, and 
suicidal behavior in identified gene carriers.7-9 However, given that the most 
cited reasons to undergo testing were to seek relief from uncertainty, and to 
get some control over the future (particularly with a view to planning a 
family), we expected that a reduction of anxiety and gaining more certainty 
about one’s risk could improve the test candidates’ quality of life.10 
Effects of testing on potential carriers 
A number of recent studies have examined the psychological effects of DNA 
testing.11-19 Generally, the results have indicated that tested individuals 
found relief from their prior psychological distress and that they benefited 
psychologically from testing. It appeared as though most carriers coped well 
up to this point, although this was largely based on strong psychological 
defenses and dependence on satisfactory relationships.20 These studies 
also suggested that carriers tend to minimize the impact of their test results 
on their future. Although heightened distress was found in carriers, 
compared with noncarriers, this remained within normal limits.16 19 The 
Baltimore Group17 reported that identified carriers estimated that their risk 
after 6 months was much lower (60%) than was initially revealed at 
disclosure (>95%). 
 A substantial subgroup of noncarriers was found to have a lack of relief, 
survivor’s guilt, and emotional numbing.13 16 The Vancouver Group14 found 
that, 6 months after test disclosure, psychological functioning in both 
carriers and noncarriers was significantly better than in individuals who had 
not been tested. In our study, carriers reported significantly more intrusive 
thoughts with respect to Huntington’s disease than noncarriers in the 6-
month follow-up, especially those who had suffered most from the burden 
before the test. Both carriers and noncarriers who tried to avoid thoughts 
about Huntington’s disease before test disclosure did this also after the test 
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results. Posttest hopelessness in both carriers and noncarriers, 6 months 
after the test result, proved to be dependent on relative absence of avoidant 
thoughts and unsatisfactory supportive allies at baseline. High scores on 
avoidant thoughts in both groups at the 6-month follow-up were associated 
with low satisfaction with social support and low levels of hopelessness 
before disclosure.20 
 Severe adverse reactions in carriers have not been reported to date. 
However, at the 6-month follow-up, one quarter of the carriers were sus-
pected of psychopathological states.20 These carriers were characterized by 
increased avoidant thoughts and decreased intrusive feelings about 
Huntington’s disease compared with baseline levels. Moreover, we have 
observed that carriers, who initially could cope satisfactory with the test 
result, showed disturbed functioning, depression, suicidal behavior, or all of 
these, after Huntington’s disease diagnosis was confirmed. This was also 
reported by Quaid and Wesson.19 
Effects of testing on partners 
Huntington’s disease is a family disease that inevitably will impose a direct 
imprint on the life of the partner.21 Partners found the mental deterioration 
and the personality changes in the affected spouse or affected relatives to 
be the most difficult aspects to cope with, and the threat that their own 
children may later develop the same disease is one of the most dramatic 
aspects.11 Partners have reacted to the clinical diagnosis with disbelief and 
denial but, after full awareness of the threat of transmission to the children, 
their responses changed to resentment and hostility.21 In predictive testing 
programs, partners received little empirical attention.11 16 19 22 Although 
Quaid and Wesson found that spouses of prospective carriers were more 
distressed about their marriage than partners of noncarriers at baseline, 
there were no differences at the follow-up measures. Spouses were more 
depressed than their at risk partners at baseline. In our study, partners of 
carriers reported the most difficulties in coming to terms with the impending 
burden.16 Codori and Brandt17 reported that the majority of carriers and 
noncarriers stated that the test result had no impact on their relationships. 
We found that satisfactory support of partners before test disclosure was 
associated with less feelings of hopelessness and avoidant thoughts at the 
6-month follow-up in carriers and noncarriers, which emphasizes the 
important role of partners.20 
Process of coping with DNA test results 
The DNA test result can be considered as a psychologically distressing life 
event. Learning about a serious threat to the individual’s wellbeing may 
have a profound impact on the future perspective of both the individual at 
risk and his or her intimate relationship. An unfavorable test result may be 
experienced with intense fear, terror, and helplessness, whereas a 
favorable may generate relief. Clinical and empirical evidence have 
consistently indicated that potentially traumatic events produce 
psychological symptomatology. The stress response theory of Horowitz 
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suggests that the central features of adjustment problems after a test result 
would involve (re) experiencing untoward intrusive feelings and thoughts 
and denial—avoidance of stimuli associated with Huntington’s disease.1 23 
 Anticipating their future, some identified carriers may oscillate between 
facing the impending burden and distraction from the appalling future 
perspective. There may be a group that suffers from overwhelming fears 
and preoccupation with early signs of the disease and may have difficulty 
with the inevitable deterioration. Others may strongly deny any impact of 
Huntington’s disease on their lives. Given that carriers approach the 
moment when the early signs of the disease may develop, an increase of 
both intrusive thoughts and avoidance may be expected. Noncarriers 
reported that the result had activated the past and that they were 
overwhelmed by early experiences with Huntington’s disease in the affected 
parent. They also had difficulties coping with bad results in their relatives or 
facing the disease developing in their relatives.13 20 The alternating phases 
of intrusions and avoidance in noncarriers apparently refer to working 
through the distressing events. Over time a reduction of both intrusive 
experiences and avoidant thoughts and an accommodation to new life 
perspectives would be expected. 
The present study was a longitudinal study designed to follow up the course 
of responses of potential carriers and noncarriers and their partners over 3 
years after the DNA test results. In the current research we measured 
psychological distress as indicated by intrusive feelings and thoughts, 
avoidant thoughts, and hopelessness at four points in time: one prior to the 
test and 1 week, 6 months, and 3 years after the test results. We examined 
whether the course of responses (as measured by intrusion, avoidance, and 
hopelessness) after the test result is different in carriers and noncarriers. 
We hypothesized that the psychological distress would show an increase for 
carriers—carrier partners and a decrease for noncarriers—noncarrier 
partners over the entire period after disclosure of test results. In addition, we 
investigated whether there were differences between carriers—noncarriers 
and their partners with regard to psychological responses over time. 
METHOD 
DNA testing program 
In the Netherlands, 2,644 individuals at 50% risk were registered in 1991, 
belonging to 281 families that could be traced genealogically to at least two 
generations.24 The presymptomatic test for Huntington’s disease, in which 
DNA linkage analysis was used, has been available at the Clinical Genetics 
Center in Leiden since October 1987.25 No official announcement was made 
by the Genetics Center, as a restrained policy was applied. Information 
about the availability of the test was given by the general practitioner, 
neurologist, clinical genetics service, relatives, or the patients organization. 
The counseling protocol included at least two sessions of pretest counseling 
and was undertaken along the lines of a structured protocol following the 
international guidelines. The testing protocol has previously been 
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described.25 Inclusion criteria for the testing program included the following: 
age 18 years or older, absence of major mental illness or the intention to 
commit suicide after an unfavorable result, no neurological manifestations of 
Huntington’s disease, and the ability to give informed consent. Results were 
disclosed about 3 months after the intake session. 
Participants 
In 1989, a psychological follow-up study on the effects of test results was 
added to the testing program. Previously, 18 individuals at risk had received 
results. Between 1989 and 1991, a total of 114 applicants who were at risk 
applied for the presymptomatic test. All applicants were requested to 
participate in the psychological follow-up study that included a series of in-
depth interviews (6 weeks before disclosure and 1 week and 6 months after 
the test disclosure) and the completion of questionnaires. Applicants were 
informed of the follow-up study in the invitation letter for the first counseling 
session, and they were requested to consider participation. In addition to 
the first counseling session, they were further informed by the researcher. 
After they had consented, participants received the questionnaires for the 
baseline assessment. Partners were also requested to join in the study. No 
distinction was made between spouses and cohabitants because of the 
assumption that there are no differences. 
 Forty out of 114 individuals did not receive DNA test results for reasons 
described in detail elsewhere.10 In brief, the main reasons for this were that 
the family structure was not informative, that applicants were already 
affected and clinically diagnosed, that applicants withdrew from the program 
after consideration of the possible effects of unfavorable test results, or that 
test candidates postponed testing. Seventy-three out of 74 individuals at 
risk, who eventually received test results, consented to participate in the fol-
low-up study; 1 nonparticipant wished to maintain in contact with the 
researcher. Partners in seven couples who did not share a household, but 
who expressed their intention to marry or to live together in the future, were 
also asked to participate in the study. Three individuals out of the study 
group failed to complete most of the questionnaires, although they did not 
withdraw from the study and appreciated the follow-up contacts. At the 3-
year follow-up assessment, 49 individuals of the initial study group 
participated in the present study. Two individuals who had consented to 
participate, but who did not complete the questionnaires, were considered 
as lost to follow-up. 
Procedure 
Individuals who applied for the presymptomatic test were informed by letter 
about the follow-up study and were encouraged to participate. At the initial 
counseling session, eligible male and female participants were given an 
introduction to the research protocol and were requested to take part in the 
long-term follow-up study on the psychosocial effects of the DNA test 
results. The research protocol was approved by the Medical Ethics 
Committee of the University Hospital of Leiden. The psychometric battery 
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included the Impact of Event Scale1 and the Beck’s Hopelessness Scale2 3 
as measures of psychological distress. Additionally, biographical data, 
including gender, age, marital status, number of children, and level of 
education, were assessed. The questionnaires were completed at the first 
meeting (before disclosure of results) and I week, 6 months, and 3 years 
after the disclosure of the DNA test results. 
Measures 
Huntington-specific distress. The Impact of Event Scale1 is a reliable, self-
report scale used to measure the current degree of subjective impact, 
experienced as a result of a specific life event, in this case, Huntington’s 
disease. The Impact of Event Scale estimates the influence of a stressor on 
two dimensions: (a) intrusion of unwanted ideas and thoughts into 
consciousness and (b) avoidance of certain thoughts, feelings, or situations. 
This scale consists of seven items that form the Intrusion subscale (score 
range 0—35) and eight items that form the avoidance subscale (score 
range 0—40). The Impact of Event Scale has good internal consistency 
(Cronbach’s a of .91 for total baseline and .88 and .83 for Intrusion and 
Avoidance subscales, respectively). 
 Hopelessness—future expectancies. The Beck Hopelessness Scale2 3 
consists of 20 true—false statements used to measure hopelessness or the 
pessimistic expectations one has for his or her future. A score of nine or 
greater (range 0—20) is indicative of depression and possible suicidal 
behavior (Cronbach’s a — .97). 
 Sociodemographic factors. These factors include the following: age, 
marital status, education, number of children, and Huntington’s disease 
awareness. An attitude questionnaire was used to assess the participant’s 
experience with Huntington’s disease in relatives, Huntington’s disease 
awareness, reasons for taking the test, and the anticipated impact of either 
results. Huntington’s disease awareness refers to the period that had 
elapsed since the participant first learned about his or her personal risk to 
get Huntington’s disease. The question was, “How old were you when you 
first learned that you are at 50% risk to develop your parent’s disease?” 
Data analysis 
All data analyses were carried out by using the Statistical Package for the 
Social Sciences.26 Associations between participants and partners and the 
categorical biographical characteristics were investigated with chi-square 
tests. Baseline differences between the pairs of groups (carriers—
noncarriers, carriers—carrier partners, noncarriers—noncarrier partners, 
and carrier partners—noncarrier partners), with respect to the psychological 
variables, were tested with a t test. In the analysis of the follow-up data, 
scores representing the difference between the follow-up scores and the 
baseline data were computed and compared by using a one-way analysis of 
variance. 
 To investigate the effect of the DNA test result over time, we performed a 
multivariate analysis of variance (MANOVA) for repeated measurements 
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with time point as the within-participant factor. Outcome measures 
(intrusion, avoidance, and hopelessness) were considered at four assess-
ment occasions: baseline and 1 week, 6 months, and 3 years after 
disclosure of the DNA test results. Between-participants factors included 
DNA test result (carrier vs. noncarrier) and participant (test candidate vs. 
partner). The four time points were decomposed into the orthonormalized 
polynomial contrasts. Linear, quadratic, and cubic trends were examined in 
which effects could be demonstrated by two, three, and four measurement 
points, respectively. At least two measurement points are needed to 
demonstrate a linear trend (one line between two points, such as the course 
of carrier partners in Figure 1). To reveal a quadratic trend, at least three 
time points are needed (a curve through three points, such as the course of 
noncarriers in Figure 1), whereas four time points can disclose a cubic trend 
(two curves along four points, such as the course of carrier partners in 
Figure 2). 
 Partner scores were considered as not independent of the scores of the 
tested individual. We therefore considered the partner scores as scores of 
the test candidates in the repeated measurements analysis. Consequently, 
analyses were performed in a subsample that had a partner in order to 
determine interaction effects of the responses of partners. An interaction 
effect would reveal a different course of psychological responses over time. 
 First, we estimated the effects of the DNA test result, partner—spouse 
and their ‘interactions, in multivariate models. Second, we tested in step-
down models whether the linear, the quadratic, or cubic trends were 
significant. A p value <. 05 (two-tailed) was considered significant. 
 The nature of the psychological tests caused skewness in the 
distributions (normal population scores zero or near zero, other scores were 
high). Therefore, raw scores were square root transformed in order to get 
normal distributions, which are paramount for MANOVAs. 
RESULTS 
Analysis of participation bias 
Twenty-four individuals were lost to follow-up at 3 years after the test 
disclosure (33%). Six gene carriers had developed symptoms, 2 participants 
moved abroad, and 4 moved without leaving an address. Twelve 
noncarriers refused to cooperate for various reasons: three of them had 
experienced severe problems with coping with the test result and did not 
wish to share experiences for fear of reactivation of the burden, 2 
individuals reported that Huntington’s disease was no longer an issue for 
them and felt no need for follow-up contacts, two had physical problems 
(bowel cancer and severe cardiac illness), 2 out of 3 noncarriers who had 
postponed the follow-up appointment several times were involved in care-
taking of the affected parent or siblings, and 2 individuals responded to the 
invitation for follow-up but failed to complete the questionnaires. The group 
that was lost to follow-up did not differ significantly from the present study 
group on age, DNA test disclosure (carrier—noncarrier), time lag, gender or 
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marital status, or the scores on psychological measures at baseline and the 
6-month follow-up (Table 1). 
Baseline assessment 
Table 2 presents the biographic characteristics of the initial study group at 
baseline (i.e., the first counseling session before disclosure of test results) 
in carriers, noncarriers, and partners. A significant difference was found 
regarding Huntington’s disease awareness; that is, the period that had 
elapsed since the participants first learned about the personal risks to 
develop Huntington’s disease. 
 The male: female ratio of the present study group was 16:33 (Table 1). 
Thirty-nine percent had at least one child. Sixty-three percent of the 
participants had completed a higher level of education than lower vocational 
school. Twenty participants had received an unfavorable test result (7 male 
and 13 female participants), and 29 had received a favorable result (9 male 
and 20 female participants). The male:female ratio did not differ significantly 
between carriers and non-carriers (chi-square, Yates corrected .20, ns). The 
carrier:noncarrier ratio was the same as in similar DNA studies for 
Huntington’s disease testing.14 19 With regard to the psychological variables, 
pairwise comparisons revealed no significant differences between the 
groups at baseline (Table 3). 
 
Table 1. Characteristics at baseline of participants in the present study 
compared with lost to follow-up after presymptomatic DNA testing for 
Huntington's disease 
 
Participants 
(n = 49) 
Participants lost to 
follow-up (n = 24) 
   
Characteristic M sd n M sd n df F p 
Age (years) 
HD awareness (years) 
Pretest 
   IES-intrusion 
   IES-avoidance 
   BHS-hopelessness 
32.2
8.1
10.6
10.2
4.9
8.9
6.8
7.7
9.0
3.8
49
49
45
45
45
31.9
10.7
12.5
9.1
4.2
12.1
7.1
10.6
7.9
3.9
23
22
21
21
20
1,71
1,70
1,64
1,64
1,63
0.01 
2.23 
 
0.68 
0.22 
0.40 
.91 
.14 
 
.41 
.64 
.53 
 n %  n % df χ² p 
Sex 
   male 
   female 
Marital status 
   single 
   married-common-law 
Children 
   0 children 
   ≥ 1 child 
Education 
   < high school 
   ≥ high school 
 
16 
33 
 
12 
37 
 
30 
19 
 
18 
31 
 
33 
67 
 
24 
76 
 
61 
39 
 
37 
63 
 
11 
13 
 
8 
16 
 
16 
8 
 
8 
16 
 
46 
54 
 
33 
67 
 
67 
33 
 
33 
67 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
1.20 
 
 
0.36 
 
 
0.20 
 
 
0.08 
 
.28 
 
 
.55 
 
 
.65 
 
 
.78 
Note.     Pearson's chi-square tests were used to obtain data reported here. DNA = 
deoxyribonucleic acid; HD = Huntington's disease; IES = Impact of Event Scale; BHS = Beck 
Hopelessness Scale. 
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Follow-up assessments 
The average changes of the psychological variables from baseline recorded 
at the follow-up assessments are summarized in Table 3. At the 
assessment 1 week after the disclosure of test results, pairwise 
comparisons showed that the decrease with regard to hopelessness in 
noncarriers differed significantly from the increased scores in carriers. The 
increased scores on intrusion and hopelessness in carrier partners differed 
significantly from the decreased scores in the noncarrier partners. No 
differences were found between the tested groups and partners. 
 At the 6-month follow-up, the increase from baseline in avoidant 
thoughts in carriers differed significantly from the decrease in noncarriers. 
The significant differences with regard to intrusion and hopelessness 
between the partner groups at the 1-week follow-up had sustained at the 6-
months measurement. Also, the differences concerning avoidant thoughts 
were significant at this time point. Again, no differences were found between 
the tested groups and partners. 
 At the 3-years follow-up assessment, pairwise comparisons revealed no 
differences between carriers and noncarriers. However, noncarriers differed 
significantly from the noncarrier partners with regard to intrusion. The 
change from baseline in the partner groups differed significantly with regard 
to all psychological measures. Carrier partners were more hopeless and 
reported more intrusive feelings and avoidant thoughts, whereas noncarrier 
partners showed the reversed change. 
Analysis of trend 
Intrusive thoughts. A repeated measures MANOVA (Table 4) indicated no 
significant differences over time between the entire group of carriers and 
noncarriers. Similar results were found in the subgroup that had a partner. 
However, in the group that had a partner, a significant cubic interaction 
effect of DNA test result modified by time and partner scores was found, F(1, 
31) = 8.52; p = .006. With regard to the course over time, partners of carriers 
had a strong increase of intrusive thoughts I week after disclosure of the 
DNA test results, whereas partners of noncarriers showed a decline. Both 
groups had lower scores at the 6-month assessment. The significant 
change from baseline sustained for the next 3 years. No differences were 
found between the tested groups and partners, indicating that partners 
followed the same pattern as tested individuals, which can also be seen in 
Figure 2. At the 3-year follow-up assessment, the increase in noncarriers 
differed significantly from the decrease in their partners with regard to 
intrusive feelings. 
 Avoidance of thoughts. With regard to avoid-ant thoughts, a significant 
quadratic DNA test result modified by time effect was found (Table 4). The 
curving course of avoidant reactions over time for carriers was opposite to 
that of the noncarriers (see Figure 1). Six months after disclosure, the level 
of avoidant~ reactions was heightened for carriers compared with baseline 
levels, whereas it was reduced for noncarriers (Table 3). The significant 
change from baseline at the 6-month follow-up disappeared at the 3-year 
Three year follow-up 31 
assessment. There was significant evidence for a step-down linear trend for 
DNA test result modified by time in the subgroup that had a partner. In this 
subgroup, the carriers reported at the 3-year assessment occasion an 
increase in avoidant thoughts compared with the 6-month assessment, in 
which the pattern was similar to the course of carrier partners. Noncarriers 
with a partner showed the same course as the entire group of non-carriers. 
The slightly increased scores on avoid-ant thoughts at the 6-month and 3-
year assessments in partners of carriers differed significantly from the 
decreased scores in partners of non-carriers. Partners followed the same 
pattern as the tested groups, as no interaction effect was found. 
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Figure 1. Mean intrusion scores of gene carriers, noncarriers and partners 
 
 Hopelessness. With regard to hopelessness (Beck’s Hopelessness 
Scale), a significant multivariate DNA test result modified by time effect was 
found (Table 4). There was evidence for a step-down cubic DNA test result 
modified by time interaction effect on hopelessness. The decrease with 
regard to hopelessness in noncarriers differed significantly from the 
increased scores in the carriers at the 1-week follow-up assessment (Table 
3 and Figure 3). Thereafter, the changes from baseline in both groups were 
no longer significant. Evidence for similar results was found when the 
analysis was conducted for the subgroup that had a partner. The increased 
hopelessness in carrier partners was significantly different from the 
decreased feelings hopelessness in non-carrier partners at all follow-up 
measurements. Noncarrier partners had a linear decline over the entire 
period, whereas carrier partners had a decline in the 6-month follow-up, 
followed by an increase of hopelessness. The course of hopelessness in 
partners could be considered as similar in the tested individuals, as no 
interaction effects were found. 
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Table 3. Means and standard deviations on psychological variables in 
individuals tested for HD and partners 
 Carriers Noncarriers Carrier partners 
Noncarrier 
partners 
Variable M sd n M sd n M sd n M sd n 
IES-intrusion 
 Baseline 
 1 week a
 > 6 months b
 > 3 years c
IES-avoidance 
 Baseline 
 1 week 
 > 6 months d
 > 3 years e
BHS 
 Baseline 
 1 week f
 > 6 months g
 > 3 years h
 
12.6 
-0.1 
-2.5 
1.4 
 
9.2 
-0.1 
1.3 
0.4 
 
5.0 
1.7 
1.2 
1.1 
 
10.2 
8.0 
7.5 
4.0 
 
9.3 
7.7 
6.7 
5.1 
 
4.3 
4.3 
4.3 
5.0 
29
29
27
19
29
29
27
18
25
23
20
17
9.9
-0.5
-3.6
0.04
10.3
-2.2
-4.3
-1.4
4.4
-1.3
-0.3
-0.4
7.1
5.9
5.4
7.0
8.2
8.3
8.6
8.8
3.5
3.6
4.0
4.3
37
37
36
26
37
36
36
27
40
39
35
28
8.2
3.5
0.8
1.9
8.3
0.3
0.8
1.2
3.7
1.5
1.0
1.9
7.2
8.0
8.5
7.2
10.2
8.4
5.7
10.1
1.8
2.8
3.5
5.0
20
20
18
14
20
20
18
14
21
20
17
14
 
8.3 
-1.5 
-3.8 
-3.6 
 
8.8 
-2.9 
-4.2 
-5.5 
 
4.2 
-1.0 
-1.3 
-2.1 
 
6.3 
5.2 
5.5 
4.2 
 
9.7 
6.1 
8.7 
8.7 
 
3.4 
2.2 
2.7 
2.8 
 
30 
29 
29 
23 
 
30 
29 
29 
23 
 
35 
34 
32 
23 
 
Note:   Values shown for follow-up intervals were calculated on the basis of the change from 
baseline scores; groups were pairwise compared at each follow-up with regard to change from 
baseline. IES = Impact of Event Scale; BHS = Beck Hopelessness Scale. 
a after disclosure; p = .01, partners of carriers versus partners of noncarriers.   b p = .03, 
partners of carriers versus partners of noncarriers.   c p = .04, noncarriers versus partners of 
noncarriers; p = .007, partners of carriers versus partners of noncarriers.   d p = .008, carriers 
versus noncarriers; p = .03, partners of carriers versus partners of noncarriers.   e p = .04, 
partners of carriers versus partners of noncarriers.   f p = .005, carriers versus noncarriers; p = 
.0007, partners of carriers versus partners of noncarriers.   g p = .01, partners of carriers versus 
partners of noncarriers.   h p = .004, partners of carriers versus partners of noncarriers. 
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Figure 2. Mean avoidance scores of gene carriers, noncarriers and partners 
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Table 4. Multivariate testing on course of psychological variables for 
carriers and noncarriers with additional analysis of effect of course in 
partners in subgroups of couples 
 
DNA test result in total 
study group 
X time point 
DNA test result in those 
who have partner X time
point 
DNA test result 
X partner 
X time point 
Variable df F p df F p df F p 
IES-intrusion 
 Multivariate a
 Step-down 
  linear trend 
  quadratic trend 
  cubic trend 
IES-avoidance 
 Multivariate a
 Step-down 
  linear trend 
  quadratic trend 
  cubic trend 
BHS 
 Multivariate a 
 Step-down 
  linear trend 
  quadratic trend 
  cubic trend 
 
3,42 
 
1,44 
1,43 
1,42 
 
3,42 
 
1,44 
1,43 
1,42 
 
3,39 
 
1,41 
1,40 
1,39 
 
1.55 
 
1.15 
1.87 
1.54 
 
2.77 
 
1.52 
6.29 
0.42 
 
4.63 
 
2.30 
2.45 
8.17 
 
.22 
 
.29 
.18 
.22 
 
.05 
 
.22 
.02 
.52 
 
.01 
 
.14 
.13 
.01 
 
3,31 
 
1,33 
1,32 
1,31 
 
3,31 
 
1,33 
1,32 
1,31 
 
3,30 
 
1,32 
1,31 
1,30 
 
2.02 
 
2.75 
1.27 
1.91 
 
5.14 
 
9.91 
4.84 
0.02 
 
3.16 
 
2.99 
1.95 
3.97 
 
.13 
 
.11 
.27 
.18 
 
.005 
 
.003 
.04 
.90 
 
.04 
 
.09 
.17 
.06 
 
3,31 
 
1,33 
1,32 
1,31 
 
3,31 
 
1,33 
1,32 
1,31 
 
3,30 
 
1,32 
1,31 
1,30 
 
5.37 
 
3.14 
2.83 
8.52 
 
0.93 
 
1.94 
0.01 
0.90 
 
0.37 
 
0.51 
0.56 
0.09 
 
.004 
 
.09 
.10 
.01 
 
.44 
 
.17 
.92 
.35 
 
.77 
 
.48 
.46 
.77 
Note.   IES = Impact of Event Scale; BHS = Beck Hopelessness Scale. 
a Pillai's multivariate repeated measures test. 
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Figure 3. Mean hopelessness scores of gene carriers, noncarriers and 
partners 
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Table 5. Means and standard deviations on psychological variables in 
partners of individuals tested for HD (distinguished by having children) 
 
Partners of carriers 
without children 
 Partners of carriers 
with children 
    
Variable M sd n  M sd n  df F p 
IES-intrusion 
 Baseline 
 1 week a
 > 6 months 
 > 3 years 
IES-avoidance 
 Baseline 
 1 week a
 > 6 months 
 > 3 years 
BHS 
 Baseline 
 1 week a 
 > 6 month 
 > 3 years 
 
7.3 
7.1 
3.9 
7.8 
 
6.8 
5.0 
3.1 
7.8 
 
3.7 
3.7 
3.7 
5.4 
6.1
5.2
4.4
6.4
11.8
5.8
4.2
6.2
1.7
2.4
1.8
3.5
9
9
7
9
9
9
7
9
9
9
7
9
 
8.2
11.3
11.3
13.0
8.3
8.6
11.3
14.1
3.8
6.5
5.8
6.1
7.2
4.9
9.2
2.3
9.1
3.2
8.5
4.9
1.9
2.8
4.1
5.8
11
11
10
7
11
11
10
7
11
11
10
7
 
1,18
1,18
1,15
1,14
1,18
1,18
1,15
1,14
1,18
1,18
1,15
1,14
 
0.20 
13.10 
4.03 
4.18 
 
0.33 
10.01 
5.46 
5.15 
 
0.03 
5.46 
1.59 
0.36 
 
.66 
.002 
.06 
.06 
 
.57 
.005 
.03 
.04 
 
.86 
.03 
.23 
.56 
Note.   IES = Impact of Event Scale;   BHS = Beck Hopelessness Scale. 
 
 
 The presence of children. As an unfavorable test result increases the risk 
of children to 50%, the presence of offspring may affect the psychological 
distress. Hence, we performed an additional exploratory analysis on the 
effect of having children on the psychological variables. No differences were 
found between carriers and noncarriers at baseline or at any of the follow-
up assessments with regard to the psychological variables. Partners of 
noncarriers who had children showed significantly higher hopelessness 
scores than those without children, F(1, 28) = 5.17, p = .03, in which the effect 
disappeared after the test disclosure. Table 5 presents the psychological 
measures in partners of carriers distinguished by the presence of children. 
At 1 week after disclosure, partners with children had significantly higher 
scores on all three variables, in which the difference was sustained for 
avoidance thoughts over the 3-year period and approached significance for 
the Intrusion subscale. 
DISCUSSION 
Our expectation that carriers would show an increase and noncarriers would 
show a decrease in psychological stress responses over time was not 
confirmed. In both groups, only slight changes from baseline were observed 
at the 3-year assessment regarding intrusion and avoidance. The shock of 
the test result in carriers and the relief of the test result in noncarriers were 
only reflected by their respective hopelessness scores 1 week after 
disclosure of the test results. After 6 months, subsequently, carriers had 
more avoidant thoughts about Huntington’s disease than noncarriers. Both 
groups did not differ significantly in the long term with regard to change from 
baseline on the psychological variables. Although this finding is consistent 
with the results of the Vancouver Group,14 it is contrary to our expectations, 
given the prognosis for carriers and the clinical features of Huntington’s 
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disease and the improved life perspective for noncarriers. This observation 
needs clarification. One explanation is that the dropouts have caused this 
result. On the one hand, noncarriers for whom Huntington’s disease was no 
longer an actual problem in their lives and who felt relieved were not moti-
vated to participate in the 3-year follow-up. This may have caused an 
overrepresentation of noncarriers who were still burdened by the presence 
of Huntington’s disease in their family and who perceived participation in the 
study as psychological support. On the other hand, some carriers were lost 
to follow-up after the Huntington’s disease diagnosis was confirmed in 
them—they had reacted with severe depression and suicidal behavior, 
although they had previously coped well (as was personally communicated 
by their partner or relatives). Therefore, relatively well-functioning carriers 
may be overrepresented in our study group. A second explanation is that 
the reactions in carriers, who have continued their participation in the study, 
reflect denial, relief from uncertainty, or both. Although the dropout group 
did not differ on any of the baseline variables, we have no insight in their 
psychological functioning at the consecutive assessment occasions. This 
limits the generalizability of the findings. 
 We investigated whether the course of psychological distress over time 
differed in tested individuals. Carriers and noncarriers showed a similar 
course over the entire period with regard to intrusion. However, carriers 
evidenced an increase in avoidant thoughts, and noncarriers evidenced a 
decrease at the 6-month follow-up. High positive correlations between both 
subscales were found at the 1-week and 6-month assessments20 and at the 
3-year follow-up measurement (r = .57 for noncarriers and r = .83 for 
carriers). These correlations were also reported by others, reflecting a 
single, general dimension of stress.27-29 However, the opposed cubic 
courses of avoidance and the similar course of intrusion (Figures 1 and 2) 
may reflect qualitatively different trajectories of intrusion and avoidance over 
time, such as low intrusion—high avoidance or high intrusion—low 
avoidance.1 27 
 Intrusion and avoidance in noncarriers showed the similar course. Most 
noncarriers were still entangled in family issues regarding Huntington’s 
disease, which may explain the increase in intrusion and avoidant thoughts 
about Huntington’s disease in the long term. The decline in the first 6 
months after disclosure may reflect the release from the personal risk to get 
Huntington’s disease; thereafter it is apparently Huntington’s disease in the 
family and guilt feelings that cause the specific distress. 
 Carriers had a different trajectory over time. The decrease in intrusion 
and the increase in avoidance at the 6-month assessment were significant 
with regard to change from baseline (p = .007), whereas after 3 years the 
reverse pattern approached significance (p = .073). This might indicate that 
carriers are frozen in avoidant states of mind regarding the implications of 
the disease in the first 6 months after disclosure of test results. Thereafter, 
carriers dose themselves with tolerable levels of intrusive thoughts so that 
effective processing of the personal meaning of Huntington’s disease can 
proceed.27 This is the nonpathological pattern according to Zilberg et al.27 
We have not observed pathological intensifications of reactions30 to the test 
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results in the study group. Further investigation of the different patterns in 
carriers and noncarriers may uncover the dynamic interplay of intrusion and 
avoidance and may also indicate which stress patterns are associated with 
adjustment disorders. 
 The significant change at the 1-week follow-up assessment between 
carriers and noncarriers with regard to hopelessness was less at the 6-
month follow-up and had disappeared at the 3-year measurement. This 
finding is in concordance with the clinical experience as reported in prior 
studies.12 16 The relatively stable estimation of perspectives regarding their 
future underlines the assumption that carriers minimize the full impact of the 
test result on their personal future and the ramifications for their families. 
Given the finding that the intrusive feelings have increased and avoidant 
thoughts decreased after 3 years, we suggest that carriers may have 
succeeded in finding a balance between facing reality (and preparing for the 
future) and continuing their current life without full awareness of the future 
disease. This in line with Wiggins et al.14 who have concluded that testing 
has maintained or even improved the psychological well-being of carriers. 
An unresolved question is how the foreknowledge of becoming a patient will 
affect carriers as they approach the impending onset of Huntington’s 
disease. 
 The pattern of hopelessness over time in noncarriers also needs 
attention. Over the long term they had an unchanged outlook with regard to 
their future. Presumably, the test result has not brought the expected effect 
on their life perspective, which is how lack of relief has previously been 
described.13 16 Contrary to their expectations, the favorable result has appar-
ently not conferred new mental resources to make decisions or solve 
personal problems. This might explain the return to baseline levels of the 
intrusive and avoidant thoughts. Moreover, non-carriers may have realized 
that being identified as a noncarrier is not a release from the shadow of 
Huntington’s disease in the family. 
 The second issue that was investigated in the current study concerned 
the comparison of the course of psychological responses in tested indi-
viduals and their partners. Partners of both groups did not differ at baseline. 
Quaid and Wesson19 however, found that partners of prospective carriers 
were more distressed about their marriage at baseline than partners of 
prospective noncarriers, which might indicate that the group of partners of 
prospective carriers contained some individuals who had reasons to 
anticipate unfavorable test results because of early signs of Huntington’s 
disease such as clumsiness or changes in mood. We also found no 
differences between the tested groups and the respective partner groups, 
which is different from the findings of Quaid and Wesson who reported that 
spouses were more depressed at baseline than individuals at risk. 
 The results reveal that, generally, partners showed similar patterns over 
the first 6-month follow-up compared with the tested individuals, which were 
sustained for the carriers—carrier partners group over the period that 
followed. Interestingly, noncarriers reported at the 3-year follow-up similar 
intrusion levels and slightly lower avoidant thoughts as in the pretest period, 
whereas their partners had significantly lower levels on both dimensions. 
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The better prospects of noncarrier partners reflect obviously the relief that 
Huntington’s disease has disappeared from their life and that the future was 
now open for them, with the inclusion of planning a family. The different 
course of psychological distress has led to marital discord in some couples 
that can be explained by the partners’ inability to appreciate the reactions in 
noncarriers.16 Quaid and Wesson19 have found that carrier couples were 
more distressed about their marriage than noncarrier couples at the follow-
up assessments. However, they have analyzed the distress in partners as 
independent of the tested individuals. In the present study, the similar 
course of avoidant thoughts and hopelessness in tested individuals and 
partners have confirmed that their scores should not be treated as 
independent. The increase on all psychological variables in carrier partners 
differed significantly from the decrease in noncarrier partners over the 3-
year follow-up— this finding emphasizes the completely different future 
prospects for either partner group. Further investigation is needed on the 
relationship of avoidance—intrusion patterns in marital couples and marital 
functioning. 
 Having children proved to be an additional stress factor for partners. 
Partners of prospective noncarriers with children were significantly more 
hopeless than those without children at baseline. Understandably, this effect 
disappeared after the test result. Partners of carriers who had children had 
significantly higher scores on all three variables at the 1-week follow-up 
than partners without children, and this difference sustained for avoidant 
thoughts and intrusive feelings over the 3-year period. Besides all of the 
problems with the future disease in the carrier, carrier partners with children 
have also the difficult task of informing the children about their risk and help-
ing them cope with the problems raised by their at risk status. The threat 
that their own children may develop Huntington’s disease as well is one of 
the most dramatic aspects of their life and may cause feelings of anxiety 
and hopelessness, but also feelings of resentment and hostility.11 21 
 The meaning of quadratic and cubic trends may seem difficult to 
understand for those who are unfamiliar with these statistical methods. We 
chose this approach to data analysis because the process of psychological 
responses is not merely a linear process.31 32 The trends in this study have 
demonstrated that the psychological process of coping with being at risk, 
receiving test results, and facing new life perspectives is very complex. 
However, whether the patterns found in this study were real or were due to 
chance must be further evidenced by follow-up studies in other samples 
with other late-onset inherited disorders. 
 The major limitation of this study was the relatively small number of 
participants and, subsequently, the quarter of the initial study group that 
was lost to follow-up—as was also found in the Vancouver Study.14 
Systematic evaluation of this group is necessary for interpretation of the 
results. In addition, the study group was overrepresented by female indi-
viduals. Interaction effects with regard to gender were not found, perhaps 
because of small groups. This issue should be addressed in future studies 
when larger samples are available. Another bias may have been caused by 
a number of siblings in the study: Eleven individuals belonged to four 
Three year follow-up 39 
different families. The numbers were too small to investigate the possible 
effect on outcome, but this must be considered as a potentially strong bias 
in every study. Furthermore, the duration of marriage or relationship might 
mediate the psychological conditions in tested individuals. Some 
relationships were ended before test disclosure, others in the 3-year period 
after the test. Some individuals had started a new relationship; these 
partners were not involved in the study. The effects of these confounders 
were not investigated in the current study, as no complete data were 
available. As was suggested by Wiggins et al.,14 the studied group may not 
be representative of the entire population at risk for Huntington’s disease. 
Moreover, the results may have been biased by the extensive psychological 
attention the researchers had given the participants. An important limitation 
is that the data were obtained by means of self-report. The disadvantages 
of self-report data are well-known and include possible social desirability 
bias. Therefore, case studies conducted by individuals who are able to 
objectively observe tested individuals and marital functioning can improve 
the understanding of the observations that will consequently increase the 
clinical significance.33 Yet, although the limitations of the study restrict the 
generalizability of the results, they generally are consistent with the findings 
of other groups. 
 After a decade of monogenic disorders, the current focus is on 
multifactorial disorders with more complex transmission patterns and a 
variety of therapeutic options for some disorders, but with no prospects of 
treatment for others. This development will have a tremendous impact on 
health care because people are offered new options that will influence their 
life perspectives— they are challenged to cope with these risks. The 
psychological impact of prediction of genetic diseases should be further 
studied with the emphasis on risk perception and on the ramifications for 
intimate relationships and the family system. 
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ABSTRACT 
The 7-10 year psychological effects of presymptomatic testing for 
Huntington disease are described in 142 individuals and 104 partners. 
Questionnaires included the Beck Hopelessness Scale,1 the Impact of 
Event Scale2 and the General Health Questionnaire.3 Carriers and their 
partners were more distressed immediately after the test result, although 
their outlooks improved somewhat in the 2-3 year posttest period. However, 
they became more pessimistic thereafter, when approaching the age of 
onset. Carriers, who were lost to follow-up after disclosure of test results, 
reported pretest more distress than did retained carriers. This demonstrates 
that studies that report few harmful effects, may have underestimated the 
real impact. Moreover, follow-up studies need to investigate time effects for 
longer than a few years. 
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INTRODUCTION 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative 
disease, characterized by involuntary movements (chorea), progressive 
dementia, and affective disturbances.4 Children of an affected parent are at 
50% risk of inheriting the disease. A linkage-based test was developed in 
1983.5 The gene was identified in 1993,6 which made a direct test for pre-
symptomatic diagnosis possible. Because it was expected that people who 
received a high risk test result would develop severe adverse psychological 
consequences,7-9 extensive psychological support was offered,10 and world-
wide follow-up studies were started.11-13 
Effects of testing on identified carriers and noncarriers 
In a study by Tibben et al.,14 increased scores on feelings of hopelessness 
were found following high risk test results, and reduced scores were found 
for those who tested out as low risks. In both cases, the scores returned to 
baseline levels after 6 months. Unwanted intrusive thoughts about HD 
decreased in both groups after 6 months. Carriers showed an increase in 
denial-avoidance behavior, whereas noncarriers showed a clear decrease. 
A later follow-up study by Tibben, Timman, Bannink, and Duivenvoorden15 
showed that hopelessness scores remained stable after 3 years. 
 In general, past studies on the psychological effects of predictive testing 
for HD have revealed temporary effects on psychological measures taken, 
although no long-term adverse emotional consequences have been 
observed.11-13 It has been concluded that tested individuals benefit 
psychologically from testing.16 Carriers seemed to minimize the impact of 
the test results on their future.17 18 
Effects of testing and parenthood on people at risk and their partners 
HD imposes a considerable burden on the family, especially on the spouse. 
Tibben et al.15 observed that partners of carriers followed the same course 
of distress as the carriers themselves. In addition, partners of carriers with 
children were significantly more distressed than those without offspring, 
whereas partners of noncarriers were significantly less distressed than 
noncarriers after 3 years, regardless of whether they had children. Codori et 
al.19 observed that carriers without children were more hopeless than 
noncarriers without children throughout the 12 months of their investigation. 
In this respect, one can pose the question of how important children are as 
a determinant of distress, and whether there are other or more important 
determinants that will surface 4 to 7 years later. 
 The first goal of this study was to asses whether psychological effects of 
testing are mainly short-time effects and whether tested individuals and their 
partners benefit psychologically from testing in the long term, 7– 10 years 
after the disclosure of the test result. Second, we examined whether the 
course of the responses (as measured by intrusion, avoidance, and 
hopelessness) changed with the age of onset approaching for carriers. We 
hypothesized that the distress and hopelessness would show an increase 
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over the long term for identified carriers and their partners, and a decrease 
for noncarriers and their partners. 
 We finally address the issue of dropout, one of the vulnerabilities of long-
term longitudinal studies. In course of time, participants are lost to follow-up 
due to mortality, moving to an unknown address, refusing to participate 
further, exclusion from the study because of early symptoms of HD, or due 
to other reasons. Dropout is never at random but systematic.20 
METHOD 
Subjects 
Between October 1987 and October 1993, 209 at-risk individuals were 
offered an informative test result obtained by linkage analysis at the Clinical 
Genetics Center in Leiden, the Netherlands. individuals who came for the 
test were encouraged to be accompanied by their spouse or a close family 
member. Twenty-eight individuals at risk were tested before the start of the 
psychological follow-up study, of whom 18 were evaluated retrospectively.21 
The other 181 individuals were included at the start of this evaluation 
program and were accompanied by 134 spouses. A structured predictive 
testing procedure for HD was introduced in 1987 in Leiden.17 The testing 
protocol followed the international guidelines,22 23 with the inclusion of two 
pretest and up to five posttest counseling sessions. All participants gave 
their informed consent. The Medical Ethics Committee of Leiden University 
Medical Center approved the protocol. For inclusion in the longitudinal 
analyses, participants required to have participated in at least one of the 
pretest and one of the posttest counseling sessions. Ten individuals were 
excluded from further follow-up sessions when they were clinically 
diagnosed as having HD; the other individuals had not yet exhibited signs of 
HD and thus remained included in the study. 
 After identification of the mutation,6 people who had had a linkage test 
with a residual risk of 1% to 9 % were informed about the mutation test. In 
addition, they were offered the mutation test and were requested to 
cooperate with the last follow-up of this study. Of those who had a mutation 
retest performed (30%), no risk reversals were revealed.24 
Measures 
At each counseling session, the Beck Hopelessness Scale (BHS), the 
Impact of Events Scale (IES), and the General Health Questionnaire (GHQ) 
were administered. 
 Hopelessness-future expectancies. The BHS is a reliable 20-item scale. 
Subjects are requested to indicate whether they agree with these items, 
resulting in a hopelessness score between 0 and 20.1 A score of 9 or higher 
is a possible predictor of suicidal behavior.25 
 Huntington specific distress. The IES is a reliable 15-item, four-answer 
category, Likert-type self-report scale that can be linked to a certain disease 
or a distressing event, in this case HD.2 It estimates the current degree of 
subjective impact, experienced as a result of HD. This subjective impact is 
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estimated on two dimensions: intrusion of unwanted ideas and thoughts into 
consciousness and avoidance of certain thoughts, feelings, or situations. 
The Intrusion subscale contains seven items, ranging in scores from 0 to 
35, and the Avoidance subscale contains eight items, ranging in scores 
from 0 to 40. 
 General well-being. The GHQ-60 is a reliable estimator of 
psychopathological states, such as depression, anxiety, somatic complaints 
and social dysfunction.3 A general score can be computed, with a range of 0 
to 60. 
Data analysis 
In contrast to repeated measure analysis of variance, which is often used 
for longitudinal data, we used linear mixed models, using the PROC MIXED 
procedure in SAS.26 This analysis method allows the use of incomplete 
cases. In these models, parameters can be random or fixed. A random 
intercept allows a different baseline measure. A random time parameter 
allows shorter or longer courses. Whether parameters should be random or 
fixed is determined by examining the covariance structure. First, a model is 
postulated with a saturated fixed part, including all interaction effects 
between relevant independent variables, and a large-as-possible random 
part with an unstructured covariance matrix. Then, the covariance model is 
simplified step by step without significant loss of information. This loss of 
information is estimated with the restricted maximum likelihood (REML) test. 
If a simpler model is not significantly different, that is, the difference in the 
maximum likelihood estimations is not significant, then the model is 
assumed to be more parsimonious than the more elaborate model, without 
evident loss of information. 
 Hereafter, the fixed part of the model is simplified by using the ordinary 
likelihood ratio test until a model is obtained that is as parsimonious as 
possible. The final model can include regression loadings on relevant 
independent variables, such as gender, age, DNA-test outcome, and time. 
Linear, quadratic, cubic, and higher order time effects can be revealed. For 
a linear effect at least 2 time points are needed, 3 time points for a quadratic 
effect, 4 for a cubic effect, and so forth. The resulting regression parameters 
can be used in a graph to make the significant effects visible, as an aid to 
interpretation. 
RESULTS 
Description of the sample, participants and nonparticipants 
Of the 181 test applicants who were included at the start of the study, 142 
(78%) returned for follow-up and additional counseling and hence were 
included in the longitudinal analyses. Of 134 partners, 104 (78%) were 
included. This sample for longitudinal analyses was composed of 81 
noncarriers and 61 carriers, accompanied by 59 and 45 partners 
respectively (Table 1). No significant differences in age were found between 
carriers, noncarriers and partners. Note that there is a trend that gene 
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carriers are older than noncarriers, F (54, 1) = 3.73, p = .06. This is in contrast 
to other studies,19 27 in which the group of carriers has a lower mean age, 
because symptomatic -and thus older- carriers are excluded from the study. 
In our study, we have information on 9 carriers with a mean age of 34.9 
years at baseline, who were excluded because they had HD symptoms. 
However, we have also information on a group of 7 carriers who returned 
for prenatal testing but who dropped out of the study. The dropout of this 
young group of carriers (mean age = 24.7 years) may be an important 
reason for the high mean age of the remaining group of carriers. 
 At the last time point, 56 (31%) carriers and noncarriers participated in 
the study (Table 1). At Time Point 5 (1½ years after the test) fewer 
respondents (n = 40, 22%) participated. The project was temporarily called 
off at the time, with the consequence that only the first half of the  
consecutively tested participants (those who had the test before October 
1990) were contacted for follow-up. This selection can be considered 
random. In previous analyses this time-point was unusable because we had 
used repeated measure multivariate analyses of variance (MANOVAs). For 
this study, the data of this time-point were added to the database to make 
use of as much information as possible. 
 Thirty-nine of 181 individuals at risk who had come for the predictive test 
and of whom we had pretest measures did not return for follow-up and 
additional counseling. No significant differences regarding gender, marital 
status, having children, and education were found between participants and  
 
Table 1. Number, mean age (in years), and gender ratio of participants in 
the follow-up study at different time-points 
 At risk Partners   
 Gender a Non-carriers Carriers
Non-
carriers Carriers Total 
Time point Men Women n age(M) n 
age
(M) n 
age
(M) n 
age
(M) n 
age 
(M) 
Intake 
Blood taking 
Test disclosure 
½ year 
1½ years 
3 years 
7-10 years 
All participants 
     at baseline 
66 
54 
52 
26 
12 
14 
18 
 
66 
102 
86 
83 
50 
28 
36 
38 
 
107 
95
75
78
42
27
30
32
98
32
33
33
33
35
35
39
32
73
65
57
34
13
20
24
75
33
33
34
32
29
34
44
33
73
56
57
32
21
23
21
74
34
34
35
33
36
35
43
33
 53
47
42
21
6
14
20
55
34
33
34
32
33
34
45
33
 294 
243 
234 
129 
67 
87 
97 
 
302 
33 
34 
34 
33 
34 
35 
43 
 
33 
a There was no significant difference between time points, F2(6) = 3.93, p = .69. 
 
non-participants (Table 2). However, individuals who turned out to be 
carriers and who did not return for follow-up scored at pretest significantly 
higher on hopelessness, intrusion, avoidance, and lower general well-being 
than did individuals who turned out to be carriers and who did return for 
follow-up. No significant pretest differences in hopelessness, intrusion, 
avoidance, and general well-being were found between noncarriers who 
returned for follow-up and noncarriers who did not. 
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 Reliability coefficients of the measures turned out to be satisfactory: 
Cronbach's alpha was .82 for the BHS, .87 for the Intrusion sub-scale of the 
IES, .83 for the Avoidance sub-scale, and .95 for the GHQ. A large 
correlation between the intrusion and avoidance sub-scales of the IES was 
found: r = .71 over all time points. The BHS has a very skewed and peaked 
distribution because many respondents have scores at the lower end of the 
scale. Therefore, a log transformation was performed on the BHS scores. In 
addition, because the first time intervals were much shorter than the later 
time intervals, the square root of time was used for analyses. 
 
Table 2. Differences in baseline characteristics of people who did and did 
not return for follow-up, for people who turned out to be a noncarrier or a 
carrier 
 Noncarriers Carriers 
Retained 
(n = 81) 
Dropouts 
(n = 21) 
 Retained 
(n = 61) 
Dropouts 
(n = 18) 
 
Baseline 
characteristic n % n % p a n % n % p a
Gender 
 Men 
 Women 
Marital status b
 Single 
 Married c
Children d
 No children 
 One or more 
Education e
 < vocational 
 ≥ vocational 
 
32 
49 
 
28 
53 
 
52 
28 
 
42 
37 
 
40 
60 
 
35 
65 
 
65 
35 
 
53 
47 
  
11 
10 
 
6 
12 
 
12 
6 
 
7 
11 
 
52 
48 
 
33 
67 
 
67 
33 
 
39 
61 
.21 
 
 
.58 
 
 
.56 
 
 
.20 
  
22 
39 
 
15 
46 
 
29 
32 
 
36 
24 
 
36
64
 
25
75
 
48
52
 
60
40
 
3 
15 
 
6 
11 
 
9 
8 
 
9 
8 
 
17 
83 
 
35 
65 
 
53 
47 
 
53 
47 
.10 
 
 
.28 
 
 
.45 
 
 
.40 
 Noncarriers Carriers 
 Retained 
(M) 
Dropouts
(M) F (1,94) p 
Retained
(M) 
Dropouts
(M) F (1,94) p 
Age (years) 
BHS 
Intrusion 
Avoidance 
GHQ-60 
32.4 
4.6 
10.7 
9.8 
9.4 
28.2 
5.2 
11.9 
8.9 
11.2 
3.27 
0.60 
0.73 
0.44 
0.33 
.07 
.44 
.40 
.51 
.57 
 33.6 
5.2 
12.0 
9.9 
10.2 
32.6 
7.6 
17.9 
16.2 
18.2 
0.08 
5.86 
11.61 
8.05 
7.50 
.77 
.02 
.00 
.01 
.01 
Note.     BHS = Beck Hopelessness Scale; GHQ-60 = General Health Questionnaire. 
a Significance was determined with Fisher's exact test. b For 4 persons, no data on marital 
status were available. c This included participants in common-law marriages. d At intake, for 4 
persons no data on number of children were available. e For 7 persons no data on education 
were available. 
The final model 
There were two pretest measures: at intake and about 3-6 weeks later when 
blood was taken. No significant differences were found between scores at 
intake and scores at blood sampling in participants who filled out 
questionnaires on both occasions. Therefore, these measures were taken 
together as one baseline measure. If a respondent had filled out 
questionnaires at intake as well as at blood taking, the mean of these two 
was used; otherwise, either the intake or the blood taking measure was 
used as the pretest measure. This resulted in more parsimonious models. 
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 Using the restricted maximum likelihood function (REML),26 it appeared 
that models with time as a fixed parameter were to be preferred over 
models with time as a random parameter, F²(3, N = 492) = 1037.2 versus F²(1, N = 
492) = 1032.3, p = .09). This means that there was no indication that there 
were differences in the time course by which people cope with the test 
results. The intercept was maintained as a random parameter, which means 
that the model was better if it was taken into account that individuals differ 
at baseline. We do not report on models with the GHQ as an outcome 
variable, because no significant test-outcome interaction effects remained in 
these models. 
Hopelessness 
Because a considerable proportion (27%) of at-risk individuals did not have 
a partner, it was not possible to use people at risk and partners in combined 
analyses. For establishing the final model, we used the at-risk sample. 
Although for partners a somewhat more parsimonious model was 
appropriate because there were no interactions with gender, we estimated 
the parameters of the models equivalent to the solution for participants at 
risk, for means of comparability. 
 
 
Table 3. Beck Hopelessness Scale (BHS) parameter estimates, and 
standard errors for the final at-risk and partner models 
 At risk Partners 
Effect Estimate SE p Estimate SE p 
Intercept   1.44 0.22 .0001   1.24 0.32 .0002 
Main effects 
DNA 
Gender 
Age 
Linear time trend 
Quadratic time trend 
Cubic time trend 
Quaternary time trend 
- 0.03 
- 0.01 
  0.01 
- 0.47 
  0.21 
- 0.03 
  0.002 
0.30 
0.32 
0.01 
0.12 
0.07 
0.01 
0.001 
.92 
.99 
.35 
.0001 
.01 
.02 
.03 
- 0.44 
- 0.06 
  0.01 
- 0.58 
  0.28 
- 0.05 
  0.002 
0.54 
0.42 
0.01 
0.14 
0.08 
0.02 
0.001 
.42 
.90 
.14 
.0001 
.001 
.003 
.004 
Interaction effects 
DNA X gender 
DNA X age 
Gender X age 
DNA X linear time trend 
DNA X quadratic time trend 
DNA X cubic time trend 
DNA X quaternary time trend 
DNA X gender X age 
- 1.12 
  0.003 
- 0.003 
  0.85 
- 0.41 
  0.07 
- 0.003 
  0.03 
0.51 
0.01 
0.01 
0.19 
0.12 
0.02 
0.01 
0.01 
.03 
.69 
.77 
.0001 
.001 
.003 
.01 
.04 
  0.12 
  0.01 
- 0.01 
  0.86 
- 0.41 
  0.07 
- 0.004 
  0.001 
0.67 
0.02 
0.01 
0.23 
0.15 
0.03 
0.001 
0.02 
.86 
.47 
.66 
.0002 
.01 
.01 
.01 
.97 
Note.     Regression coefficients are based on the logarithm of the BHS and on the square root 
of time in months. Proportion of variance accounted for was in the at risk solution: .46, and .53 
in the partner solution. 
 
 No significant main effects on hopelessness were found for test result, 
gender, and age (Table 3). Significant time effects were found for the whole 
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group: carriers, noncarriers and their respective partners. The weak test 
outcome-gender interaction effect was caused by female carriers who had 
higher hopelessness scores than did male carriers throughout the study. 
Among noncarriers, no gender differences were found. The test outcome-
gender-age interaction effect reflected a larger correlation between age and 
BHS for carriers, especially male carriers, than for noncarriers. Linear, 
quadratic, cubic, and quaternary interaction effects of test outcome with 
time were found for at-risk people and their partners. One week after the 
test outcome, carriers reported more hopelessness (Figure 1). After that, 
the level of hopelessness decreased dramatically to a lowest level 1½ year 
after the test, and then increased again. Seven to 10 years after the test, 
hopelessness level was higher than at baseline. 
 Partners followed the same pattern. However, noncarriers reported 
extremely reduced feelings of hopelessness after disclosure of the test 
results; levels return towards baseline after that. Their partners followed the 
same pattern. 
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Figure 1. Hopelessness for carriers, noncarriers and partners based on 
final model parameters 
Intrusion 
Female carriers and noncarriers reported more intrusive thoughts than did 
men. For their partners, no significant gender effect was found (Table 4). 
Older participants, those tested, as well as their partners, reported more 
intrusive thoughts. Significant main effects over time were found for 
intrusion. Generally, participants scored higher 1  
week after the test results; thereafter, scores decreased to a lowest level 
1½ years after the test disclosure, returned to baseline 3 years after the 
test, and decreased eventually 7-10 years later (Figure 2). The pattern of 
the significant interaction effects between test outcome and time was similar 
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to the more significant avoidance pattern described below. The linear time-
test result interaction effect for partners means that partners of carriers had 
higher intrusion scores after the test than did partners of noncarriers. 
 
Table 4. Intrusion parameter estimates, and standard errors for the final at-
risk and partner models 
 At risk Partners 
Effect Estimate SE p Estimate SE p 
Intercept   8.59 1.88 .0001   3.16 2.20 .16 
Main effects 
DNA 
Gender 
Age 
Linear time trend 
Quadratic time trend 
Cubic time trend 
Quaternary time trend 
  0.85 
- 4.03 
  0.11 
  4.29 
- 3.26 
  0.64 
- 0.04 
1.24 
1.08 
0.05 
1.26 
0.75 
0.14 
0.01 
.50 
.0001 
.02 
.001 
.0001 
.0001 
.0001 
  0.60 
- 1.23 
  0.17 
  4.73 
- 3.30 
  0.60 
- 0.03 
1.26 
1.09 
0.05 
1.27 
0.75 
0.14 
0.01 
.63 
.26 
.002 
.0002 
.0001 
.0001 
.0001 
Interaction effects 
DNA X linear time trend 
DNA X quadratic time trend 
DNA X cubic time trend 
  1.93 
- 0.54 
  0.04 
0.94 
0.28 
0.02 
.04 
.05 
.06 
  2.10 
- 0.38 
  0.02 
0.93 
0.28 
0.02 
.02 
.17 
.32 
Note.     Regression coefficients are based on the square root of time in months. Proportion of 
variance accounted for in at was .57 in the at risk solution, and .60 in the partner solution. 
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Figure 2. Intrusion for carriers, noncarriers and partners based on final 
model parameters 
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Table 5. Avoidance parameter estimates and standard errors for the final at 
risk and partner models 
 At risk Partners 
Effect Estimate SE p Estimate SE p 
Intercept   7.67 2.09 .0004   5.54 2.37 .02 
Main effects 
DNA 
Gender 
Age 
Linear time trend 
Quadratic time trend 
Cubic time trend 
Quaternary time trend 
- 0.40 
- 2.43 
  0.10 
  1.84 
- 1.81 
  0.39 
- 0.02 
1.39 
1.19 
0.06 
1.43 
0.85 
0.16 
0.01 
.77 
.04 
.07 
.20 
.03 
.01 
.01 
  0.34 
- 0.51 
  0.09 
  2.66 
- 2.21 
  0.41 
- 0.02 
1.38 
1.69 
0.06 
1.47 
0.87 
0.16 
0.01 
.81 
.66 
.14 
.07 
.01 
.01 
.01 
Interaction effects 
DNA X linear time trend 
DNA X quadratic time trend 
DNA X cubic time trend 
  3.33 
- 0.91 
  0.06 
1.07 
0.32 
0.02 
.002 
.004 
.007 
  0.84 
  0.12 
- 0.02 
1.07 
0.32 
0.02 
.43 
.71 
.45 
Note.     Time trend regression coefficients are based on the square root of time in months. 
Proportion of variance accounted for was .55 in the at risk solution and .55 in the partner 
solution. 
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Figure 3. Avoidance for carriers, noncarriers and partners based on final 
model parameters 
 
Avoidance-denial 
Female carriers and noncarriers also reported more avoidance behavior 
than did men; there was no such difference among partners. About the 
same significant main time effects were found for avoidance as for intrusion 
(Table 5). In general, participants score higher 1 week after the test 
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outcome. The scores decreased to a lowest level 1½ years  after the test 
outcome, rose again 3 years after the test, and decreased eventually 7-10 
years after the test (Figure 3). Carriers reported more avoidance behavior 1 
week after the test outcome than did noncarriers. One and a half years later 
this difference disappeared, but after 7-10 years noncarriers again had 
lower avoidance scores than carriers. 
Effects of parenthood on people at risk and their partners 
Initially, parenthood was included in the regression models. However, as 
parenthood is highly related with age (mean age of at risk parents = 40.1 
years, mean age of people without children = 26.5 years, F(1, 188) = 163, 
Cohen's d = 1.83, p = .00), problems of multicollinearity arose. 
Multicollinearity in regression analysis makes it impossible to distinguish 
which independent variable explains the variance in the dependent variable. 
If the shared variance is large, only a small part of the non-shared variance 
of the dependent variables can be allocated. One of the solutions to this 
problem is to remove the collineated independent variable with the weakest 
predictive qualities. Comparing a model that includes having children with a 
model that includes age, the fit measure is in favor of the model with age 
(at-risk model for BHS: F²(16, N = 492) = 633.8 vs. F²(16, N = 492) = 645.1). 
Consequently, parenthood is not included as a variable in the model. 
DISCUSSION 
In general, few harmful effects of predictive testing for HD have been 
reported in previous studies,11-13 which led to the suggestion that tested 
individuals have benefited from testing.16 This study, however, 
demonstrates that such a conclusion must be made with caution. Test 
candidates who reported less hope for the future, had more intrusive 
thoughts, reported more avoidance reactions, and had a worse sense of 
well-being at pretest returned significantly less often for follow-up and for 
additional counseling after they received an unfavorable test result than did 
distressed people who received a favorable test outcome. Intrusive thoughts 
are, and to a lesser extent avoidance behavior is, more frequent directly 
after the test and gradually become less frequent in course of time - this is 
in accordance with the findings of Horowitz et al.28 There is a temporal peak 
a few years after the test. We found different patterns of avoidance behavior 
and intrusive thoughts in carriers and noncarriers. Noncarriers reported less 
avoidance and intrusion shortly after the test, and although they also had a 
maximum, or peak in reporting of avoidance and intrusion, after a few years, 
they reported less avoidance and intrusion in the long run. It can be inferred 
that the test did not change the level of intrusion and avoidance for carriers 
eventually, but it revealed that noncarriers benefited from the test in this 
respect. Some carriers were lost to follow-up after they were diagnosed with 
HD. They reacted to the diagnosis with severe depression and suicidal 
behavior, although they had previously coped well, as was personally 
communicated by their partners or relatives.15 In addition, we speculate that 
individuals who had pessimistic future expectancies, had many intrusive 
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thoughts, reported much avoidance behavior, and had a worse sense of 
well-being may have reacted with extreme avoidance behavior and denial to 
an unfavorable test outcome. This reaction was also directed at everything 
that is associated with testing, including the messengers of the bad news 
(geneticists) and their associates (psychologists-researchers). 
Psychological functioning in the past has been regarded as the best 
predictor of psychological functioning.29 If one assumes that the effect of an 
unfavorable test outcome has the same effect on these people as on the 
people in our study group, there is cause to be concerned about the level of 
psychological functioning in these people. 
 The sample dropout in this and other studies was not random. Therefore 
dropouts need to be carefully examined. Tibben et al.15 studied differences 
between participants and those lost to follow-up and found no differences. 
However, they did not distinguish between identified carriers and 
noncarriers. A serious problem in long-term clinical follow-up studies is the 
dropout over time. The longer a follow-up study is maintained, the more 
people will drop out of the study. After a number of years a dropout rate of 
40% to 60% is not uncommon.20 The dropout rate after 10 years in this 
study is 69%. A relatively high proportion is expected to drop out because of 
the onset and clinical diagnosis of HD. Because of this selective dropout, 
the mean age of the group of carriers is lower than the mean age of the 
group of noncarriers in some other studies.19 27 In this study, no significant 
difference in age is found. This discrepancy can be explained by the higher 
age of onset as established in the Dutch study group.30 31 Because the age 
of onset is established as about 10 years higher in the Netherlands, this 
selective dropout effect is much weaker in our study. 
 From a dropout analysis, differences between dropouts and follow-up 
participants can be made, but results must be regarded with caution, in 
particular when data are not missing at random.32 In this study, missing data 
were not random at all, but dependent on outcome (e.g., BHS) and input 
(test outcome) measures. Missing data are not only responsible for loss of 
information, but they bias the findings and interpretations.26 The use of 
linear mixed models is an advantage over repeated measure MANOVA for 
analyzing incomplete cases, but there is, up to now, no method to 
compensate for dropout immediately after disclosure of a DNA test result. 
The only way to cope with this problem is to try to find ways to improve the 
participation of individuals and their partners. Another reason to reconsider 
former conclusions that predictive testing for HD does not have harmful 
consequences in the long run16 is that feelings of hopelessness rose again 
for carriers, 7-10 years after the test outcome. Feelings of hopelessness in 
carriers were increased immediately after the test result, reduced thereafter, 
but eventually rose again. For carriers themselves, this effect could have 
been caused by the disease itself. Although in principle participants who 
received a clinical diagnosis of HD were excluded from the follow-up, it is 
difficult to determine the exact point at which symptoms emerge. No formal 
neurological and neuropsychological examinations were performed. 
Nevertheless, 10 persons showed signs of HD and were excluded from 
further follow-up analyses. A high hopelessness score may be suggestive of 
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the first symptoms. This cannot hold for the partners, however, and they 
have similar hopelessness scores 7-10 years after the test. For this reason 
it is likely that the test outcome, the approaching age of onset, the onset of 
HD in relatives, loss experiences, and so forth are responsible for their 
enhanced feelings of hopelessness, Because the mean age of carriers at 
the last measurement was 45 years (range 27-73), many of these 
participants will probably develop HD in the near future, because the mean 
age of onset is 47 years in the Dutch cohort.31 
 Follow-up studies on predictive testing and the reviews have not 
comprehensively reported on the issue of dropouts.13 33 Hence, we would 
suggest that other groups also have a close look at their data over time, 
with the inclusion of those lost to follow-up, in order to better understand the 
well-being of all who were involved in predictive testing programs. 
 Testing for fatal inherited diseases creates a long term, life long stress 
reflected by gradually increasing levels of hopelessness as the onset of the 
disease approaches. This pattern may have implications for follow-up of 
cases. Increased avoidance behaviors may signal difficulties in returning to 
see those who performed the test and may warrant instituting alternative 
sources of follow-up care. 
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ABSTRACT 
In the last two decades predictive testing programs have become available 
for various hereditary diseases, often accompanied by follow-up studies on 
the psychological effects of test outcomes. The aim of this systematic 
literature review is to describe and evaluate the statistical methods that 
were used in these follow-up studies. A literature search revealed 40 
longitudinal quantitative studies that met the selection criteria for the review. 
Fifteen studies (38%) applied adequate statistical methods. The majority, 25 
studies, applied less suitable statistical techniques. Nine studies (23%) did 
not report on dropout rate, and 18 studies provided no characteristics of the 
dropouts. Thirteen out of 22 studies that should have provided data on 
missing values, actually reported on missing values. It is concluded that 
many studies could have yielded more and better results if more appropriate 
methodology had been used. 
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INTRODUCTION 
Fifteen years ago, predictive genetic testing became available for hereditary 
diseases with onset later in life. Since then, quantitative and qualitative 
psychological follow-up studies have shown that predictive testing offers 
several benefits. Although most psychological research on genetic testing 
has focused on the tests for Huntington’s disease (HD) and the BRCA1 and 
BRCA2 mutations, clinical experience has provided evidence that the 
findings can be extrapolated to other diseases with similar inheritance 
patterns. Research included the characteristics of tested individuals, why 
they make certain choices, their understanding of the information conveyed 
by the test, and how they adjust after the test results. Generally, people are 
able to make informed decisions and they can cope with the test results. 
However, little is known about those who did not apply for predictive testing, 
or those who withdrew from the follow-up studies.1 The latter individuals 
who drop out of studies may bias the findings. Obviously, careful statistical 
modelling is required to provide reliable conclusions, but also to make 
optimal use of the data. This has led to growing interest in the 
methodological quality of the studies. Although sophisticated software 
enables almost everyone to carry out the most exotic of statistical and 
epidemiological analyses, the methodological implications are too often 
incompletely understood.2 This review aims to investigate the statistical 
methods used in the studies of psychological effects of DNA testing for 
genetic diseases. 
METHODS 
Search methods and inclusion criteria 
First, the reviews of Broadstock et al.,3 Meiser & Dunn4 and Duisterhof et 
al.5 provided insight into the studies that have been published. In addition, 
we used the databases MEDLINE and PsycLIT from 1988 onwards. The 
key words used for the searches were: Huntington* disease, HBOC, 
BRCA*, FAP, familial adenomatous polyposis, HNPCC, colon cancer, SCA 
or spinocerebellar ataxia. 
 Follow-up studies encompass the prediction of psychological adjustment 
or the course of adjustment over time. Firstly, studies are included if they 
analyse quantified measures statistically. Secondly, studies should have 
investigated the psychological effects of a genetic test outcome for 
hereditary diseases. Thirdly, studies should have a longitudinal, not a cross-
sectional or retrospective design. 
Categorisation strategy for longitudinal research methods 
This review categorises and discusses articles according to the longitudinal 
methods that are used. Methods that could be valuable for longitudinal 
research such as structural equation models were not observed and hence 
are not discussed. For a more complete overview of longitudinal research 
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we refer to Bijleveld et al.6 Statistical methods can be classified as less 
adequate for two reasons. First, when the measurement level of the variable 
does not correspond with the level that is required for the method that is 
used. Second, when the study includes more than three waves, but the 
method used is only suitable for two waves at most. We distinguished in this 
review five issues of interest: (1) the measurement level of the variables, (2) 
the number of measurement moments (waves), (3) dropout handling, (4) 
missing value handling, and (5) the groups and subgroups that are studied. 
For classifying the studies we considered the measurement level 
(continuous or discrete) and the number of waves (two wave or multiple 
wave studies). 
 A longitudinal effect study must contain a pre-test baseline measure, and 
one or more post-test measures. Depending on the number of waves, 
several effects can emerge over the course of time. With two waves, a 
linear effect can be found. With multiple waves a quadratic effect can be 
found, which implies that the linear effect between baseline and first post-
test follow-up is not continued at a later follow-up. In studies with more than 
three waves, cubic effects can be found, analogous to a third power 
polynomial. We will categorise firstly according to measurement level: 
continuous and discrete; and secondly to longitudinal capabilities: higher 
order time effects, only linear time effects, and no time effects. 
Dropout analyses and reporting 
Dropout, caused by subjects who do not return for follow-up measurements, 
is a serious problem in virtually all longitudinal research. Dropout can 
invalidate the findings of a study when dropouts have characteristics or 
psychological outcomes different from the persons who remain in the study. 
Missing value handling and reporting 
Related to the dropout problem, but different in nature, is the handling of 
missing measurement points. Dropouts are subjects who participated at the 
start of the study, but do not return for follow-up after a certain time-point, 
for instance after the disclosure of a test result. We refer to missing values 
when subjects did not complete questionnaires at a certain time point, but 
did return for follow-up at other time points. It should be noted that this 
problem emerges only in longitudinal studies with multiple waves. 
RESULTS 
The search was carried out in November 2003. The first search resulted in 
41840 references. This search was then combined with the keywords: 
genetic* and psychol*, which decreased the number of references to 585. 
From the abstracts it was concluded that 86 of these could be useful for this 
study.
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Table 1. Studies categorized by measurement level and number of waves, 
diseases, psychological outcome variables and statistical methods 
Study Disease † Outcome variables ‡ Statistical method § 
Continuous variables, more than two waves 
Codori (1997) 60 HD BDI, BHS GLMM + 
Meiser (2002) 82 BRCA IES, BDI, STAI, MBSS GLMM + 
Codori (2003) 85 FAP SCL-90, BDI  GLMM + 
Almqvist (2003) 84 HD SCL-90, BDI, GWB GLMM ~ 
Timman (2004) 1 HD IES, BHS GLMM + 
Wiggins (1992) 51 HD SCL-90, BDI, GWB Repeated measures MANOVA ~ 
Tibben (1994) 52 HD IES, BHS, GHQ Repeated measures MANOVA + 
Campodonico (1996) 54 HD SCL-90, BDI, WAIS-R, 
HVLT, SCWT, WCST, QNE
Repeated measures ANOVA ~ 
Tibben (1997) 64 HD IES, BHS Repeated measures MANOVA + 
DudokdeWit (1998) 65 HD, FAP, 
HBOC 
IES Repeated measures MANOVA + 
Aktan-Collan (2001) 75 HNPCC STAI, IAS Repeated measures ANOVA ~ 
Lodder (2002) 81 BRCA IES, SCL-90, HADS, BIS Repeated measures ANOVA + 
Decruyenaere (2003) 86 HD STAI, BDI, SCL-90, IES, 
HOS, MMPI 
Repeated measures ANOVA ~ 
Tercyak (2001) 79 BRCA STAI Regression ~ 
Schwartz (2002) 83 BRCA IES, HSCL Regression, ANOVA ~ 
Decruyenaere (1996) 56 HD STAI, BDI, MMPI, UCL Paired t-test, regression ~ 
Dorval (2000) 71 BRCA-LF SCL-90, BSI-53 Paired t-test, regression ~ 
Friedman (1999) 68 BRCA IES, POMS-SF Logistic regression ~ 
Oostrom (2003) 87 BRCA HADS, IES, CWS, ODCFS Logistic regression ~ 
Horowitz (2001) 76 HD IES, BDI ANCOVA ~ 
Brandt (1989) 50 HD STAI, SCL-90, BDI, BHS T-test for independent samples + 
Lerman (1998) 66 BRCA IES, CES-D Logistic regression ~ 
Michie (2001) 78 FAP IES, STAI, HADS, RCBS, 
HOS, LOT 
Friedman's test for ordinal data ~ 
Broadstock (2000) 70 HBOC IES, STAI, GHQ, CWS Friedman's test for ordinal data ~ 
Abe (1997) 59 SCA STAI, SDS Kruskal-Wallis ~ 
Quaid (1995) 53 HD SCL-90, BDI, BHS, MSI Mann-Whitney U test ~ 
Lawson (1996) 57 HD SCL-90, BDI, SSQ,  
adverse events 
No longitudinal analyses 
performed 
~ 
Continuous variables, two waves 
Codori (1996) 55 FAP SCL-90, BDI, CDI, RADS, 
RCMAS, CBCL 
Repeated measures ANOVA + 
Lodder (2001) 77 BRCA IES, HADS Repeated measures ANOVA + 
Kirkwood (2002) 80 HD MMPI Repeated measures ANOVA + 
Marteau (1997) 62 CF STAI, GHQ, 12 
dichotomous questions 
Regression, logistic regression + 
Croyle (1997) 61 BRCA IES, STAI Regression ~ 
Decruyenaere (1999) 67 HD STAI, BDI, MMPI Regression + 
Smith (1999) 69 BRCA IES, STAI Regression ~ 
Ritvo (2000) 73 BRCA STAI, CES-D, LOT, MOSS Regression ~ 
Grosfeld (2000) 72 MEN IES, STAI, SCL-90 Paired t-test ~ 
Lerman (1996) 58 BRCA IES, CES-D ANOVA on difference scores, 
regression 
~ 
Wood (2000) 74 BRCA IES, HSCL Wilcoxon's sign rank/rank sum + 
Taylor (1997) 63 HD SCL-90, BDI, BHS Fisher's exact test ~ 
Discrete variables, more than two waves 
Aktan-Collan (2000) 90 HNPCC 5-answer categories 
questions 
Repeated Measurements 
ANOVA, paired sample t-tests 
~ 
Note:     † BRCA - Breast Cancer (BRCA1 and BRCA2); CF - Cystic Fibrosis; FAP - Familial 
Adenomatuous Polyposis; HBOC - Hereditary Breast and Ovary Cancer; HD - Huntington 
Disease; HNPCC - Hereditary Non-Polyposis Colon Cancer; MEN - Multiple Endocrine 
Neoplasia; LF - Li-Fraumeni cancer syndrome; SCA - Spino Cerebellar Ataxia. 
§ - + adequate; ~ less adequate 
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Forty-six articles did not meet our inclusion criteria as: 
• fourteen were qualitative studies. Although some of these studies used 
quantitative measures, the data were not statistically analysed and thus 
the studies were classified as qualitative for our purpose.7-20 
• ten studied psychological effects, but not of a genetic test outcome.21-30 
• thirteen studies were not longitudinal but cross-sectional or 
retrospective.31-43 
• three did not investigate psychological outcomes of genetic testing.44-46 
• six were reviews on effects of (genetic) testing.3-5 47-49 
Studies that could be classified in more than one category were mentioned 
in the first of the exclusion criteria involved. Forty articles met the inclusion 
criteria1 50-87 (Table 1). 
Categorisation of methods 
Methods for continuous outcome variables and three or more waves. 
General linear mixed models (GLMM), also referred to as random effect 
modelling, random coefficient regression modelling, mixed models or 
multilevel regression analysis. This method, used in five studies,1 60 82 84 85 
has three advantages: (1) incomplete cases can be analysed, (2) different 
time spans for individuals between the waves can be handled, and (3) the 
method allows control for confounding variables, for example age or the 
number of children, by entering these as covariates into the model equation. 
Missing data that are dependent on the observed outcome variables and 
other observed characteristics can be dealt with by including these in the 
analysis.88 89 
 Repeated Measures Analysis of Variance. Eight studies used repeated 
measures analysis of variance on continuous data with multiple waves.51 52 
54 64 65 75 81 86 Repeated measures analysis of variance has three main 
advantages: (1) it is relatively easy to perform, (2) several outcome 
variables can be analysed simultaneously, and (3) confounding variables 
can be included as covariates. The disadvantage, that only complete cases 
can be analysed, can be reduced by imputing the missing values of 
incomplete cases. A second, but less serious problem is that the time spans 
between the waves must be equal for each participant. 
 Five studies did not report on quadratic or higher order time effects, 
which suggests that they have not made optimal use of repeated measure 
analysis.51 54 75 81 86 Three studies have used missing value imputation,51 65 81 
which is discussed in the section on missing data. One study,90 used SPSS 
MANOVA on discrete variables, which must be considered as less 
adequate. 
 
Methods for continuous outcome variables and two waves. Repeated 
measures analysis of variance. Three studies55 77 80 used this highly 
appropriate method for analyses on two waves. 
 Regression analysis,(multiple) linear regression analysis, sequential or 
hierarchical regression analysis. The follow-up outcome variable is defined 
as the dependent variable in the regression equation. The baseline scores, 
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DNA test outcome, and other variables (gender, age education) are defined 
as independent variables. Two studies58 67 used this method adequately on 
two waves. Four studies,61 62 69 73 did not include the baseline measure in the 
analysis, which is less adequate when there are baseline differences. One 
of these62 did not include the baseline measure because of missing baseline 
data. Four studies56 71 79 83 used this analysis for multiple waves, which is 
less adequate, because only two by two comparisons can be made. 
 Analysis of variance or covariance of change scores. In principle this 
method is the same as regression analysis. Two studies76 83 used it to 
analyse multiple waves, which is not optimal. One of these83 did not use the 
baseline score as a covariate, and differences were analysed at baseline in 
separate t-tests. 
 Logistic regression. By using the DNA test outcome as the dependent 
variable, logistic regression can be used for analysing continuous outcome 
variables. Baseline, follow-up scores and confounding variables can be 
entered as independent variables. This method is unconventional since the 
role of determinant (DNA test outcome) and outcome (psychological test) 
are interchanged. The advantage of this method is that very few 
requirements are posed on the independent variables. Two studies,68 87 
used logistic regression in this way for their multiple wave study. 
 Paired samples t-test. With two time points, the paired samples t-test 
yields the same solution as a repeated measure ANOVA. However, no 
comparisons for change in course of time between groups can be made. 
One study72 used it for two time points, and they analysed the differences 
between groups separately. It is better to use one integrative method, so 
that interaction effects can be revealed. Two studies56 71 used this technique 
less adequately for multiple waves and for more than one group. 
 
Methods for continuous outcome variables that are not longitudinal. T-test 
for independent samples. Brandt et al.50 used this method for their study 
comprising of eight waves. Probably because the sample size was relatively 
small compared to the number of waves, repeated measures analysis of 
variance would yielded invalid results. As more advanced methods were not 
common in 1989, there is no reason to object to this method. Lawson et 
al.57 used this test to analyse baseline characteristics of persons who had 
an adverse event after the prediagnostic test for HD. 
 
Methods for discrete outcome variables and three or more waves. 
Friedman's test for ordinal data. This test is regarded as the non-parametric 
equivalent of a one sample repeated measures design. It neither reveals 
differences between groups, nor can it reveal quadratic, cubic or higher 
order time effects. If a significant time effect within a group is revealed, pair-
wise comparisons between waves must be analysed separately for 
significance. Two studies used this procedure70 78 for their continuous data. 
This could be adequate if the variables could not be successfully 
transformed to normality. Neither study reported on the distribution of the 
variables. 
 
66 Chapter 4 
 
Methods for discrete outcome variables and two waves. Logistic regression. 
Logistic regression is an appropriate analysis when the outcome variable is 
dichotomous. One study,66 dichotomised the continuous outcome variable, 
and performed logistic regression analysis which is less efficient. The 
authors also report that measures were taken at three time points, but they 
barely touched on the third wave in the result section. 
 Wilcoxon signed ranks test in combination with Wilcoxon rank sum test. 
These are non-parametric equivalents to a paired samples t-test and a t-test 
for independent samples. One study74 used these tests for one group and 
two waves, on continuous variables that were not normally distributed. This 
is a reasonable alternative when variables cannot be transformed to 
normality, though no interactions can be analysed. 
 
Methods for discrete outcome variables that are not longitudinal. Kruskal-
Wallis H test. This is a non-parametric equivalent to one-way ANOVA. One 
study59 seem to have used this test to compare three groups with respect to 
differences between the follow-up measure and baseline. Analyses for each 
of the three follow-up measurements were performed separately. 
 Mann-Whitney U test. This test is equivalent to a Kruskal-Wallis H test, 
but restricted to compare only two groups. One study53 used this test on 
continuous data for multiple waves, because of a small sample size. 
Carriers were compared with non-carriers, at each time point separately. 
Another study57 used this test to analyse baseline characteristics of persons 
who had an adverse event after the prediagnostic test for HD. 
 Fisher's exact test. One study63 used Fisher's exact test for analysing the 
difference between the number of people who had an increase and those 
who had a decrease since baseline with regard to certain outcome 
variables. When continuous variables are treated in this way, much 
information may be lost. 
Dropout analysis and reporting 
In this review we differentiate between individuals lost to follow-up (that is, 
dropouts) and those for whom data are incomplete as a consequence of 
missing time points. Incompleteness of data within questionnaires because 
participants did not answer all questions is not discussed here. In general, 
questionnaire manuals provide rules for handling this problem. Moreover, 
this is not a specific issue of longitudinal designs. 
 We divided the studies into four groups; (1) baseline differences 
analysed and found, (2) baseline differences analysed but not found, (3) 
dropout rate reported, but no analysis for differences reported, and (4) no 
mention of dropout (Table 2). 
(1). Thirteen studies reported differences between dropouts and participants 
who returned for follow-up questionnaires.1 53 58 63 65 66 68 78 83-86 90. 
(2). Ten studies reported that differences between dropouts and persons 
participating with follow-up were analysed, but no differences were 
found.51 60 64 71 75-77 81 82 87. 
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(3). Eight studies reported the dropout rate, but did not analyse possible 
characteristics of dropouts.50 54 56 59 61 67 70 72. 
(4). Nine studies reported neither on dropout analyses, nor on dropout 
rate.52 55 62 69 73 74 79 One study57 seemed to claim that there were no 
dropouts at all, though from the text it can be inferred that there must 
have been between one and 18 dropouts. And one study80 reported 
that unfortunately no baseline records of dropouts were kept. 
Missing value handling and reporting 
Twenty-eight studies included three or more waves, which made these 
studies vulnerable to missing values. Five studies used GLMM for analysis, 
and one study performed no longitudinal analysis.57 From the remaining 22 
studies information is needed about how they dealt with missing values. 
Three studies imputed missing values before performing repeated 
measures analysis of variance. One77 used singular regression imputation, 
which is considered inferior to multiple imputation,88 91 one65 used mean 
substitution, which is generally insufficient, and one51 did not report which 
method they used. In 10 studies participants with missing time points were 
excluded from the analyses54 56 66 68 70 71 75 78 86 90 and nine studies did not 
report on the handling of missing time points at all.50 52 53 59 64 76 79 83 87 
The groups and subgroups that are studied 
In 35 studies carriers were compared to non-carriers. Several of these 
studies also included other groups; people with an uninformative test 
outcome,50 51 57 82 83 85 people who refrained from testing,57 58 66 partners,1 64 81 
parents of individuals tested for FAP,85 and people who had had a 
spinocerebellar attack.59 One study compared unaffected Li-Fraumeni, 
unaffected BRCA1 tested individuals and women who were carriers of 
BRCA1 mutations.71 One study68 compared high and average risk groups of 
BRCA 1/2 mutation negatives. One study72 compared parents with children 
tested for the MEN2 gene: all children positive, all negative and mixed. Two 
studies included only one group.70 73 
Accuracy of reporting 
Some studies reported in an incomplete or unclear fashion. Sometimes the 
size of the study group and inclusion criteria remained unclear, or no actual 
p-values were reported. In other studies the presented p-values were 
different from values that could be calculated from the tables. Sometimes, 
the number of participants inferred from df or F²-values was not in 
accordance with the reported number of participants. 
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Table 2. Sample sizes, dropout, missing values, study length, number of 
waves, compared groups and accuracy of reporting 
Study 
Sam
ple size 
D
ropout rate 
D
ropout 
analysis 
M
issing 
value 
handling 
Tim
e span in 
m
onths 
W
aves 
W
ithin group 
G
roups 
Betw
een 
group  
Continuous variables, more than two waves 
Codori (1997) 60 160 4% no difference NA 12 5 Y 2; C/NC Y 
Meiser (2002) 82 143 20% no difference NA 12 4 Y 3: C/NC, no test Y 
Codori (2003) 85 48 27% differences NA 55 4 Y 4; C/NC, ditto parents 
3; C/NC, mixed families 
Y 
Almqvist (2003) 84 202 48% differences NA 60 7 Y 2; C/NC Y 
Timman (2004) 1 302 22% differences NA 120 6 Y 4; C/NC, partners Y 
Wiggins (1992) 51 135 26% no difference imputed 12 4 Y 3; C/NC, uninformative Y 
Tibben (1994) 52 73 ? none ? 6 3 Y 2; C/NC Y 
Campodonico(1996)54 59 75% none excluded 24 3 Y 2; C/NC Y 
Tibben (1997) 64 86 33% no difference ? 36 4 Y 4; C/NC, partners Y 
DudokdeWit(1998) 65 58 36% differences imputed 6 3 Y 2; C/NC Y 
Aktan-Collan(2001) 75 271 19% no difference excluded 12 4 Y 2; C/NC Y 
Lodder (2002) 81 102 50% no difference imputed 12 4 Y 4; C/NC, partners Y 
Decruyenaere(2003)86 57 25% differences excluded 60 3 Y 2; C/NC Y 
Tercyak (2001) 79 107? ? none ? 2 3 Y 2; C/NC Y 
Schwartz (2002) 83 279 20% differences ? 6 3 Y 3; C/NC, uninformative Y 
Decruyenaere(1996)56 53 7% none excluded 12 3 Y 2; C/NC Y 
Dorval (2000) 71 65 9% no difference excluded 6 3 Y 3;unaffected LF, BRCA1
affected BRCA1 
Y 
Friedman (1999) 68 289 31% differences excluded 6 3 Y 2; non-carriers: 
in- / decreased risk 
Y 
Oostrom (2003) 87 65 24% no difference ? 60 5 Y 2; C/NC Y 
Horowitz (2001) 76 79 47% no difference ? 12 4 Y 2; C/NC Y 
Brandt (1989) 50 55 75% none ? 24 8 N 3; C/NC, uninformative N 
Lerman (1998) 66 327 18% differences excluded 6 3 Y 3; C/NC, not tested Y 
Michie (2001) 78 19? 39% differences excluded 18 3 Y 2; C/NC N 
Broadstock (2000) 70 21 36% none excluded 12 4 Y 1; unaffected at risk NA
Abe (1997) 59 62 5% none ? 12 4 Y 3; C/NC, affected N 
Quaid (1995) 53 19 24% differences ? 12 5 N 2; C/NC Y 
Lawson (1996) 57 135 ? none NA 12 4 N 4; C/NC, uninform., not 
tested 
Y 
Continuous variables, two waves 
Codori (1996) 55 41 ? none NA 3 2 Y 2; C/NC Y 
Lodder (2001) 77 78 16% no difference NA 1 2 Y 2; C/NC Y 
Kirkwood (2002) 80 43 ? none NA 44 2 Y 2; C/NC Y 
Marteau (1997) 62 743 ? none NA 36 2 N 2; C/NC Y 
Croyle (1997) 61 60 3% none NA 1 2 N 2; C/NC Y 
Decruyenaere(1999)67 69 27% none NA 12 2 Y 2; C/NC Y 
Smith (1999) 69 212 ? none NA 1 2 N 2; C/NC Y 
Ritvo (2000) 73 60 ? none NA 12 2 N 1; tested women N
A 
Grosfeld (2000) 72 25 4% none NA 1 2 Y 3; parents with: C/NC 
child(ren), both 
Y 
Lerman (1996) 58 192 31% differences NA 1 2 Y 3; C/NC, not tested Y 
Wood (2000) 74 35 ? none NA 1 2 Y 2; C/NC Y 
Taylor (1997) 63 16 20% description NA 10
8 
2 Y 2; C/NC Y 
Discrete variables, more than two waves 
Aktan-Collan (2000) 90 334 19% differences excluded 12 3 Y 2; C/NC ? 
Note:   N - No    NA - Not applicable    Y - Yes    ? - Unknown    C/NC - carriers and non-carriers 
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DISCUSSION 
The aim of this review was to describe the methodology and statistics of 
psychological follow-up studies on effects of predictive genetic testing. 
Fifteen studies were found to have applied more or less adequate statistical 
methods. The majority of the studies, however, applied statistical 
techniques that were less suitable or less efficient for the data that were 
available to the researchers. We evaluated studies on five issues; (1) the 
measurement level of the variables, (2) the number of waves, (3) dropout 
handling, (4) missing value handling, and (5) the groups and subgroups that 
are studied. 
The measurement level of the variables 
Generally, most studies used variables with a continuous measurement 
level. Many statistical methods that are appropriate for this measurement 
level require normal distribution. If not, an attempt can be made to transform 
it to normality.92 93 If transformation is not successful, a non-parametric test 
should be used, as is prescribed for discrete variables. Generally, 
parametric tests are more efficient than non-parametric tests.94 For this 
reason it is recommended that a parametric test is used whenever 
permitted. Thirty-one studies used a parametric test on continuous data, 
seven studies used a non-parametric test on continuous data, one study 
used a parametric test on discrete data, and one study did not perform any 
longitudinal analysis. 
Dropout analyses and reporting 
Eighteen studies gave no evidence of having performed any analysis on the 
characteristics of dropouts. These differences should include outcome 
variables and all biographical measures that have been assessed. We 
favour the suggestion of Moher95 who reports that a flow diagram should be 
provided with the number of participants in any condition and any moment, 
and that reasons for these numbers should be given. Only two studies in 
this review actually provided such a flow chart.58 90 
Sample size 
An important characteristic of a study is the number of participants. The 
costs and efforts needed to conduct a large sample study will be higher than 
a small sample study. Obviously, a study with a large sample will reveal 
more (significant) effects. Although sample size issues are not within the 
scope of this review, it should be noted that a minimum sample size is 
needed to perform quantitative analyses. Our scope is to review the 
effectiveness and correctness of the methodology used, which is an issue 
independent of the sample size. 
70 Chapter 4 
 
A model for study design and analysis 
The type of study for examining the effects of testing for late onset genetic 
diseases is a longitudinal design in which one or more post-test measures 
are compared with a pre-test measure. Admitted, there is not one ideal 
study design, as it depends on the resources the researcher have access 
to, the subjects who can and want to participate, and the questions that are 
to be answered. We provide some recommendations. The study should 
include a baseline measure, an intervention such as a genetic test outcome, 
and follow-up measures. Generally it is concluded from previous research5 
that test results have a large impact directly after the test, but measures 
stabilise some time after baseline measurement. Timman et al.1 suggested 
that the genetic test outcome does have long term effects. For this reason it 
is recommended that a study be continued over several years. For an initial 
study report, for example when baseline and the first follow-up are 
undertaken, analysis can be done with repeated measures analysis of 
variance. For reports on subsequent follow-ups, GLMM is recommended. 
Although GLMM can handle incomplete cases, all efforts should be made to 
avoid missing values and retain as many participants in the study as 
possible. 
 In many articles no rationale was given for the analytic approach used. 
Sometimes the method used for the analysis was not clearly described, and 
we had to infer the analysis from the reported results. In some cases this 
may have meant that a different procedure was used than we inferred. 
 The use of an inadequate method can result in incorrect conclusions, but 
more often it can result in a failure to find a significant effect. To determine 
whether studies would have produced different findings if a more adequate 
method had been used, one needs to reanalyse the data. In a number of 
circumstances we performed the method described on our own data, and 
we compared the results of the various analyses. It is beyond the scope of 
this article to report on this extensively. Often the use of a non-parametric 
test where a parametric test could be used, does not lead to a dramatic loss 
of power efficiency. Mostly the power of a non-parametric test is about 95% 
compared to a F-test when conditions for this test are met. In some 
circumstances however, for example when distributions are dichotomised 
before analysing, this power can drop dramatically to a lower 63%.94 
 In this review, we found a number of studies that used sound methods 
and reported their findings and dropout handling in an excellent way. Our 
purpose is to present these methods and ways of reporting to all 
researchers in the field of psychological effects of genetic testing. Using an 
inadequate technique can cause loss of information, for example when a 
technique excludes incomplete cases. If more up-to-date and sophisticated 
techniques are included in one's statistical package, these should be used. 
In hindsight it can be said that some of our own new findings were already 
present in our previous data, but the statistical packages available to us at 
the time did not reveal these. We hope that this study can be of help to 
other researchers for finding more, and better founded results. 
Methodology in longitudinal studies 71 
 
ACKNOWLEDGEMENTS 
We thank Vicky Kraver for correcting our use of the English language. 
REFERENCES 
  1. Timman R, Roos RAC, Maat-Kievit A, Tibben A. Adverse Effects of 
Predictive Testing for Huntington Disease Underestimated: Long Term 
Effects 7-10 years after the test. Health Psychol 2004;23(2). 
  2. Bouter LM, Rosendaal FR, editors. Dwalingen in de methodologie. 
Amsterdam: Nederlands Tijdschrift voor Geneeskunde, 2002. 
  3. Broadstock M, Michie S, Marteau TM. The psychological consequences 
of predictive genetic testing: a systematic review. Eur J Hum Genet 
2000;8(10):731-738. 
  4. Meiser B, Dunn S. Psychological impact of genetic testing for 
Huntington disease: An update of the literature. J Neurol Neurosur Ps  
2000;69(5):574-578. 
  5. Duisterhof M, Trijsburg RW, Niermeijer MF, Roos RAC, Tibben A. 
Psychological studies on Huntington's disease: Making up the balance. 
J Med Genet 2001;38:852-861. 
  6. Bijleveld CCJH, van der Kamp LT, Mooijaart A, van der Kloot WA, van 
der Leeden R, van der Burg E, editors. Longitudinal data analysis: 
Designs, models and methods. London: Sage, 1999. 
  7. Evers-Kiebooms G, Fryns J-P, Cassiman JJ, Van den Berghe H. 
Psychosocial aspects of genetic counseling. New York, NY, US: Wiley-
Liss, 1992. 
  8. Bloch M, Adam S, Wiggins S, Huggins M, Hayden MR. Predictive 
testing for Huntington disease in Canada: the experience of those 
receiving an increased risk. Am J Med Genet 1992;42:499-507. 
  9. Huggins M, Bloch M, Wiggins S, Adam S, Suchowersky O, Trew M, et 
al. Predictive testing for Huntington disease in Canada: adverse effects 
and unexpected results in those receiving a decreased risk. Am J Med 
Genet 1992;42:508-515. 
10. Petersen GM, Boyd PA. Gene tests and counseling for colorectal cancer 
risk: lessons from Familial polyposis. J Nat Cancer Inst M 1995;17:67-
71. 
11. Hayden MR, Bloch M, Wiggins S. Psychological effects of predictive 
testing for Huntington's disease. In: Weiner WJ, Lang AE, editors. 
Behavioral neurology of movement disorders. Advances in neurology. 
New York, NY: Raven Press, 1995:201-210. 
12. Michie S, McDonald V, Bobrow M, McKeown C, Marteau T. Parents' 
responses to predictive genetic testing in their children: report of a 
single case study. J Med Genet 1996;33(4):313-8. 
13. Grosfeld FJM, Lips CJM, Kroode ten HFJ, Beemer FA, Spijker van HG, 
Brouwers-Smalbraak GJ. Psychosocial consequences of DNA analysis 
for MEN Type2. Oncology 1996;10(2):141-146. 
14. Lynch HT, Lemon SJ, Durham C, Tinley ST, Connolly C, Lynch JF, et al. 
A descriptive study of BRCA1 testing and reactions to diclosure of test 
results. Cancer 1997;79(11):2219-2228. 
72 Chapter 4 
 
15. DudokdeWit AC, Tibben A, Frets PG, Meijers-Heijboer EJ, Devilee P, 
Klijn JGM, et al. BRCA1 in the family: A case description of the 
psychological implications. Am J Med Genet 1997;71:63-71. 
16. Robins Wahlin T-B, Lundin A, Bäckman L, Almqvist E, Haegermark A, 
Winblad B, et al. Reactions to predictive testing in Huntington disease, 
Case reports of coping with a new genetic status. Am J Med Genet 
1997;73:356-365. 
17. Marteau TM, Croyle RT. The new genetics: Psychological responses to 
genetic testing. Brit Med J 1998;316:693-696. 
18. Shoda Y, Mischel W, Miller SM, Diefenbach M, Daly MB, Engstrom PF. 
Psychological interventions and genetic testing: Facilitating informed 
decisions about BRCA!/2 cancer susceptibility. J Clin Psychol Med S 
1998;5(1):3-17. 
19. Chapman PD, Burn J. Genetic predictive testing for bowel cancer 
predisposition: the impact on the individual. Cytogenet Cell Genet 
1999;86(2):118-124. 
20. Claes E, Evers Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, 
Legius E. Communication with close and distant relatives in the context 
of genetic testing for hereditary breast and ovarian cancer in cancer 
patients. Am J Med Genet 2003;116A(1):11-19. 
21. Bloch M, Fox S, Hayden MR. Predictive testing for Huntington disease: 
II. Demographic characteristics, life-style patterns, attitudes, and 
psychosocial assessments of the first fifty-one test candidates. Am J 
Med Genet 1989;32:217-224. 
22. Adam S, Wiggins S, Whyte P, Bloch M, Shokeir MHK, Soltan H, et al. 
Five year study of prenatal testing for Huntington's disease: demand, 
attitudes, and psychological assessment. J Med Genet 1993;30(7):549-
556. 
23. Wroe AL, Salkovskis PM. Factors influencing anticipated decisions 
about genetic testing: experimental studies. Brit J Health Psych 
1999;4:19-40. 
24. Julian-Reynier C, Eisinger F, Chabal F, Lasset C, Nogues C, Stoppa-
Lyonnet D, et al. Disclosure to the family of breast/ovarian cancer 
genetic test results: patient's willingness and associated factors. Am J 
Med Genet 2000;94(1):13-8. 
25. Kinney AY, Choi Y, DeVellis BM, Millikan R, Kobetz E, Sandler RS. 
Attitudes toward genetic testing in patients with colorectal cancer. 
Cancer Pract 2000;8(4):178-186. 
26. Kinney AY, Choi YA, DeVellis B, Kobetz E, Millikan RC, Sandler RS. 
Interest in genetic testing among first-degree relatives of colorectal 
cancer patients. Am J Prev Med 2000;18(3):249-52. 
27. Biesecker BB, Ishibe N, Hadley DW, Giambarresi TR, Kase RG, Lerman 
C, et al. Psychological factors predicting BRCA1/BRCA2 testing 
decisions in members of hereditary breast and ovarian cancer families. 
Am J Med Genet 2000;93:257-263. 
28. Schwartz MD, Hughes C, Roth J, Main D, Peshkin BN, Isaacs C, et al. 
Spiritual faith and genetic testing decisions among high risk breast 
cancer probands. Cancer Epidemiol Biomarkers Prev 2000;9:381-385. 
Methodology in longitudinal studies 73 
 
29. Di Prospero LS, Seminsky M, Honeyford J, Doan B, Franssen E, 
Meschino W, et al. Psychosocial issues following a positive result of 
genetic testing for BRCA1 and BRCA2 mutations: findings from a focus 
group and a needs- assessment survey. Can Med Assoc J 
2001;164(7):1005-9. 
30. Meiser B, Butow PN, Barratt AL, Schnieden V, Gattas M, Kirk J, et al. 
Long-term outcomes of genetic counseling in women at increased risk 
of developing hereditary breast cancer. Patient Educ Couns 
2001;44(3):215-25. 
31. Codori A-M, Brandt J. Psychological costs and benefits of predictive 
testing for Huntington's disease. Am J Med Genet 1994;54:174-184. 
32. Codori A-M, Hanson R, Brandt J. Self-selection in predictive testing for 
Huntington's disease. Am J Med Genet 1994;54:167-173. 
33. Van Der Steenstraten IM, Tibben A, Roos RAC, Van Der Kamp JJP, 
Niermeijer MF. Predictive testing for Huntington disease: 
Nonparticipants compared with participants in the Dutch program. Am J 
Hum Genet 1994;55:618-625. 
34. Robinson GE, Rosen BP, Bradley LN, Rockert WG, Carr ML, Cole DE, 
et al. Psychological impact of screening for familial ovarian cancer: 
reactions to initial assessment. Gynecol Oncol 1997;65:197-205. 
35. De Villiers C, Weskamp K, Bryer A. The sword of Damocles: the 
psychosocial impact of familial spinocerebellar ataxia in South Africa. 
Am J Med Genet 1997;74(3):270-274. 
36. Vernon SW, Perz CA, Gritz ER, Peterson SK, Amos CI, Baile WF, et al. 
Correlates of psychological distress in colorectal cancer patients 
undergoing genetic testing for hereditary colon cancer. Health Psychol 
1997;16:73-86. 
37. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cloostermans T, 
Cassiman J-J, Demyttenaere K, et al. Non-participation in predictive 
testing for Huntington's disease: Individual decision making, personality 
and avoidant behavior in the family. Eur J Hum Genet 1997;5:351-363. 
38. DudokdeWit AC, Tibben A, Duivenvoorden HJ, Frets PG, Zoeteweij 
MW, Losekoot M, et al. Psychological distress in applicants for 
predictive DNA testing for autosomal dominant, heritable, late onset 
disorders. J Med Genet 1997;34(5):382-390. 
39. Williams JK, Schutte DL, Holkup PA, Evers C, Muilenburg A. 
Psychosocial impact of predictive testing for Huntington disease on 
support persons. Am J Med Genet 2000;96(3):353-359. 
40. Robins Wahlin T-B, Backman L, Lundin A, Haegermark A, Winblad B, 
Anvret M. High suicidal ideation in persons testing for Huntington's 
disease. Acta Neurol Scand 2000;102(3):150-161. 
41. Bonadonna V, Saltel P, Desseigne F, Mignotte H, Saurin J-C, Wang Q, 
et al. Cancer patients who experienced diagnostic genetic testing for 
cancer susceptibility: Reactions and behavior after the disclosure of a 
positive test result. Cancer Epidem Biomar 2002;11:97-104. 
42. Michie S, French DP, Marteau TM. Predictive genetic testing: Mediators 
and moderators of anxiety. Int J Behav Med 2002;9(4):309-321. 
74 Chapter 4 
 
43. Kirkwood SC, Siemers E, Viken RJ, Hodes ME, Conneally PM, Christian 
JC, et al. Evaluation of psychological symptoms among 
presymptomatic HD gene carriers as measured by selected MMPI 
scales. J Psychiatr Res 2002;36(6):377-382. 
44. Kirkwood SC, Siemers E, Stout JC, Hodes ME, Conneally PM, Christian 
JC, et al. Longitudinal cognitive and motor changes among 
presymptomatic Huntington disease gene carriers. Arch Neurol-
Chicago 1999;56(5):563-568. 
45. Harper PS, Lim C, Craufurd D. Ten years of presymptomatic testing for 
Huntington's disease: the experience of the UK Huntington's Disease 
Prediction Consortium. J Med Genet 2000;37(8):567-571. 
46. Cannella M, Simonelli M, D'Alessio C, Pierelli F, Ruggieri S, Squitieri F. 
Presymptomatic tests in Huntington's disease and dominant ataxias. 
Neurol Sci 2001;22(1):55-56. 
47. Shaw C, Abrams K, Marteau TM. Psychological impact of predicting 
individual's risk of illness: a systematic review. Soc Sci Med 
1999;49(12):1571-1598. 
48. Evers-Kiebooms G, Welkenhuysen M, Claes E, Decruyenaere M, 
Denayer L. The psychological complexity of predictive testing for late 
onset neurogenetic diseases and hereditary cancers: implications for 
multidisciplinary counselling and for genetic education. Soc Sci Med 
2000;51(6):831-41. 
49. Meiser B, Gleeson MA, Tucker KM. Psychological impact of genetic 
testing for adult-onset disorders. An update for clinicians. Med J 
Australia 2000;172(3):126-129. 
50. Brandt J, Quaid KA, Folstein SE, Garber P, Maestri NE, Abbott MH, et 
al. Presymptomatic diagnosis of delayed-onset disease with linked DNA 
markers. The experience in Huntington's disease. JAMA 
1989;261(21):3108-14. 
51. Wiggins S, Whyte P, Huggins M, Adam S, Theilmann J, Bloch M, et al. 
The psychological consequences of predictive testing for Huntington's 
disease. New Engl J Med 1992;327(20):1401-1405. 
52. Tibben A, Duivenvoorden HJ, Niermeijer MF, Vegter-van der Vlis M, 
Roos RAC, Verhage F. Psychological effects of presymptomatic DNA 
testing for Huntington's disease in the Dutch program. Psychosom Med 
1994;56(6):526-532. 
53. Quaid KA, Wesson MK. Exploration of the effects of predictive testing 
for Huntington Disease on intimate relationships. Am J Med Genet 
1995;57:46-51. 
54. Campodonico JR, Codori AM, Brandt J. Neuropsychological stability 
over two years in asymptomatic carriers of the Huntington's disease 
mutation. J Neurol Neurosur Ps 1996;61(6):621-624. 
55. Codori AM, Petersen GM, Boyd PA, Brandt J, Giardiello FM. Genetic 
testing for cancer in children. Short-term psychological effect. Arch 
Pediatr Adolesc Med 1996;150:1131-1138. 
Methodology in longitudinal studies 75 
 
56. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cassiman JJ, 
Cloostermans T, Demyttenaere K, et al. Prediction of psychological 
functioning one year after the predictive test for Huntington's disease 
and impact of the test result on reproductive decision making. J Med 
Genet 1996;33(9):737-743. 
57. Lawson K, Wiggins S, Green T, Adam S, Bloch M, Hayden M, et al. 
Adverse psychological events occurring in the first year after predictive 
testing for Huntington's disease. J Med Genet 1996;3:856-862. 
58. Lerman C, Narod S, Schulman K, Hughes C, Gomez-caminero A, 
Bonney G, et al. BRCA1 testing in families with hereditary breast-
ovarian cancer. A prospective study of patient decision making and 
outcomes. JAMA 1996;275:1885-1892. 
59. Abe K, Itoyama Y. Psychological consequences of genetic testing for 
spinocerebellar ataxia in the Japanese. Eur J Neurol 1997;4(6):593-
600. 
60. Codori A-M, Slavney PR, Young C, Miglioretti DL, Brandt J. Predictors 
of psychological adjustment to genetic testing for Huntington's disease. 
Health Psychol 1997;16(1):36-50. 
61. Croyle RT, Smith KR, Botkin JR, Baty B, Nash J. Psychological 
responses to BRCA1 mutation testing: preliminary findings. Health 
Psychol 1997;16(1):63-72. 
62. Marteau T-M, Dundas R, Axworthy D. Long-term cognitive and 
emotional impact of genetic testing for carriers of cystic fibrosis: The 
effects of test result and gender. Health Psychol 1997;16(1):51-62. 
63. Taylor CA, Myers RH. Long-term impact of Huntington disease linkage 
testing. Am J Med Genet 1997;70:365-370. 
64. Tibben A, Timman R, Bannink EC, Duivenvoorden HJ. Three year follow 
up after presymptomatic testing for Huntington's disease in tested 
individuals and partners. Health Psychol 1997;16(1):20-35. 
65. DudokdeWit AC, Duivenvoorden HJ, Passchier J, Niermeijer MF, Tibben 
A. A Course of distress experienced by persons at risk for an 
autosomal dominant inheritable disorder participating in a predictive 
testing program: an explorative study. Rotterdam/Leiden Genetics 
Workgroup. Psychosom Med 1998;60(5):543-549. 
66. Lerman C, Hughes C, Lemon SJ, Main D, Snyder C, Durham C, et al. 
What you don't know can hurt you: adverse psychologic effects in 
members of BRCA1- linked and BRCA2- linked families who decline 
genetic testing. J Clin Oncol 1998;16:1650-1654. 
67. Decruyenaere M, Evers-Kiebooms G, Boogaerts A, Cassiman JJ, 
Cloostermans T, Demyttenaere K, et al. Psychological functioning 
before predictive testing for Huntington's disease: the role of the 
parental disease, risk perception, and subjective proximity of the 
disease. J Med Genet 1999;36(12):897-905. 
68. Friedman LC, Webb JA, Richards CS, Lynch GR, Kaplan AL, Brunicardi 
FC, et al. Psychological impact of receiving negative BRCA1 mutation 
test results in Ashkenazim. Genet Med 1999;1(3):74-79. 
76 Chapter 4 
 
69. Smith KR, West JA, Croyle RT, Botkin JR. Familial context of genetic 
testing for cancer susceptibility: Moderating effect of siblings' test 
results on psychological distress one to two weeks after BRCA1 
mutation testing. Cancer Epidem Biomar 1999;8:385-392. 
70. Broadstock M, Michie S, Gray J, Mackay J, Marteau TM. The 
psychological consequences of offering mutation searching in the 
family for those at risk of hereditary breast and ovarian cancer--a pilot 
study. Psycho-oncol 2000;9(6):537-48. 
71. Dorval M, Patenaude AF, Schneider KA, Kieffer SA, DiGianni L, 
Kalkbrenner KJ, et al. Anticipated versus actual emotional reactions to 
disclosure of results of genetic tests for cancer susceptibility: findings 
from p53 and BRCA1 testing programs. J Clin Oncol 2000;18:2135-
2142. 
72. Grosfeld FJ, Beemer FA, Lips CJ, Hendriks KS, ten Kroode HF. Parents' 
responses to disclosure of genetic test results of their children. Am J 
Med Genet 2000;94(4):316-23. 
73. Ritvo P, Robinson G, Irvine J, Brown L, Matthew A, Murphy KJ, et al. 
Psychological adjustment to familial genetic risk assessment: 
differences in two longitudinal samples. Patient Educ Couns 
2000;40(2):163-72. 
74. Wood ME, Mullineaux L, Rahm AK, Fairclough D, Wenzel L. Impact of 
BRCA1 testing on women with cancer: a pilot study. Genet Test 
2000;4(3):265-72. 
75. Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kaariainen H. 
Psychological consequences of predictive genetic testing for hereditary 
non-polyposis colorectal cancer (HNPCC): a prospective follow-up 
study. Int J Cancer 2001;93(4):608-611. 
76. Horowitz MJ, Field NP, Zanko A, Donnelly EF, Epstein C, Longo F. 
Psychological impact of news of genetic risk for Huntington disease. 
Am J Med Genet 2001;103(3):188-192. 
77. Lodder L, Frets PG, Trijsburg W, Meijers-Heijboer EJ, Klijn JGM, 
Duivenvoorden HJ, et al. Psychological impact of receiving a 
BRCA1/BRCA2 test result. Am J Med Genet 2001;98:15-24. 
78. Michie S, Bobrow M, Marteau TM. Predictive genetic testing in children 
and adults: a study of emotional impact. J Med Genet 2001;38(8):519-
26. 
79. Tercyak K-P, Lerman C, Peshkin B-N, Hughes C, Main D, Isaacs C, et 
al. Effects of coping style and BRCA1 and BRCA2 test results on 
anxiety among women participating in genetic counseling and testing 
for breast and ovarian cancer risk. Health Psychol 2001;20(3):217-222. 
80. Kirkwood SC, Siemers E, Viken R, Hodes ME, Conneally PM, Christian 
JC, et al. Longitudinal personality changes among presymptomatic 
Huntington disease gene carriers. Neuropsychiat Neuropsychol Beh 
Neurol 2002;15(3):192-197. 
Methodology in longitudinal studies 77 
 
81. Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JGM, 
Seynaeve C, et al. One year follow-up of women opting for 
presymptomatic testing for BRCA1 and BRCA2: Emotional impact of 
the test outcome and decisions on risk management (surveillance or 
prophylactic surgery). Breast Cancer Res Tr 2002;73:97-112. 
82. Meiser B, Butow P, Friedlander M, Barratt A, Schnieden V, Watson M, 
et al. Psychological impact of genetic testing in women from high-risk 
breast cancer families. Eur J Cancer 2002;38(15):2025-2031. 
83. Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. 
Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a 
clinic-based sample. J Clin Oncol 2002;20(2):514-520. 
84. Almqvist EW, Brinkman RR, Wiggins S, Hayden MR. Psychological 
consequences and predictors of adverse events in the first 5 years after 
predictive testing for Huntington's disease. Clin Genet 2003;64(4):300-
309. 
85. Codori A-M, Zawacki KL, Petersen GM, Miglioretti DL, Bacon JA, 
Trimbath JD, et al. Genetic testing for hereditary colorectal cancer in 
children: Long-term psychological effects. Am J Med Genet 
2003;116A(2):117-128. 
86. Decruyenaere M, Evers Kiebooms G, Cloostermans T, Boogaerts A, 
Demyttenaere K, Dom R, et al. Psychological distress in the 5 year 
period after predictive testing for Huntington's disease. Eur J Hum 
Genet 2003;11(1):30-38. 
87. Oostrom Iv, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, Gool 
ARv, Seynaeve C, et al. Long-term psychological impact of carrying a 
BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J 
Clin Oncol 2003;21(20):3867-3874. 
88. Little RJA, Rubin DB. Statistical analysis with missing data. New York: 
John Wiley and Sons, 1987. 
89. Molenberghs G, Bijnens L, Shaw D. Linear mixed models and missing 
data. In: Verbeke G, Molenberghs G, editors. Linear mixed models in 
practice - A SAS oriented approach. New York etc.: Springer, 
1997:191-274. 
90. Aktan-Collan K, Mecklin JP, Jarvinen H, Nystrom-Lahti M, Peltomaki P, 
Soderling I, et al. Predictive genetic testing for hereditary non-polyposis 
colorectal cancer: uptake and long-term satisfaction. Int J Cancer 
2000;89(1):44-50. 
91. Schafer JL. Analysis of incomplete multivariate data. London: Chapman 
& Hall, 1997. 
92. Tabachnick BG, Fidell LS. Using multivariate statistics - third edition. 
New York: HarperCollins, 1996. 
93. Stevens J. Applied multivariate statistics for the social sciences - third 
edition. 3rd ed. Hillsdale, New Jersey: Erlbaum, 1996. 
94. Siegel S, Castellan NJJ. Nonparametric statistics for the behavioral 
sciences. 2nd ed. ed. New York: McGraw-Hill, 1988. 
95. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised 
recommendations for improving the quality of reports of parallel-group 
randomised trials. Lancet 2001;357(9263):1191-1194. 
78 Chapter 4 
 
 
  
 
 
CHAPTER 5 
 -  
Testing the test - why pursue a better 
test for Huntington disease? 
 
 
 
 
 
 
 
 
 
 
 
Reinier Timman1, 2, Anneke Maat-Kievit 3, Christine Brouwer-DudokdeWit 4, 
Moniek Zoeteweij 5, Martijn H. Breuning 5, Aad Tibben1, 2, 3, 5
 
1 Leiden University Medical Center, Department of Neurology; 2 Erasmus University 
Medical Center Rotterdam, Department of Medical Psychology and Psychotherapy; 3 
Erasmus University Medical Center, Department of Clinical Genetics; 4 The 
Bosgroup, Center for Psychotherapy, Research and Counseling, Amsterdam; 5 
Leiden University Medical Center, Department of Clinical Genetics, The 
Netherlands. 
Am J Med Genet, 2003;117B:79-85 
Copyright © 2003 Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.; 
Reprinted with permission of John Wiley & Sons, Inc. 
80 Chapter 5 
 
ABSTRACT 
In 1993, the gene mutation for Huntington Disease (HD) was identified and 
testing became possible with a reliability of >99%, without the need for co-
operation of relatives. In 1997 a systematic information program offered the 
mutation retest to individuals who had earlier received a linkage test result 
for Huntington disease, which has  a residual uncertainty of 1 to 9%. The 
characteristics of 129 individuals tested by linkage analysis for HD are 
reported on, as well as the reasons for their reassessment by mutation 
testing. Three groups were compared: (1) people who were retested 
between 1993 and 1997, before this study had started, (2) people who were 
retested after we provided information, and (3) persons who refrained from 
retesting. Nearly half of the linkage-tested individuals  were retested, with 
the exception of noncarriers with a residual risk of 1 or 2%. Of them, less 
than one out of five were retested. Carriers with a hopeful view on the future 
(BHS) and a better sense of well being (GHQ) were more likely to have the 
retest. Female carriers were also more likely to have the retest before we 
contacted them. Noncarriers who were retested were more anxious (HADS) 
than noncarriers who refrained from the retest. Retestees were younger at 
the time of testing. No risk reversals were revealed by this study. 
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INTRODUCTION 
Huntington disease (HD) is an autosomal, progressive neuropsychiatric 
disorder. Since the mean age of onset in the Dutch population is 47 years 1, 
the risk to a person with an affected parent is still approximately 50%, when 
decisions about future- and family planning are being made in early adult 
life.2 
 After localization of the HD gene to the chromosome band 4p16.3 in 
1983, predictive testing using linkage analysis became available.3 For 
linkage analysis, the co-operation of crucial family members is required. 
Once the gene causing HD was identified in 1993,4 a number of technical 
testing problems were solved, such as: cases of non-paternity, 
recombination, unavailability of family material, residual risk (1-9%) or an 
uninformative family structure because of too few co-operating family 
members. 
 The primary objective of predictive testing is to bring an end to 
uncertainty about the genetic status of people at risk  from a genetic 
disease. At-risk individuals, who received a linkage test result with residual 
risks of 1-9%, could benefit by a reduction of this uncertainty level to less 
than 1%. Before the mutation test became available, Babul et al.,5 
investigated whether linkage tested people were interested in a 
hypothetically more certain (99%) test, for which co-operation of relatives 
was still required, and a hypothetically 100% certain test, for which co-
operation was not required. They reported that 58% of people who had 
received an informative linkage test outcome were interested in the more 
certain test, and 72% were interested in the certain test. Of the linkage 
testees who had not received a test result, because of unavailability of DNA 
from crucial family members or uninformativeness of DNA markers, 87% 
were interested in a certain test. More individuals with an increased risk in 
their study were interested in the certain test than individuals with a 
decreased risk (82% vs. 64%). To gain in conciseness and readability, we 
will refer to these people as carriers and noncarriers. It was inferred by 
Babul et al.5 that carriers have less to lose with a retest than noncarriers. 
Reasons for reluctance to have a more certain retest performed might be 
that individuals have accepted living with the residual risk, that they could 
be frightened of being found to be a carrier after all, that they do not 
understand the implications of the test result, that they deny the residual risk 
or that they were just not aware of the new test. 
 The aim of this study was to gain more insight into the need and the 
reasons for reassessment of the risk obtained by linkage analysis by use of 
the mutation retest, and also to gain more insight into the psychological 
characteristics of retestees and individuals who refrained from retesting. 
Based on the findings of Babul et al.5 and Benjamin et al.6 we hypothesized 
firstly that more carriers will opt for the retest (before and after our 
information) than noncarriers. Secondly, we hypothesized that linkage 
testees with a high residual risk will opt more often for the retest than 
linkage testees with a low residual risk. For those with a high residual risk it 
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is probably more important to relieve dissonance caused by uncertainty. For 
noncarriers with a residual risk of 1% or 2 % there is not much gain in 
having the retest with a residual risk of 1% or less, but there is much to lose 
in case of a risk reversal. Thirdly, we hypothesized that those who opt for 
the retest will be younger. In general, for younger people it is more 
important to be certain of the test result in order to plan for the future and 
family. Moreover, the probability that an asymptomatic at-risk individual has 
a disease-causing mutation gradually decreases with increasing age.7 
Fourthly, we inferred that more optimistic carriers, in a better state of well 
being, will choose more often to have the retest. Optimistic carriers will 
clutch more at this piece of straw than pessimistic carriers. Also, just as the 
way of adapting to the linkage test result will be different for noncarriers, we 
predict that the psychological characteristics of noncarriers that opt for the 
retest will also be different. 
METHODS AND PARTICIPANTS 
Participants 
In The Netherlands the estimated prevalence of HD is 6.5:100.000, based 
on the number of living affected individuals, recorded at the Leiden Roster 
for HD. At least 3115 individuals at 50% risk are registered.8 
 Pre-symptomatic DNA testing for HD has been performed in The 
Netherlands by linkage analysis since 1987. When the mutation test 
became available in 1993, the people who had received an informative 
linkage test result, were not immediately informed. An active policy was not 
applied because it could be interpreted as if the linkage test had been 
unreliable, according to the Medical Ethics Committee of Leiden University 
Medical Center. Life important decisions were based on it, and people might 
become upset. Moreover, people had the right not to know. Only 35 
individuals who previously could not be given an informative linkage test 
outcome were actively approached by letter in 1993. They were offered the 
new test, to have an appointment with a clinical geneticist for more 
information and additional psychological counseling. Eventually, in 1997 the 
Department of Genetics was allowed to start a systematic information 
program to inform and offer retesting to those who had received linkage test 
results. Prior to this program, a number of linkage testees opted for more 
certainty regarding their at-risk status for HD by making use of the retest. 
Three groups are compared in this study: (1) the group that had the retest in 
the period from 1994 to 1997 before our information program started, (2) the 
group of linkage testees who were retested after our information, and (3) the 
group of linkage testees who were not retested. 
 Twelve out of the 35 individuals who could not receive an informative 
test outcome did not receive it due to uninformativeness of markers. The 
other 23 could not be tested because of an uninformative family structure. 
Those at-risk individuals who did not receive a linkage test result were 
contacted and informed by our department about the new test in 1993. 
Eleven individuals (92%) who received no test result due to uninformative 
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markers and 7 (30%) who could not be tested because of their family 
structure then decided to be tested by mutation analysis. Taken together, 18 
(51%) out of these 35 individuals who did not receive a linkage test result at 
the time, had the mutation test performed in 1993. 
Procedures 
Two letters were sent together to 210 individuals who had received an 
informative linkage test outcome and who were eligible for this investigation. 
Before they were contacted, their addresses were checked with great care 
in order to ensure that letters would be delivered accurately. This was 
carried out using the address database of the Dutch telecom and the 
registry office. If a person was no longer listed in these databases, the 
family practitioner was contacted, on the condition that he or she had been 
informed about the linkage test results. 
 In the first letter, they were reminded of their personal residual risk 
percentage, and they were informed about the possibility of reassessment 
with a much higher accuracy by mutation testing. They were offered an 
appointment with a clinical geneticist for more information, and they were 
offered additional psychological counseling. In the second letter, their co-
operation was requested for a psychological follow-up investigation on the 
long-term effects of predictive testing for HD. A reminder was sent after 6 
weeks if there was no response. 
 Eighty-one out of the 210 eligible individuals could not participate in this 
study. Eight individuals already had received a mutation test in combination 
with the linkage test in 1993, three were deceased (not due to HD), 15 had 
developed symptoms, 15 had come for prenatal testing and a retest was 
automatically performed, three did not want to receive the test outcome at 
the time, (they had only co-operated to enlarge the reliability of their 
children’s test result), one wished to have no further contact, for one the 
physician advised against contact, two had moved abroad, for seven  the 
addresses were unknown, one was retested because a family member had 
received a reversed outcome and 25 did not react to either of the two letters 
and they had not been retested in The Netherlands. A total of 129 
respondents remained as the retest study group. 
Questionnaires 
Sixty-four of the 129 respondents also participated in the psychological 
follow-up investigation. Questionnaires, administered before respondents 
were retested, included: the Beck Hopelessness Scale (BHS),9 the Impact 
of Events Scale (IES),10 the General Health Questionnaire (GHQ-12),11 and 
the Hospital Anxiety and Depression Scale (HADS).12 The BHS is a twenty-
item scale. Subjects are requested to indicate whether they agree or not 
with the items, resulting in a feeling of hopelessness score between zero 
and twenty. A score of nine or higher is indicative of suicidal danger.13 The 
IES is a fifteen item four-answer categories likert type scale with two sub-
scales: intrusion and avoidance. It can be linked to a certain disease or a 
(traumatic) event. The intrusion sub-scale contains seven items that indicate 
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whether thoughts about HD come in to one’s mind involuntarily. The 
avoidance sub-scale contains eight items that indicate whether one tries to 
avoid these intrusive thoughts. The GHQ-12 is a four-answer categories 
likert type questionnaire with 12 items that is used to measure well being. 
The HADS is also a four-answer categories likert type questionnaire with 14 
items. It has a sub-scale with 7 items for depression and a sub-scale with 7 
items for anxiety. 
 
Table 1. Number and mean age of noncarriers and carriers by gender and 
retest decision 
 Noncarriers Carriers Total 
 n (mean age) n (mean age) n (mean age) 
Gender 
 Men 
 Woman 
 
34 (42.4) 
54 (40.5) 
 
13 (45.9) 
28 (40.8) 
 
47 (43.4) 
82 (40.6) 
Retest decision 
 No retest 
 Retest after info 
 Retest before info 
 
61 (42.3) 
21 (39.3) 
6 (37.2) 
 
21 (43.0) 
8 (38.0) 
12 (44.3) 
 
82 (42.5) 
29 (39.0) 
18 (41.9) 
Total 88 (41.3) 41 (42.4) 129 (41.6) 
 
Statistical Analysis 
Statistical analysis was carried out with SPSS. Differences between the 
number of participants who opted for the retest and the number of 
participants who did not, were analyzed with Pearson’s chi-square test or 
Fisher’s exact test, differences in age or in psychological variables between 
groups were determined with analysis of variance. 
RESULTS 
Description of the Sample 
The retest study group consisted of 129 respondents; 34 male and 54 
female noncarriers, and 13 male and 28 female carriers (Table 1). No risk 
reversals were revealed. Eighteen subjects who had received a linkage test 
result, were retested before our information between 1994 and 1997, 29 
subjects were retested after our information, and 82 others refrained from 
having the retest. If the 129 linkage testees included in the investigation are 
compared with the 81 who were not included, fewer carriers were in than 
out of the study sample (32% vs. 58%; p < .0002). The reasons are obvious; 
people who already have a clinical diagnosis of HD, have no need for a 
better test, and people who were excluded because they were retested 
when they came for prenatal diagnosis, are carriers. There were no gender 
differences, 59% of the men and 63% of the women were included (p = 
.315). There were also no age differences between participants and non-
participants (mean 42.0 vs. 41.9 years, F1, 208 = 0.01; p = .94). In the study 
group, there was no significant age difference found between carriers and 
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noncarriers, and men were older than women (Table 1). People who opted 
for the retest after our information, participated more often in the 
psychological part of the investigation (76%) than people who were retested 
before our information (56%), and people who refrained from the retest 
(39%; F2(2) = 11.93; p = .003). One interaction effect for age was found; 
carriers who were retested before our information were significantly older 
than carriers who were retested after our information. 
Differences in reassessment 
The first hypothesis, that more carriers would have the retest than 
noncarriers, was confirmed (49% vs. 31%). More carriers were retested 
before our information than noncarriers (29% vs. 7%, Table 2). Differences 
were also found between male and female carriers. Of the female carriers 
39% were retested and 8% of the male carriers were retested before our 
information. Male carriers were more often retested after our information 
than female carriers were (46% vs. 7%). 
 The second hypothesis, that more people with a high residual risk would 
have the retest, was confirmed for noncarriers, but not for carriers. For 
analysis of the residual risk, the linkage test receivers were divided into two 
groups of equal magnitude, that is, a low (≤ 2%) and a high residual risk 
(=3%) group. While there was no significant difference in uptake of the test 
among carriers, there was a significant difference among noncarriers. Of the 
noncarriers with a low residual risk, 9 out of 48 (19%) were retested, and in 
the high residual risk group 18 out of 40 (45%) were retested (figure 1). 
Noncarriers with a low residual risk had the retest significantly less often 
than noncarriers with a high residual risk. 
 
Table 2. Relation of genetic status, sex and magnitude of residual risk on 
the choice for the retest 
 
No retest 
 
Retest after
information 
Retest before 
information   
 n (%) n (%) n (%) χ² (2) p 
Noncarriers 
Carriers 
Men 
Women 
Residual risk ≤ 2% 
Residual risk ≥ 3% 
61 (69) 
21 (51) 
27 (57) 
55 (67) 
49 (73) 
33 (53) 
21 (24) 
8 (20) 
16 (34) 
13 (16) 
10 (15) 
19 (31) 
6 (  7) 
12 (29) 
4 (  9) 
14 (17) 
8 (12) 
10 (16) 
 
11.8 
 
6.4 
 
6.0 
 
.003 
 
.041 
 
.051 
Noncarriers 
 Men 
 Women 
 Residual risk ≤ 2% 
 Residual risk ≥ 3% 
 
21 (62) 
40 (74) 
39 (81) 
22 (55) 
 
10 (29) 
11 (20) 
7 (15) 
14 (35) 
 
3 (  9) 
3 (  6) 
2 (  4) 
4 (10) 
 
 
1.5 
 
7.1 
 
 
.473 
 
.029 
Carriers 
 Men 
 Women 
 Residual risk ≤ 2% 
 Residual risk ≥ 3% 
 
6 (46) 
15 (54) 
10 (53) 
11 (50) 
 
6 (46) 
2 (  7) 
3 (16) 
5 (23) 
 
1 (  8) 
11 (39) 
6 (32) 
6 (27) 
 
 
10.0 
 
0.3 
 
 
.007 
 
.848 
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 The third hypothesis, that younger people would have a retest more 
often, was confirmed for those people who were retested after our 
information. Individuals who were retested after our information, had a 
mean age of 39.0 years and people who were not retested had a mean age 
 
 
Figure 1. Percentage of carriers and noncarriers, with a low and high 
residual risk opting for retest 
 
of 42.5. There were no significant interactions with test outcome and 
gender. Carriers who were retested before our information were older than 
carriers who were retested after our information. 
 
Table 3. Differences in psychological indicators between carriers and 
noncarriers 
 Noncarriers 
(n = 42) 
Carriers 
(n = 22) F p 
Multivariate 
 
BHS 
IES-intrusion 
IES-avoidance 
GHQ-12 
HADS-anxiety 
HADS-depression 
 
 
3.5 
7.0 
3.9 
1.2 
3.2 
1.8 
 
 
6.7 
11.6 
8.5 
2.4 
5.2 
3.3 
2.88 
 
15.53 
6.39 
7.54 
2.30 
4.61 
4.01 
.016 
 
.000 
.014 
.008 
.134 
.036 
.050 
 
 In general, carriers had higher hopelessness scores (BHS), reported 
more intrusion and avoidance (IES) and scored higher on anxiety and 
depression (HADS) than noncarriers (Table 3). The fourth hypothesis, that 
carriers with a better psychological state will be more likely to choose to 
have the retest was confirmed for hopelessness (BHS) and well being 
(GHQ, Table 4). Carriers who were not retested had significantly higher 
scores on the BHS and GHQ than carriers who were retested (before and 
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after our information taken together). For noncarriers there were no 
significant differences in hopelessness and well being, but those who were 
retested (before and after our information) had higher HADS-anxiety scores 
than noncarriers who refrained from the retest. 
 
Table 4. Differences in psychological indicators between retestees and non-
retestees by test outcome 
 Noncarriers Carriers 
 No retest 
(n = 20) 
Retest 
(n = 22) F p 
No retest 
(n = 12) 
Retest 
(n = 10) F p 
Multivariate 
 
BHS 
IES-intrusion 
IES-avoidance 
GHQ-12 
HADS-anxiety 
HADS-depression 
 
 
3.0 
7.6 
4.6 
0.7 
1.8 
1.5 
 
 
4.1 
6.5 
3.4 
1.8 
4.5 
2.1 
3.55 
 
2.06 
0.30 
0.52 
2.61 
7.82 
0.85 
.01
.16
.59
.48
.11
.01
.36
 
 
8.3 
12.4 
10.1 
4.1 
6.1 
3.9 
 
 
4.8 
10.6 
6.6 
0.4 
4.2 
2.6 
2.92 
 
5.76 
0.28 
1.05 
6.08 
1.29 
0.68 
.04 
 
.03 
.60 
.32 
.02 
.27 
.42 
Missing hopelessness data 
Twenty-two out of the 41 carriers in our sample have filled out psychological 
questionnaires. Five of them had a hopelessness score of 9 or higher, 
which is indicative of suicidal risk.13 None of the carriers with such a high 
score choose for reassessment, while 10 of the 17 with a low hopelessness 
score did (Fisher's p = .03). We studied the possibility of extrapolating  this 
to the carriers who did not fill out questionnaires. We reasoned that the best 
predictor of the present hopelessness is the hopelessness score in the 
past,14-17 and therefore we examined the scores one  week after disclosure 
of the linkage test 7 to 10 years ago. For 10 out of 19 carriers for whom we 
did not have recent hopelessness scores, scores of one week after the 
linkage test were available. Three of them were in the range of 9 or higher. 
None of these individuals choose for reassessment either. If we combine 
these hopelessness scores, none of the 8 high scoring carriers choose for 
reassessment, while 14 of the 24 carriers with a low hopelessness scores 
did (p = .004). 
DISCUSSION 
HD carriers, as identified by linkage analysis (with a residual risk uncertainty 
of 1-9%) were more likely than noncarriers to have the linkage test 
confirmed  by mutation testing. This is in agreement with the expectation, 
which was based on the findings of Babul et al.5 Their reasoning was that 
carriers have less to lose. However, Babul et al. did not differentiate 
between levels of residual risk, and this can be a motive too. Nearly half of 
linkage tested individuals wanted to have more certainty and eventually had 
the mutation retest  carried out (figure 1). There is one exception however; 
only a minority of the group of noncarriers with a residual risk of 1 to 2% had 
the retest. Probably they did not feel the need to reduce their residual risk 
any further. Noncarriers with a residual risk of 3% or more, on the other 
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hand, and, in particular, anxious noncarriers, chose to retest as often as 
carriers. 
 Carriers had the retest more often carried out before we contacted them. 
This holds especially for female carriers and carriers with a positive view on 
the future. It can be inferred that for them the need for certainty was 
strongest. Also, carriers may have more contacts with other carriers, family 
members, or members of the Huntington Association, they might be more 
eager for information about HD in general, and they may have had more 
knowledge of innovation in the field of testing for HD than noncarriers. 
 People who were not retested were older than people who were retested 
after our information. Reasons that were mentioned by them to have the 
test, were planning for the future and the family. Another reason for a lower 
age of the retest group is that the probability that an a-symptomatic at risk 
person has a disease causing mutation gradually decreases with increasing 
age.7 For example, if someone with a decreased linkage based test result, 
is over 70 years of age, the chance of developing HD has become minimal, 
and there will be hardly any motivation to have the retest. 
 In general, identified carriers had more feelings of hopelessness, were 
more anxious, had more intruding thoughts, and reported more avoidance 
behavior than noncarriers, which may reflect the depressing, frightening and 
intrusive impact of a perspective overshadowed by the disease. These 
feelings however, could also be a result or symptom of HD in an early 
stage. Interestingly, carriers who decided to have a retest had fewer 
hopeless feelings and had a better sense of well being than carriers who 
refrained from the retest. A possible explanation for this is that those 
carriers with a relatively positive view on the future are more inclined to 
have the retest in the (slight) hope of a low risk test outcome. None of the 
persons with a high score on hopelessness who had received a high-risk 
linkage test outcome chose to have the retest. Noncarriers who had the 
retest were more anxious than noncarriers who did not have it. The anxious 
noncarriers may have opted for the retest as an attempt to reduce their 
anxiety, while less anxious noncarriers may not have a need to reduce 
anxiety. 
 We observed a gender difference for carriers who were retested before 
our information and the carriers who were retested after our information. 
Female carriers were more often retested before our information than men 
were, and men were more often retested after our information. Women may 
be more inclined to be actively sure of their genetic status, this may reflect 
the more intimate involvement of women with the process of reproduction 
and child rearing, both biologically and emotionally.18 Moreover, if women 
wish to have children, most would like to have them before they reach a 
critical age. An indication of this is the fact that women in our sample are 
younger than men. 
 Remarkably, 92% of the at risk people, who had not received a linkage 
test result because of uninformative DNA markers, opted for the retest, and 
only 30% who had not received it because of an uninformative family 
structure were retested. We reasoned that individuals who did not receive a 
linkage test outcome because of uninformative DNA markers had gone 
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through the whole process of counseling testing, giving blood etc. They may 
have been more involved in the process of testing, and much more eager to 
receive eventually a test outcome. The people at risk who were not tested 
because of an uninformative family structure had not gone through that 
whole process, and the testing procedure was terminated at a much earlier 
stage. They may have had family members who objected, they may have 
found it too troublesome to ask co-operation of relatives, or they may have 
found a way to cope with this uncertainty. 
 Fifty-one percent of the people at risk who did not receive a linkage test 
outcome, either due to an uninformative family structure, or due to 
uninformative markers, were retested. This is considerably lower than the 
87% that Babul et al.5 found for a hypothetically certain test. Also, in their 
study, a much larger proportion of linkage testees with an informative 
outcome indicated that they would have a certain test carried out, than in 
our study. It is obvious that there is a discrepancy between the hypothetical 
option of a more certain test and actual behavior. An analogous discrepancy 
was observed between interest in a predictive test before such a test was 
available and actual participation after the linkage test was introduced. 
Before the predictive test became available, 57% to 84% of the at-risk 
individuals, indicated interest in the predictive test.19-21 Since its introduction 
in 1987 the uptake (2-24%), has fallen significantly behind expectation.8 18 22-
24 
 Most studies show that the rate of retesting is low; Benjamin et al.6 
reports a rate of 10.4%, Holloway et al.25 a rate of 6% and Maat-Kievit et al.8 
a rate of 7%. The retest rate in our study group is larger than the retest rate 
mentioned in a study from Maat-Kievit et al.8 due to selection of the study 
group; people whose addresses were unknown and those who did not react 
to the invitation letter for example, were not included in our study. Also, in 
our study a number of people were discovered to have had a retest in 
another center for clinical genetics in The Netherlands. Our study showed 
that the retest rate was enlarged by the information program from 14% to 
36% retests. Although this information program enlarged the number of re-
assessments, the majority of the linkage testees did not have the retest, 
even after our information. It seems that the residual risk of the linkage test 
is not seen by most as a burden that must be extinguished. It is also 
possible that the group who had gained more certainty about their genetic 
status with the linkage test, did not want to risk that certainty with a new test 
procedure and they did not want to disturb the subject of HD in their minds, 
which a retest would inevitably do. 
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ABSTRACT 
Background and objective: The majority of individuals at risk for 
Huntington's disease (HD) is reluctant to learn more precisely about the risk 
of becoming affected, as is suggested by the low uptake of the predictive 
test for HD. Subsequently, the future expectancies of individuals at risk are 
often based on rough risk estimates such as 50% (child of a patient) or 25% 
(grandchild of a patient). Individuals at risk can be offered a better risk 
estimate based on their current age, length of the disease causing CAG-
repeat in close relatives, information on the age at onset (AO), or test 
results of family members. 
 Method: Regression modelling and Cox regression determined relations 
between ages at onset and CAG repeat length in a sample of 755 tested 
individuals. 
 Results: A model for calculating the adjusted residual risk status was 
constructed. This model is implemented in a spreadsheet that can be used 
in genetic counselling. 
 Conclusions: This model and accompanying spreadsheet broadens the 
information clinical geneticists and genetic counsellors can offer. They will 
be able to provide a best estimation of the residual risk status for individuals 
in their circumstances. This might help in the decision to be tested and the 
preparation for the test result. 
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INTRODUCTION 
As an exemplary autosomal dominant hereditary late-onset disorder, 
Huntington disease (HD) shows a wide variability in age at onset (AO), with 
a mean between 38.6 and 55.8 years for proven carriers of the HD-gene, 
and a range of 2 to 80 years.1 HD is caused by a CAG expansion mutation, 
coding for an expanded polyglutamine stretch in the cognate protein. 
Affected individuals have CAG repeat lengths between 36 and 250 in the 
HD gene2-4 with some overlap between normal and disease ranges, 
because reduced penetrance is observed in the lower range of the CAG 
repeat length (36-39).5 CAG repeat length is the major determinant of, and 
inversely related to AO.5 6 Other modifiers for AO than the expanded CAG 
repeat are GluR6 gene polymorphism,7 the normal CAG repeat length,8 9 
UCHL1 gene polymorphism,10 the adjacent CCG repeat,11-14 a ∆2642 
deletion codon,14-17 apolioprotein E with genotype ε2ε3,18 possibly other, yet 
unknown genes at 4p16, 6p21-23 and 6q24-26,19 and also the gender of the 
affected parent and grandparent.20-24 
 Boundaries of the CAG repeat length have been defined for HD: < 27 is 
normal, 27-35 intermediate, 36-39 disease with reduced penetrance, and > 
39 regular disease.25 Not all carriers of the HD-gene with a CAG repeat 
length in the reduced penetrance range will develop HD-symptoms during 
an average life-span of 75 years, whereas few with a CAG repeat length of 
more than 48 remain symptom free beyond the age of 40. Two research 
groups5 6 26 have calculated ages at HD-onset for various CAG repeat 
lengths, based on large sample sizes, though with substantial differences. 
For the expanded repeats studied, Maat-Kievit et al.5 reported a 10 years 
higher median AO than Brinkman et al.6 did. Perhaps, this difference is due 
to the sampling strategies used or to the ways in which the age of first HD-
symptomatology, or lack thereof, were defined and determined. 
 Predictive testing is possible since 1983, though the majority of the 
individuals at-risk (76-98%) do not wish to be tested.27-31 The fear of being 
unable to cope with the personal diagnosis of a future disease is the main 
reason for reluctance.27 32-40 Other reasons for refraining from having the 
predictive test are concern for the possible risk increase for their children, 
absence of treatment for HD, potential problems with insurance, financial 
costs of testing, and the definite nature of the results.27 28 31-33 35 41-46 The low 
uptake of the predictive test may reflect that the majority of the individuals at 
risk is reluctant to learn more precisely about their risks of becoming 
affected. Future expectancies of individuals are mostly based on rough lay 
risk estimates such as 50% (child of a patient) or 25% (grandchild of a 
patient). When age advances without signs of the disease, the risk of being 
a mutation carrier decreases.47 Indeed, each child of an affected patient has 
an a priory probability of 50%, regardless of the sex of parent or child. The 
actual risk, however, may differ considerably and is critically dependent on 
the age of the individual. Harper and Newcombe47 provided tables with the 
actual residual risk at a certain age. The probability that an asymptomatic 
person at risk has a disease-causing mutation remains close to 50% during 
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childhood and young adulthood, but gradually decreases with increasing 
age. At the age of 55, the risk, based on these tables, of being a carrier of 
the gene is about 25%. Consequently, the children at 50% risk for HD will 
often have to make reproductive decisions before there is any substantial 
decrease in risk. The Harper and Newcombe tables47 are useful in older age 
groups, where the question often is the age at which one can reasonably be 
sure of having escaped the disease. It turns out however, that the risk at 
older ages remains higher than expected. 
 Some individuals from large families with a considerable number of 
patients over two generations or more refer to the age of onset in their 
affected relatives. There is often hope for a relatively late onset when the 
affected relatives became ill at higher age, but also despair when the mean 
age at onset is relatively low. A number of studies, however, reported a 
wide range of variation in AO within families, which can now mainly be 
explained by the instability of the CAG repeat.48 Another situation in which 
one could depart from the Harper and Newcombe tables,47 was when a 
sibling had already developed juvenile HD. 
 Prior to considering a predictive test, individuals at risk may wish to learn 
about their residual risk status (RRS), that is, their risk of being an HD-
carrier given their present age and unaffected state. In addition, if they 
remain symptom-free, they may wish to learn what their expected RRS will 
be in the years to come. As part of the predictive testing process, a more 
precise residual risk estimate could broaden the genetic counsellor's 
repertoire of tools for informing test applicants in a pre-test situation or 
counselling session. Moreover, informing a test candidate about the RRS 
can help him or her to prepare for the test result or to withdraw from the 
test. Consider, for instance, an individual with a prior risk of 50% who has 
reached the age at which the mother displayed the first symptoms. The 
mother’s CAG repeat length is a straightforward estimate of his or her own 
CAG repeat length given that he or she is a carrier. Likewise, because AO 
is related to repeat length, the best estimate of one's own AO is one's 
mother’s AO. Therefore, if this individual has inherited the mutation with the 
same length, the probability of developing symptoms is 50% both before 
and after this age. Given the fact that he or she is symptom free at this age, 
it can be shown that the prior risk of 50% has been reduced to 0.5/(1+0.5) = 
33%. Assume further that this individual has an adult child who is hesitant to 
start a family because of the risk of HD for his or her offspring. Then the risk 
of this child has decreased from the prior risk of 25% to 33% / 2 = 16.7%. 
Generally, if the relevant RRS is disclosed to the adult child, he or she is 
then —without being tested— optimally informed of the changed risk for any 
future children, which has, under these circumstances, diminished from a 
prior risk of 12.5% to approximately 8%. In conclusion, determining the RRS 
for asymptomatic individuals at risk, whose ages are beyond the AO of the 
affected parents, is clearly important for themselves and for their (future) 
offspring. 
 In order to estimate the RRS, one must first verify, preferably by 
neurological examination, that the proband is asymptomatic, if the at risk 
person wants to be informed about his or her neurological status. Secondly, 
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the CAG repeat length, in case the proband inherited the HD-gene, must be 
estimated, by using the CAG repeat length of the parent. If the parent did 
not have a mutation test, the repeat length of the parent can be estimated 
from the parent’s AO. Also, the gender of the affected parent is critical, as 
has been shown in several studies.20-22 24 Paternal transmission frequently 
results in a larger CAG repeat length than maternal inheritance. Thirdly, the 
probability that he or she is still without symptoms must be determined, 
given the estimated repeat length. Finally, the RRS can be calculated. To 
improve RRS-accuracy of asymptomatic target individuals even further, 
counsellors must also take into account any close family members who 
have been tested mutation negative.49 
 The aim of this study is to estimate the RRS of a proband as a risk 
refinement to broaden the information possibilities of the genetic counsellor. 
The robustness of this estimate, as indicated by confidence intervals (CI), 
can be of importance for the clinical value. There is a difference between a 
RRS with a large CI and one with a small CI. The former has less clinical 
value than the latter. Nevertheless, the best estimate of the RRS is 
independent of the CI. 
 For practical purposes we will provide a spreadsheet in which the age of 
the proband, the CAG repeat length or AO of the affected parent, and the 
number of negatively tested family members can be entered, resulting in the 
best estimate of the RRS. The more data will become available, the more 
precise RRS estimates can be effectuated using this method. 
METHODS 
Subjects 
Data from all 755 individuals enrolled in the Dutch cohort study, tested 
between 1993 and 2000, with a CAG repeat length of more than 35, were 
included. Our subjects came from 344 different HD families, 614 were 
affected, and 141 were asymptomatic gene carriers. More details have been 
described elsewhere.5 Data were available in two sets (I and II), including 
755 cases with CAG repeat lengths, AOs, and information on clinical status 
(I), and a subset of 127 individuals for whom CAG repeat length of the 
affected parent was also available (II). 
Data Analysis 
Relations between CAG repeat length of the affected parent and the child 
were analysed with regression modelling in data set II. Relations between 
AO and CAG repeat length and the probabilities that carriers were still 
asymptomatic were analysed with Cox regression in data set I. Dependent 
on the pedigree, favourable test outcomes of family members can decrease 
the RRS. This influence was determined with Bayes' theorem. 
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RESULTS 
Estimation of Repeat Length. 
Regression modelling, with CAG repeat length of the proband as the 
dependent variable, and CAG repeat length and gender of the affected 
parent as the independent variable resulted in a regression equation with 
significant linear and quadratic CAG components for the parent. This model 
accounted for 71% of the total variance of the CAG repeat length of the 
child, and has the following equation: 
 
parentparentparentchild genderCAGCAGCAG *16.2)8.44(*04.0)8.44(*88.03.44
2 +−+−+=  (1) 
 
with genderparent = 0 for an affected mother, and genderparent = 1 for an 
affected father. 
 
If the CAG repeat length of the affected parent is not known, but the CAG of 
a sibling is, then the parent's CAG can be estimated from the siblings CAG 
using equation (1). In a second step the proband's CAG can be estimated, 
resulting in an CAG estimate that is equal to the sibling's. Thus the best 
estimate for the proband's CAG is the CAG of the sibling. 
Estimation of being unaffected. 
Let the probability that an individual is without symptoms, given that he or 
she is a carrier, equal q. The proportional Cox regression model from AO 
and CAG repeat length in the data set I resulted in the following equation: 
 
 
)8.45−(*305.0= CAGeSq  (2) 
 
In this equation, S is the survival function at the mean of the covariates 
(Appendix 1). The probability that an individual has developed symptoms 
before the estimated AO is 50%. Consequently, the probability that the first 
symptoms emerge thereafter is also 50%. To estimate the CAG repeat 
length of the parent from the AO of the parent, the CAG repeat length 
corresponding to a q of 0.5 must be estimated. Thus, if one substitutes 0.5 
for q in equation (2), this can be converted into: 
 
8.45
305.0
))ln(ln())5.0ln(ln( +−−−= SCAG  (3) 
 
 To illustrate the procedure, we will compute the RRS of a proband 
without symptoms at age 40, in a case where the father had his first 
symptoms at age 40. The probability of being without symptoms at age 40 is 
.710, given that one has inherited the gene (Appendix 1). From (3) we can 
estimate the CAG repeat length of the father: 
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Substitution in (1) gives the estimate of the repeat length of the proband: 
 
 50*16.2)8.44(*04.0)8.44(*88.03.44 2 ≈+−+−+= parentparentparentchild genderCAGCAGCAG
 
Finally, substitution in (2) gives the estimate of q, i.e. the probability that the 
proband is without symptoms at age 40 and a father who had the first 
symptoms at age 40: 
 
 
 
30.071.0
)8.4550(*305.0 ≈= −eq
Calculation of Residual Risks. 
We used Bayes’ theorem as follows. Let the prior risk Pr(C) of an individual 
being a carrier of the HD-gene at a given age, based on the family pedigree, 
equal p and the probability that this individual is without symptoms at this 
age Pr(NS|C) equal q. Let Pr(C|NS) denote the probability that the individual 
is a carrier of the HD-gene, given that he or she is without symptoms, 
Pr(NC) the probability that an individual is a non-carrier, and Pr(NS) the 
prior probability of being without symptoms, then Bayes’ theorem states 
that: 
 
Pr(C|NS) =>Pr(NS|C)*Pr(C)@/Pr(NS) 
 =>Pr(NS|C)*Pr(C)@/>Pr(NS|C)*Pr(C) + Pr(NS|NC)*Pr(NC)@ 
 = (q*p)/{(q*p)+>1*(1-p)@} 
 = p*q/>p*(q-1)+1@ (4) 
 
For individuals at a prior risk of 50% (p=0.5), this formula (4) reduces to: 
 
Pr(C|NS) = 0.5q/(0.5q-0.5+1) 
 = q/(q+1) (5) 
 
And: 
 
Pr(NC|NS) = 1 –>q/(q+1)@ 
 = 1/(q+1) (6) 
 
Consider, the foregoing example of an asymptomatic individual with a prior 
risk of 50%, who has a 0.30 probability of being without symptoms if he or 
she is a carrier, based on age and AO of the affected parent. Then the 
estimated risk of being a carrier Pr(C|NS), following formula (6), equals 
0.30/1.30= 0.23. 
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 Now let us also take into account any children of the asymptomatic 
individual who have been tested mutation negative. Let Pr(C|NS;n) be the 
probability that an individual is a carrier, given that he or she is without 
clinical signs or symptoms and has n children tested mutation negative. It 
can then be shown49 that: 
 
RRS = Pr(C|NS;n) = q/(q+2n) (7) 
 
This holds on the condition that no child has been tested positive. As an aid 
for calculating the RRS, we provide an MS-Excel spreadsheet that can be 
downloaded from our website (see correspondence information). 
 Further information about calculating risk changes in more complicated 
pedigrees is available upon request, including a general formula that can be 
used for all situations. 
DISCUSSION 
The increased number of data on CAG-repeats and ages at onset within 
families allowed us to develop the presented model. This model provides 
new alternatives for risk refinement that can be offered to individuals at risk 
who have not (yet) been tested. Applying this model can only lead to an 
estimation of decreased risk, while the mutation test can yield the 
irreversible outcome that one carries the HD gene. Nevertheless, this model 
is not primarily aimed at individuals who do not wish to be tested for a 
variety of reasons. Our model is aimed at broadening the information that 
genetic counsellors can offer, based on absence of symptoms. Establishing 
early HD signs is difficult. Self-reports of the individuals at risk with regard to 
being unaffected are not sufficient to rely on, and neurological examination 
remains the most accessible, reliable, and cost-effective means of 
determining onset of clinical disease.50 However, De Boo et al.51 reported 
considerable disagreement amongst HD-experienced neurologists with 
regard to neurological examinations in the earliest phase of the disease. 
Neuropsychological motor assessment proved to be more sensitive to early 
changes than neurological judgments. Obviously, the first HD-symptoms are 
hard to recognize, and not all individuals show the same first symptoms52 
Some individuals display motor symptoms first, whereas in others first 
symptoms are psychiatric. Further studies may reveal the extent to which 
hereditary components contribute to these differences. 
 It must be noted that all our estimates are based on empirical data, and 
hence all values contain some uncertainty: the estimate of CAG repeat 
length of an affected or at-risk individual depends to some extent on the 
techniques used in the mutation test and all regression analyses put 
confidence limits to the coefficients in the equations. This means that all 
calculations are based on the best possible estimates of a parameter, and 
consequently all values of the CAG of a proband and the Residual Risk 
Status (RRS) must be considered as best possible estimates too. Given this 
uncertainty, counselees will generally be interested to learn whether the 
original (prior) risk of the target individual has substantially changed with 
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increasing age, and what the best possible estimate of the RRS would be, 
given their situation. This might help in their decision to be tested and their 
preparation for the test result. This decision can depend on the actual RRS 
and the RRS in the near future. From the CAG repeat length estimated with 
our model and the tables published by Langbehn et al.26 it can be 
determined whether the individual is at a critical age regarding onset. During 
this critical period the decrease in RRS is most prominent, which can affect 
the decision to be tested soon or to postpone the test for a few years. 
 Recently, concern has arisen for individuals at risk for HD regarding 
employment.53 Burgermeister described how a teacher at risk was refused a 
job because of a family history of HD.54 In fact this topic is an extension of 
insurance problems that have been raised previously.38 55 Assuming that 
many will hold on the a priori risk, all those involved should be better 
informed about the actual risk to develop HD. A refinement of the actual risk 
for HD without actually performing a test can help to make judgements that 
are more adequate. Moreover, this is always beneficial for individuals at risk 
because the RRS is always lower than the a priori risk. 
 With our model and the accompanying spreadsheet, clinical geneticists 
and genetic counsellors will be able to provide a best estimation of the 
residual risk status for individuals in their circumstances. The model also 
allows establishing the slope of decline in risk status for the years to come 
by determining the changed risks for future ages, given that the individual at 
risk remains symptom-free. 
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APPENDIX 1. 
Survival function at the mean of covariates. 
 
Age 
in years Survival 
 Age 
in years Survival 
Age 
in years Survival 
4 0,9998648296 32 0,9211905093 60 0,0629806062 
5 0,9998648296 33 0,9078111164 61 0,0602230337 
6 0,9998648296 34 0,8983660080 62 0,0498256866 
7 0,9995683096 35 0,8725536578 63 0,0359824731 
8 0,9993674982 36 0,8511427002 64 0,0279641391 
9 0,9993674982 37 0,8256689172 65 0,0209831443 
10 0,9988069390 38 0,7992705745 66 0,0137979672 
11 0,9988069390 39 0,7737601077 67 0,0102777203 
12 0,9984927618 40 0,7102701388 68 0,0061011707 
13 0,9984927618 41 0,6872908368 69 0,0046470872 
14 0,9984927618 42 0,6479470703 70 0,0024215613 
15 0,9984927618 43 0,5865683119 71 0,0018075845 
16 0,9978580841 44 0,5543537282 72 0,0011619988 
17 0,9972068868 45 0,5093739451 73 0,0011619988 
18 0,9965294999 46 0,4714799104 74 0,0010279425 
19 0,9965294999 47 0,4484252329 75 0,0004266614 
20 0,9945680373 48 0,4043457776 76 0,0002448453 
21 0,9908924474 49 0,3804504242 77 0,0001586526 
22 0,9884457913 50 0,3126109815 78 0,0000512595 
23 0,9845913076 51 0,2924192908 79 0,0000094335 
24 0,9821489122 52 0,2650219915 80 0,0000023917 
25 0,9773467405 53 0,2289791507 81 0,0000008359 
26 0,9733702412 54 0,2037671950 82 0,0000001716 
27 0,9679857532 55 0,1714190410 83 0,0000000063 
28 0,9634262994 56 0,1390389326 84 0,0000000063 
29 0,9574896216 57 0,1163949018 85 0,0000000063 
30 0,9434607655 58 0,0937128217 86 0,0000000000 
31 0,9407665592 59 0,0854611583   
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ABSTRACT 
Objective: The Behavior Observation Scale Huntington (BOSH) was 
developed to obtain a detailed description of the manifestation of 
Huntington's disease in the final stages in a nursing home. 
 Background: The Unified Huntington's Disease Rating Scale (UHDRS), 
developed to assess Huntington's patients' clinical capacities, does not 
differentiate adequately in later stages of the disease. A scale easy to 
administer by nursing personnel for progression of the disease in later 
stages was needed. 
 Method: Two pilot questionnaires preceded the final version of the 
BOSH. Observers administered the final version twice independently on 91 
patients in four nursing homes. 
 Results: The BOSH contains 32 items in three subscales: 1) Activities of 
daily living (ADL), 2) social-cognitive functioning, and 3) mental rigidity and 
aggression.  Internal and inter-rater reliabilities were between .83 and .95.  
 Conclusions: A linear relation was found between disease duration and 
deterioration of ADL. Non-linear relations were found between 1) ADL and 
rigidity-aggression, and 2) ADL and social-cognitive capabilities. Rigidity 
and aggression become more frequent as the disease progresses, later on 
this behavior diminishes. Social-cognitive capabilities deteriorate more 
rapidly in later stages. 
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INTRODUCTION 
Huntington's disease (HD) is an autosomal dominant neurodegenerative 
disease, characterized by disturbance of movements (chorea and 
hypokinesia), progressive dementia and affective disturbances.1 The end 
stages of the disease often warrant admission in a nursing home. The mean 
age at onset is between 30 and 50 years and the specific features of the 
disease have justified the establishment of specialized wards. Since the mid 
eighties of the previous century much experience and knowledge has been 
acquired in caring for HD patients. In later stages of the disease, the patient 
can hardly perform any action without help, and communication is difficult or 
impossible. In these stages, there is a lack of insight in the nature and 
course of the clinical manifestations of the disease. This lack of insight 
hardly allows an individually tailored caring program. 
 Shoulson & Fahn2 described a categorization of the course of the 
disease in five stages according to engagement in occupation, capacity to 
handle financial affairs, capacity to manage domestic problems, capacities 
to perform activities of daily living (ADL), and the place where care can be 
provided. They proposed this categorization for functional designations of 
patients for care evaluation, and it was to be confirmed by further 
investigation. However, Shoulson and Fahn indicated that the broad 
assessment of functional capacities is probably not sufficiently sensitive to 
register marginal clinical effects,2 and it seems not to be adequately 
sensitive to cognitive and psychiatric symptoms.3 
 The Huntington Study Group4 developed the Unified Huntington's 
Disease Rating Scale (UHDRS) to assess four domains of clinical 
performance and capacities in Huntington's disease: motor, cognitive, 
behavioral and functional assessment. A word fluency test, the Symbol Digit 
Modalities Test and the Stroop Color Interference Test assess cognitive 
abilities These tests can hardly be administered in the later stages of HD, 
when speech or write capacities have deteriorated too far. Functional 
capacities are administered by 25 dichotomous (yes/no) items. In later 
disease stages, all functional capacity items are scored as "no". For these 
reasons, differentiation of the UHDRS is limited in the later stages of the 
disease. For administration of the UHDRS more than an hour is needed, 
requiring a skilled neurologist and a physician or psychologist familiar to the 
patient.  We developed the Behavior Observation Scale Huntington (BOSH) 
as a quicker and easier instrument. The BOSH should allow repeated 
monitoring for longitudinal assessment, and it is meant to make an inventory 
of the behavior in the later stages of the disease. 
SUBJECTS AND METHODS 
Two pilot questionnaires preceded the final version of the BOSH. The first 
pilot was constructed in two Dutch nursing homes (Overduin in Katwijk, 
Heemhof in Beekbergen). We developed the second pilot and the final 
version also in two other nursing homes (St. Jacob in Amsterdam, The 
Netherlands, Home Marjorie in Heist-op-den-Berg, Belgium). The pilot and 
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final version of the BOSH were administered for all but two patients. The 
latter were admitted to a psychiatric hospital, one patient because of 
extreme aggressive behavior, the other because of extreme anxiety and 
delusions. The clinical details of the participants are given in Table 1. 
 
Table 1. Number of participants, age and years of care in pilots and final 
questionnaire 
   n mean age (years) 
mean years of 
admission 
 Nursing Home  ♂ ♀ total ♂ ♀ total ♂ ♀ total 
Overduin a
   day-treatment 
 11
5
11
1
22
6
48
52
48
55
48
53
2.4
1.2
2.7 
0.2 
2.5 
1.0 
Heemhof  11 10 21 40 41 41 3.2 1.3b 2.3 
1st
pilot 
Total  27 22 49 45 45 45 2.5 1.8 2.2 
Overduin a
   day-treatment 
 9
4
17
1
26
6
46
55
51
45
50
53
3.3
2.8
3.2 
0.8 
3.9 
2.0 
Heemhof  14 17 31 46 50 48 3.6 3.8 3.7 
St. Jacob  4 7 11 59 51 54 1.8 3.3 2.7 
Marjorie  6 4 10 43 43 43 1.2 1.8 1.4 
2nd  
pilot 
Total  38 46 84 48 50 49 2.8 3.2 3.0 
Overduin a
   day-treatment 
 10
4
18
3
28
7
47
56
55
50
52
53
3.1
3.5
4.4 
0.8 
3.9 
2.0 
Heemhof a
   day-treatment 
 15
1
17
6
32
7
48
49
49
53
49
53
3.8
0.5
3.6 
0.3 
3.7 
0.3 
St. Jacob  5 3 8 50 54 52 1.8 4.3 2.8 
Marjorie  6 3 9 45 38 42 1.8 2.7 2.1 
Final 
version 
Total  41 50 91 49 51 50 3.0 3.2 3.1 
Note.     a Clinic only;     b F(1,18) = 4.87; p = .04. No other differences are below p = .05 level for 
gender. 
 
 The first pilot questionnaire was based on 11 characteristics of the HD-
patient, according to the observations of the staff of the nursing homes: 1) 
inflexible behavior, 2) need for social care, 3) need for mental care, 4) need 
for physical care, 5) communication problems, 6) choking problems, 7) 
uncontrolled eating and drinking behavior, 8) self-orientated behavior, 9) 
repetitive behavior, 10) aggressive behavior, and 11) inability to perform 
complex actions. The pilot questionnaire contained 32 four-answer-category 
items and was administered by nursing personnel to 49 patients. Nursing 
personnel were given written instructions for filling in the rating scale. 
Principal component analysis (PCA) revealed 6 designated components; 
speech capability, mental rigidity-aggression, social-cognitive capacities, 
obsessive-compulsive behavior, voraciousness and deterioration of ADL. 
 For the construction of the second version we restructured the items in 
line with the 6 components that emerged from the first pilot. Twenty-four 
items with the highest loadings on each component were selected, on the 
premise that these did not have too large a conceptual overlap. The 
inclusion of items with a high conceptual overlap, such as "choking while 
eating" and "choking while drinking" would unduly raise the internal 
consistency measure. Four items with lower component loadings, which 
were considered as clinically essential aspects of HD, were added. Four 
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items from the functional assessment sub-scale of the UHDRS4 were 
included because they were also considered essential to the manifestation 
of HD. Infrequently scored response categories were reformulated. 
Behavior such as "the patient bolts every portion of food at once, and 
cannot be controlled" was not observed. We toned this response category 
down to "tends to bolt food and cannot be corrected". Ambiguous items, 
double questions and items with an overlap in the response possibilities, as 
well as items with gaps between answer possibilities were reformulated. 
The layout was made uniform for all items and carefully arranged after the 
recommendations of Dillman.5 The second version was administered to 84 
patients in one Belgian and three Dutch nursing homes. For each patient 
different nurses in charge of the daily care of the patients administered the 
scale twice independently. Instructions were printed on the questionnaire. 
 For the third and final version, we reformulated the 32 items again to 
avoid overlap and gaps. Ambiguousness was reduced and items were 
rearranged in a more logical order. Routings for outpatients and for tube fed 
patients were introduced. The final version was administered in Dutch to 91 
patients in the 4 nursing homes. 
 Factor or principal component analysis requires that the number of cases 
is at least 5 times the number of items,6 which meant that at least 160 cases 
were needed. For the third version of the BOSH, 91 patients were available, 
largely the same population as was included in the second version. The 
required number of cases was achieved by having the scale completed for 
the 91 patients twice, independently by different observers. Two data sets 
were created in this way and single measure intraclass correlation 
coefficients (ICC's) could be computed. 
 Missing values were imputed using the singular Expectation 
Maximization procedure (EM)7 in the SPSS missing value module. EM is an 
algorithm that estimates the means, covariances, and the Pearson 
correlations of quantitative variables. It is an iterative process, which uses 
two steps for each iteration. The E step computes expected values 
conditional on the observed data and the current estimates of the 
parameters. The M step calculates maximum likelihood estimates of the 
parameters based on values computed in the E step.8 This imputation 
procedure was performed in both samples separately before performing 
PCA. The component structures in both data sets should be comparable. 
 Duration of care was computed from the administered date of admission 
to the nursing home or start of the day treatment. Disease duration was 
computed from medical information on age at onset. We determined the 
age at onset from the first neurological or psychiatric signs that could be 
attributed to HD. Relations between principle components among each 
other and with disease and nursing duration were analyzed with regression 
modeling. 
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RESULTS 
Administration of the questionnaires took 10 to 15 minutes, with a mean of 
14 minutes. The 91 patients included 41 men (mean age 48.5 years, sd 9.5) 
and 50 women (mean age 51.2 years, sd 11.1), 77 inpatients and 14 
outpatients. 
Principal components 
A three-component PCA solution was found in both samples. After a 
VARIMAX rotation, these components could be labeled as ADL, social-
cognitive capabilities, and rigidity-aggression. Principal component loadings 
of the individual items are summarized in Table 2. Characteristics of the 
subscales are summarized in Table 3. The statistics for all three scales 
suggest an acceptable level of internal consistency.9 
 
Table 2. Principal component loadings for 3 factors of 32 BOSH items 
Component / item loading 
ADL  
  4. Going to the toilet .84 
  2. Going to bed .83 
  5. Mobility .82 
  9. Comprehensibility through nonverbal communication .81 
  7. Voice control and articulation .79 
30. Eating and drinking .78 
  1. Washing and getting dressed .77 
  8. Intelligibility .74 
29. Choking while eating or drinking .57 
Social-cognitive  
18. Seeking contact and receptiveness .78 
12. Recollection of recent events important to patient .77 
15. Patient knows staff members and fellow inpatients by name .73 
10. Ability to understand verbal communication .73 
16. Emotionalism .70 
13. Remembering appointments .69 
14. Ability to occupy himself/herself and participate in organised activities .66 
17. Awareness of being ill .65 
  6. Ability to understand complex actions .61 
19. Contact with family, friends or fellow inpatients .61 
11. Ability to understand nonverbal communication .58 
Rigid-aggressive  
26. Patient is open to correction .81 
25. Patient accepts what you say .80 
21. Degree to which verbal and physical aggression can be corrected .77 
24. Patient causes problems if a fixed routine is not adhered to .72 
22. Tendency towards verbal and physical aggression .72 
23. Patient tries to exceed the limits of standing agreements or house rules .72 
20. Showing consideration for fellow inpatients .67 
27. Performance of specific activities is impeded .59 
28. Patient performs stereotypical, apparently aimless activities .42 
32. Bolting food .42 
31. Voracity and insatiability .40 
  3. Going to bed on time .25 
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Table 3. Characteristics of the subscales 
Scale number of items 
% variance 
sample 1-2 
α 
sample 1-2 ICC mean (sd) 
ADL 
Social and 
   cognitive abilities 
Rigidity and 
   aggression 
9 
 
11 
 
12 
23-20 
 
18-20 
 
16-16 
.94-.94 
 
.92-.91 
 
.83-.86 
.95 
 
.90 
 
.85 
2.25 (0.88) 
 
2.10 (0.79) 
 
1.63 (0.48) 
Note.     ICC = intraclass correlation coefficient;  ADL = activities of daily living 
 
 Individual sub-scale scores were computed by dividing the total score by 
the number of valid items of the subscale involved. In this way, the original 
clinical meaning of the values was preserved (Table 4). 
 
Table 4. Scale values and clinical denotation 
 1 2 3 4 
ADL self-supporting guidance needed care needed nursing required 
Social-cognitive unaffected first signs of decay 
contact still 
possible 
contact not 
possible 
Rigidity-aggression never sometimes often always 
Note.     ADL = activities of daily living 
Relations with disease and care duration 
A linear relation was found between ADL deterioration and duration of care 
(Table 5). Patients had higher ADL deterioration scores when they had 
been longer institutionalized or had been in day treatment for a longer 
period. Women tended to have (p = .04) worse ADL scores than men, 
means 2.45 and 2.00 respectively. 
 
Table 5. Regression modeling of principal components on duration illness, 
of institutional care, gender and age. 
 ADL (R² = 0.38) 
Social-cognitive 
(R² = 0.35) 
Rigid-aggressive 
(R² = 0.24) 
Independent variables β p β p β p 
Duration of illness 
Squared duration of illness 
Duration of care 
Squared duration of care 
Gender (men=1; women=2) 
Clinic / day care 
Age 
.10 
.12 
.50 
-.14 
.21 
-.19 
-.07 
.48 
.37 
.001 
.31 
.04 
.07 
.54 
-.07 
.27 
.14 
.14 
.03 
-.32 
.21 
.63 
.04 
.34 
.34 
.74 
.004 
.07 
-.34 
.14 
-.05 
-.11 
.00 
-.30 
-.11 
.03 
.32 
.77 
.49 
1.00 
.01 
.34 
Note.     ADL = activities of daily living 
 
 For 74 patients, an indication for the age of onset of HD was found. A 
weak significant quadratic relation of social-cognitive deterioration with 
duration of illness was found. Social-cognitive abilities decline more rapidly 
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in the later stages of the disease. A weak significant linear relation between 
duration of illness and the rigid-aggressive component indicates that 
patients who are affected for a longer period display less rigid and 
aggressive behavior. Outpatients had significantly lower social-cognitive 
deterioration and rigidity-aggression scores than institutionalized patients. 
 
Table 6. Regression modeling of social-cognitive and rigid-aggressive 
components on ADL 
 Social-cognitive (R² = 0.59)  
Rigid-aggressive 
(R² = 0.35) 
Independent variables β p  β p 
ADL 
Squared ADL 
Gender (men=1; women=2) 
Clinic / day care 
Age 
.56 
.22 
-.04 
-.16 
.23 
.000 
.004 
.64 
.03 
.002 
 
.10 
-.50 
-.07 
-.31 
-.10 
.32 
.000 
.46 
.002 
.27 
Note.     ADL = activities of daily living 
Relations between components 
Regression modeling of the social-cognitive component on the ADL 
component revealed significant linear and quadratic relations (Figure 1, 
Table 6). The interpretation of the linear relation is that as ADL declines 
(higher ADL deterioration scores), social-cognitive abilities also decline 
(higher disability scores). The positive quadratic relation implies that social-
cognitive abilities deteriorated faster in more advanced stages of HD. 
 
 
 
Fig 1. Regression model of social-cognitive and rigidity-aggression on ADL 
 
 
The BOSH 115 
 
 A significant, negative quadratic effect was found between ADL and 
rigid-aggressive behavior, reflecting that aggressive behavior was most 
frequent in the intermediate stages. 
 The significant clinic/day care effects can be interpreted as outpatients 
having better social-cognitive competence and displaying less rigid-
aggressive behavior. The significant age effect implies that older patients 
had worse social-cognitive abilities. 
Missing values 
For 14 outpatients (15% of the total number of patients) the three items 
regarding washing, dressing and going to bed (items 1 - 3) could not be 
administered. The items related to washing and dressing (item 1) and going 
to bed (item 2) for these outpatients were imputed with values between 2 
and 4, with means of 2.8 and 2.6 respectively. The values of the estimates 
indicate that these patients needed assistance from their spouse or 
caregiver, but were able to cooperate. Going to bed in time (item 3, was 
imputed for outpatients with values between 0.4 and 3.4 (mean 1.7), which 
indicated that most outpatients needed not too much persuasion to get them 
to bed. 
 For the 3 tube fed patients (3% of the total number of patients) the 3 
items concerning consuming food were not applicable. For these patients 
the eating ability item (30) was imputed with values higher than 4, indicating 
complete assistance. The items on voracity (item 31) and bolting of food 
(item 32) were imputed with values below 1.5, which indicates that these 
patients caused hardly any problems. In addition to these structural missing 
values, there were totally 21 other missing values (0.4% of the total number 
of items in all administered questionnaires). 
DISCUSSION 
Main findings 
The final version of the BOSH contains 32 items. A principal component 
analysis with varimax rotation revealed 3 designated components: 1) 
deterioration of ADL, 2) deterioration of social and cognitive abilities and 3) 
mental rigidity and aggressive behavior. Internal reliabilities and inter-rater 
reliabilities were acceptable. Non-linear relations were found between these 
components. 
Relations with duration of disease and care 
Weak relations between disease duration and deterioration of social-
cognitive abilities and rigid-aggressive behavior were found. The weakness 
of these relationships may be caused by the less precise way in which the 
age at onset, and thus disease duration, were determined retrospectively.10 
The insidious course of the disease in the first stages makes it very difficult, 
if not impossible, to determine the exact onset. If the age at onset was 
inferred from the first psychiatric signs, obtained from medical information, 
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there are two possibilities. On the one hand, the age at onset was estimated 
too high if the first psychiatric signs were indeed clinical signs of HD. On the 
other hand, the age at onset was estimated too low if the first psychiatric 
signs were not a clinical manifestation. Hence disease duration was 
estimated too short or too long respectively. The problem may be solved in 
the future by the results of current studies in the USA, Australia, and 
Europe, which address the transition from health to HD in persons at risk for 
developing HD (http://www.euro-hd.net). The intent of these studies is to 
learn more about the beginning changes in thinking skills, emotional 
regulation, brain structure and brain function as a person begins the 
transition from health to HD. 
  A significant linear relation between the care period and deterioration of 
ADL was found. We argue that the institutional care period is a biased 
indicator for the progression of the disease. Though impairment of motor 
functioning is important in the decision for placement in a nursing home, the 
decision of placement in a nursing home is principally dependent on the 
absence of a caring spouse or other person. 
Relations between components 
Nehl et al.3 did not find a significant relation between aggression, and 
obsessive/compulsive behavior with the total functional capacity scale 
(TFC) of the UHDRS. They argue that TFC scale may not be a particular 
good indicator of a person's cognitive and psychiatric difficulties. Another 
reason might be that they only analyzed linear relations. We found a strong 
significant quadratic relation between rigidity-aggression and the ADL level. 
This can be interpreted as rigid and aggressive behavior becomes more 
frequent at first, and less frequent later. A similar relation, between 
inflexibility and disease duration was observed in the study of Craufurd et 
al.11 but it was not clear whether that relation was significant.12 
 Strong significant linear and quadratic relations are also found between 
social-cognitive functioning and ADL level. Again applying ADL deterioration 
as an operationalization of disease duration, the interpretation of these 
relations is that the deterioration of social-cognitive capabilities progresses 
more rapidly in later stages of the disease, when rigid and aggressive 
behavior is decreasing. In other words, the decline of ADL precedes the 
decline of social-cognitive behavior. This is consistent with the observation 
of Bamford et al.13 that memory did not deteriorate until patients reached 
advanced stages of the disease. 
Influence of medication 
The level of aggression is moderated, because nursing homes try to reduce 
this behavior by several means. Firstly, this includes psychological and 
pharmacological interventions, though a restrictive policy is maintained for 
sedating medication. Secondly, patients are referred to a psychiatric 
hospital in extreme cases when these interventions fail to reduce the risk of 
aggressive outbursts that may be dangerous for staff personnel, fellow 
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patients, or the patient himself. These moderating effects may reduce 
relations with the rigid-aggressive component. 
Relation to the UHDRS 
The UHDRS rates four domains of clinical performance and capacities in 
HD: motor function, cognitive function, behavioral abnormalities, and 
functional capacity. In later stages of HD, the cognitive function and 
functional capacity cannot be assessed adequately. Motor function is 
assessed by a trained neurologist. Cognitive functioning is assessed by a 
neurologist or psychologist with a word fluency test, the Symbol Digit 
Modalities Test and the Stroop Color Interference Test. Behavioral 
abnormalities and functional capacity is assesses by a physician or 
psychologist. In short, the UHDRS is to be assessed by qualified personnel, 
and assessment takes more than one hour. The BOSH covers more or less 
the same domains and is administered within a quarter of an hour by 
nursing personnel who are in charge of the daily care of the patients. The 
UHDRS can be used adequately for longitudinal studies,14 but is more 
laborious to assess. We expect that the BOSH is also sensitive to small 
changes in behavior, and is thus suitable for detecting changes in relatively 
small time spans, which is advantageous in longitudinal studies. 
Implications for further research 
We developed the BOSH in order to gain detailed insight into the progress 
of the disease and to distinguish individual differences between patients. A 
more detailed insight into these differences will facilitate a study of the 
relation of the phenotypic expression of HD with the pre-morbid personality 
and social support system. A better insight into this relation can be of help in 
better tailoring treatment to individual patients. The relation of the BOSH 
with other relevant scales will be determined thoroughly in an extensive 
study to the syndrome description of HD. Finally, the BOSH can be used as 
outcome measure in addition to functional measures in clinical trials. 
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APPENDIX - THE BOSH 
 
 
BEHAVIOUR 
OBSERVATION 
SCALE 
HUNTINGTON 
 
(BOSH) 
 
 
 
 
George Huntington 
at the time he presented his classic 
article in 1872 
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Patient (name): .......................................................................................... 
 
 
BEHAVIOUR OBSERVATION SCALE HUNTINGTON (BOSH) 
 
INSTRUCTION 
 
The aim of this questionnaire is to describe the behaviour of a patient 
suffering from Huntington’s Disease. The questionnaire applies to 
inpatients or outpatients. 
 
The assessment covers your observation of the patient’s behaviour in the 
past two weeks. 
 
If an inpatient/outpatient displays changeable behaviour, you should base 
your assessment on the behaviour which you thought most prominent 
during the assessment period. Please tick the answer that, in your opinion, 
matches the inpatient’s/outpatient’s behaviour. If more than one answer is 
appropriate, please tick the one that best describes your observation of the 
patient’s behaviour in the past two weeks. 
 
If you find none of the answers appropriate, please tick the answer that 
most approximates the patient’s behaviour. Please answer all the 
questions, unless it is explicitly stated that this is not necessary. 
 
Patient number: ............................ 
Sex:  male  female 
Date of birth: ........... - ............ - ........................ 
Team: .......................................................................................... 
Completed by: .......................................................................................... 
On: ........... - ............ - ........................ 
Date of admission: ........... - ............ - ........................ 
Outpatient treatment:   no   yes (start at question 4) 
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  1. Washing and getting dressed: 
         Independently (if necessary under supervision) 
         Needs some assistance 
         Needs full assistance, but does cooperate 
         Completely dependent, cooperates hardly or not at all 
 
  2. Going to bed: 
         Independently (if necessary under supervision) 
         Needs some assistance 
         Needs assistance, but does cooperate 
         Cooperates hardly or not at all 
 
  3. Going to bed on time: 
         Causes no problems (not too early, not too late) 
         Has to be reminded 
         Has to be persuaded to go to bed on time 
         Difficult or impossible to get to bed on time 
 
  4. Going to the toilet: 
         Completely independently 
         Needs some assistance 
         Needs almost full assistance 
         No longer able to go to the toilet 
 
  5. Mobility: 
         Independent for short distances, if necessary using wheelchair or walker 
         Needs assistance, can move independently with difficulty 
         Can no longer move independently, but is capable of calling for 
 assistance 
         Is completely dependent 
 
  6. Ability to understand complex actions, such as operating an electric 
      wheelchair, a communicator, other electrical appliances, etc.: 
         Poses no problems (besides restrictions resulting from motor 
 dysfunction) 
         Rough explanation and/or encouragement are necessary 
         Intensive step-by-step assistance is necessary 
         Patient is no longer capable of understanding complex actions 
 
  7. Voice control (control of sound and volume) and articulation: 
         Normal or almost normal 
         Affected 
         Bad 
         Voice is used for little more than uncontrolled cries
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  8. Intelligibility: 
         Is intelligible to everyone, perhaps with some difficulty 
         Is intelligible only to those who know patient well 
         Tries to say things, but is hardly intelligible or not at all, even for those 
 who know patient well. Utterances consist mainly of making noises and 
 crying out 
         Hardly or no longer uses voice for communication 
 
  9. Comprehensibility through nonverbal communication: 
         Patient is verbally clear to the extent that nonverbal communication is 
 usually unnecessary 
         Capable of often making himself/herself clear by using gestures or 
 communication aids 
         Uses gestures and aids to express himself/herself, but it is often 
 necessary to inquire what he/she means 
         Can no longer make functional use of nonverbal communication 
 
10. Ability to understand verbal communication: 
         Patient usually understands what is said in immediate vicinity 
         Patient only understands what is said if addressed personally 
         Limited, understands simple information 
         It is no longer clear if anything is understood 
 
11. Ability to understand nonverbal communication: 
         Nonverbal support is not necessary 
         Nonverbal support is sometimes necessary 
         Understanding is difficult even with use of nonverbal support 
         It is no longer clear if anything is understood 
 
12. Recollection of recent events important to patient (birthdays, trips, weddings): 
         Patient usually refers to the event himself/herself 
         Patient sometimes refers to the event himself/herself 
         Patient only shows signs of recognition or recollection when others refer 
 to the event 
         Patient never shows signs of recognition or recollection 
 
13. Remembering appointments: 
         Remembers appointments himself/herself, if necessary using a diary 
         Tries to remember appointments himself/herself, 
 but usually forgets them 
         Always needs to be reminded of an appointment 
         It is no longer possible to make appointments 
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14. Ability to occupy himself/herself and participate in organised activities: 
         Generally reasonable to good 
         Needs assistance, encouragement and guidance  
         Hardly shows any initiative, or fills time with passive activities 
         No longer occupies himself/herself 
 
15. Patient knows staff members and fellow inpatients by name: 
         All or almost all 
         Most 
         Some 
         None, or there is no way of telling 
 
16. Emotionalism: 
         Emotions are appropriate and understandable 
         Strong mood swings, little control of emotions 
         Mood is flat, sometimes emotional distress or great restlessness, 
 not always for an explicable reason 
         Emotions are hardly observable or difficult to recognise 
 
17. Awareness of being ill: 
         Sufficient or reasonably sufficient awareness of being ill 
         Awareness of being ill, but has no real understanding of the seriousness 
 and consequences 
         Seems to lack awareness of being ill because of incomprehension or 
 denial 
         No longer speaks, utterances are hard to interpret 
 
18. Seeking contact and receptiveness: 
         Usually seeks contact himself/herself, or is receptive 
         Often avoids contact, or contact is difficult because of demanding or 
 attention-seeking behaviour 
         Passive, but responds briefly to attention and acquaintances 
         Contact practically impossible, does not respond to acquaintances 
 
19. Contact with family, friends or fellow inpatients: 
         Usually goes well, or there is no contact, but that is not a problem 
         Frequent tension because of contact (or the lack of it) 
         Response usually flat, sometimes more responsive to certain persons 
         Little or no contact possible 
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20. Showing consideration for fellow inpatients: 
         There are few problems regarding contact with fellow inpatients  
         Patient does not show enough consideration, but does accept correction 
 or rejection 
         Contact with fellow inpatients may lead to arguments, but the team can 
 resolve the matter verbally 
         Patient is obtrusive to such an extent that arguments often cannot be 
 prevented  
 
21. Degree to which verbal and physical aggression can be corrected: 
         Aggression occurs hardly or not at all 
         Patient can be corrected verbally 
         Patient can only be corrected physically 
         Cannot be corrected with the means usually available on the ward 
 
22. Tendency towards verbal and physical aggression: 
         Aggression occurs hardly or not at all 
         Tends to react evasively to frustrations and setbacks 
         Tends to react aggressively to frustrations and setbacks 
         Displays aggression at unpredictable moments 
 
23. Patient tries to exceed the limits of standing agreements or house rules: 
         Never or n/a 
         Sometimes 
         Often 
         Always 
 
24. Patient causes problems if a fixed routine is not adhered to: 
         Never 
         Sometimes 
         Often 
         Always 
 
25. Patient accepts what you say: 
         Always, at least does not contradict it 
         Usually, sometimes with difficulty 
         Only if much cogency is used 
         Hardly ever, does completely what he/she wants 
 
26. Patient is open to correction: 
         Always 
         Often 
         Sometimes 
         Never 
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27. Performance of specific activities is impeded because patient cannot 
      dissociate from subjects or events that are not or are no longer relevant: 
         Never or n/a 
         Sometimes 
         Often 
         Almost always 
 
28. Patient performs stereotypical, apparently aimless activities (such as walking 
      and then sitting down again immediately), which take precedence over 
      everything: 
         This never happens 
         This is only noticeable if you pay special attention to it 
         This happens remarkably often 
         This happens all the time 
 
29. Choking while eating or drinking: 
         Patient does not choke often  
         Regularly, but can easily cough it up 
         Regularly and cannot easily cough it up 
         No longer capable of taking in food or liquids orally. (If this is the case 
 you do not need to answer questions 30, 31 and 32) 
 
30. Eating and drinking: 
         Completely independently 
         Independently, using special equipment 
         Needs supervision and partial assistance 
         Needs to be assisted completely 
 
31. Voracity and insatiability: 
         Usually finds quantity satisfactory 
         Often asks for more, but accepts refusal 
         Eats or drinks everything he/she comes across, 
  but does not go looking for it 
         Is constantly looking for something to eat or drink 
 
32. Bolting food: 
         Patiently finishes one bite before taking the next 
         Tends to bolt food but can be corrected verbally 
         Tends to bolt food and can only be corrected physically 
         Tends to bolt food and cannot be corrected
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Sir, 
 
Craufurd et al.1 found three factors in their study of the behavioral changes 
in Huntington disease (HD): Apathy, Depression and Irritability. The 'Apathy' 
factor was highly correlated with duration of illness, whereas no such 
relationship was observed for 'Depression' and 'Irritability'. However, in our 
opinion they have underestimated their findings due to inappropriate 
statistical methodology. 
 In figure 1(B) of their article all variables in factor 2, labeled as irritability, 
have a peak in the middle of the progression of the disease. The overall 
range of illness duration the authors monitored was 1 to 23 years. The peak 
in the figure suggests a non-linear relationship in their data. Although they 
did mention that there was a tendency for factor 2 symptoms to occur more 
frequently in subjects with illness duration between 6 and 11 years, they did 
not report whether they tested the significance of this tendency. Dividing 
duration of illness into 7 equal groups has the consequence that the 
measurement level is reduced from continuous to categorical. The authors 
have used Spearman rank-order correlations for analyzing the relationship 
of behavioral symptoms to disease duration. Generally, the efficiency of 
Spearman correlations are 91% relative to Pearson correlations.2 3 It is less 
efficient to categorize data and use Spearman correlations than it is to use 
Pearson correlations on the original continuous data. Much information is 
lost by categorizing the continuous variable. 
 In a similar study on developing a 32 four-answer items rating scale for 
Huntington patients in the final stages of the disease (Behavior Observation 
Scale Huntington), we found five principal components in two clusters.4 The 
first cluster includes activities of daily living, social-cognition and speech 
capacity, representing the progression of the disease. The other cluster 
contains inflexibility and obsessive-compulsive behavior, representing 
unmanageability of the patient. Using regression analysis, we found a 
significant non-linear relation between these two clusters (F(2, 81) = 6.56; p = 
.0023). Unmanageability was found to be highest half way through the 
progression of the disease. Although it is possible to find a quadratic 
relation by correlating the square of the progression with the 
unmanageability, it is less effective to find non-linear effects, such as 
quadratic, cubic or logarithmic effects. Commonly used statistical packages, 
such as SPSS5 provide a curve-fitting module, based on regression, that 
facilitates the finding of nonlinear relations. If our data would have been 
analyzed with Spearman rank order correlations, after categorization into 7 
equal groups, the effect would not have been significant (p = .185), which is 
particularly due to unnecessary loss of information. This loss of information 
may disguise clinical reality. Therefore, regression analysis on the 
continuous data is more suitable here and we suggest that Craufurd et al. 
reanalyze their data. 
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 In 1993, the detection of the CAG-repeat allowed direct mutation testing 
with more than 99% certainty. After an extensive debate whether the 
individuals who received previous test results from linkage testing should be 
informed and offered the mutation test, the test was offered in 1997. This 
provided the opportunity to study the uptake of the retest and to assess the 
long-term psychological effects. 
8a.1. GENERAL INTRODUCTION 
Huntington's disease (HD) is an autosomal dominant inheritable disease 
characterised by involuntary movements, cognitive deterioration, and 
psychiatric problems. The onset is usually in middle age. The mean age at 
onset ranges from 43.7 to 55.8 years,1-3 with standard deviations of 10.9 
and 13.5 years respectively.2 3 The median duration of HD is about 16.2 
years,3 and eventually the patient deceases by causes associated with the 
disease.1 The occurrence rate in people of Western European descent is 
estimated at 5-10 per 100.000 inhabitants,4 though there are indications that 
this rate is higher.5 The specific symptoms and progression of HD can be 
related to its neuropathology, which is characterised by loss of specific 
neuronal populations, most strikingly in the basal ganglia of the brain.6 HD is 
caused by a CAG repeat on the short arm of chromosome 4.7-10 Affected 
subjects have repeats from 36 to over 100.8-10 The limits of the CAG repeat 
size in the HD gene have been defined: the normal allele with 26 repeats at 
most, the intermediate allele with 27-35 repeats, the disease allele with 
reduced penetrance with 36-39 repeats, and the disease allele with 40 
repeats or more.11 The age on which the first symptoms emerge is 
negatively associated with the repeat length,12 whereas the duration is not.13 
 Individuals with a HD parent have a 50% chance of having inherited the 
disease themselves. Since the late eighties of the last century, a predictive 
DNA-test became available. This test was carefully introduced because 
severe consequences of the test were anticipated, especially for persons 
receiving an increased risk outcome. In the Netherlands 24% of people at 
risk for HD choose to have the test.14 
8a.2. BACKGROUND OF THE STUDY 
Since the advent of predictive testing a variety of psychological issues have 
been encountered that deserved close attention. Disclosure of an 
unfavourable test result was found to cause a temporal psychological 
distress, which reduced toward pre-test levels 6 months to a few years after 
the test. Individuals who received a favourable test result found a short-term 
relief of the burden, but also returned to pre-test levels in the medium-
term.15-17 The Dutch programme addressed the psychological effects in the 
long-term. 
 The findings of follow-up studies have had profound impact on 
psychosocial support and the quality of predictive testing programmes for a 
variety of genetic disorders with onset later in life. These studies ought to 
use reliable and effective methodology. The methodology of virtually all 
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follow-up studies on psychosocial effects of genetic testing, published 
between 1988 and 2003, was investigated. 
 Genetic counselling aims to offer precise risk estimation. The predictive 
test based on linkage analysis provided risk estimation, whereas the 
mutation test reached optimal certainty. The increasing knowledge on age 
of onset, its relationship with the CAG-repeat length, and the repeat length 
in close relatives allows more precise risk estimation before mutation 
testing. 
 Preparing for the future is one of the main reasons to have a predictive 
test. Individuals, who will receive unfavourable test results, have to face 
new uncertainties with regard to the onset of the disease, and to the way, 
the disease will manifest itself. The more specific information is available, 
the more identified carriers may be able to anticipate their future 
perspectives. HD is a disabling disease that progresses over time. Although 
no curative treatment is available yet, the increasing knowledge about HD 
has improved the caring and nursing considerably. Special wards for HD-
patients in the Netherlands and Belgium have developed much experience 
with HD-patients in the later stages of the disease. The perspective of good 
care in the later stages may comfort people, and may help them to distract 
from the appalling experiences with caring and nursing of relatives in the 
past. However, to better tailor the care and nursing of HD-patients, more 
insight is needed into the course and progress of the disorder at different 
stages of the disease. The Unified Huntington's Disease Rating Scale 
(UHDRS) was developed as a clinical rating scale to assess four domains of 
clinical performance and capacity in HD: motor function, cognitive function, 
behavioural abnormalities, and functional capacity.18 The UHDRS allows 
monitoring the patients' disease course over time, although the instrument is 
not very sensitive in the later stages of the disease. There was a need for a 
scale that is more directed to the later stages of HD. Also needed was a 
better indicator of a patient's cognitive and psychiatric aspects.19 The 
Behaviour Observation Scale for Huntington's disease was developed to 
provide an observational instrument for monitoring the behavioural aspects 
of the patient in later stages of HD. 
8a.3. AIMS OF THE STUDY 
In this thesis the following psychological issues related to genetic testing for 
HD are described: 
- the psychological adaptation in the long term of individuals at risk for HD 
and their partners to the genetic test result,  
- the methodology that is used in research to adaptation to genetic test 
results in general,  
- the characteristics of tested individuals who pursue a more accurate test, 
- the calculation of the risk for HD of individuals who are not tested.  
Also, a tool was developed for registration of the progression of HD that is 
easy and quick to administer by nursing personnel. 
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8a.4. RESULTS 
In chapter 2, the 3-year psychological effects of the predictive test for HD 
on tested individuals and their partners are described. The intrusion and 
avoidance subscales of the Impact of Event Scale (IES),20 measuring HD 
specific distress, and the Beck Hopelessness Scale (BHS)21 measuring 
future expectations, were administered pre-test, 1 week, 6 months and 3 
years after the test. Repeated measures analysis of variance revealed 
similar intrusion patterns for carriers and non-carriers, but opposite patterns 
for avoidance after 6 months. One week after the test outcome, carriers had 
increased and non-carriers had decreased levels of hopelessness. These 
effects were reduced after 6 months, and remained stable thereafter. 
Partners of carriers followed the same course. Partners of carriers with 
children were more distressed then those without offspring. 
 In chapter 3, the effects of the test after 7-10 years on tested individuals 
and their partners are presented. Worldwide this study covers the longest 
time-span on psychological effects of testing for hereditary diseases with 
onset later in life. Carriers and their partners were temporarily more 
distressed immediately after the test results, although their outlooks 
improved somewhat in the 2-3 year post-test period. However, they became 
more pessimistic in the long term, when they approached the mean age of 
onset of HD. Non-carriers reported strong relief after the test result, but 
eventually returned towards pre-test distress levels. Carriers, who did not 
return questionnaires after they had received their test results, had reported 
more distress at baseline than carriers who returned questionnaires and 
came back for additional counselling. Given that pre-test distress has been 
found to be a strong predictor for post-test distress, we need to consider 
how it can be provoked counsellors keep in touch with individuals who have 
high distress scores. Moreover, this observation might reveal that studies 
reporting few harmful effects among people, who had received an 
unfavourable test result, have underestimated the real impact. 
 In the study of the long-term effects of testing, the importance of an 
adequate statistical technique and the attention to dropout became 
apparent. This led to an investigation on dropout and adequacy of 
techniques used in other longitudinal studies in the field of psychological 
effects of genetic testing. The results are described in chapter 4. The aim of 
this systematic literature review is to describe and evaluate the statistical 
methods that were used in the follow-up studies. A literature search 
revealed 40 longitudinal quantitative studies that met the selection criteria 
for the review. Fifteen studies (38%) applied adequate statistical methods. 
The majority, 25 studies, applied less suitable or less efficient statistical 
techniques. Nine studies (23%) did not report on dropout rate at all, and 18 
studies provided no characteristics of the dropouts. Thirteen out of 22 multi-
wave studies that should have provided data on missing values actually 
reported these. It is concluded that many studies could have yielded more 
and better results if a more appropriate methodology was used. The most 
common shortcoming was that multi-wave studies used a statistical method 
suited for a two-wave study (14 out of 28). In these studies the analysis is 
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broken down into sub-analyses, which results in a less complete overview, 
and hence a loss of insight in the total course. 
 Dropout is a serious problem in longitudinal follow-up studies. Though 
every effort must be taken to prevent subjects from dropping out of the 
study, it can hardly be prevented completely. Dropout can have various 
reasons. In case of an unknown address or death, the effect is generally not 
very disrupting. However, loss to follow up due to lack of interest or 
disturbed mood distorts the results of the study considerably. Such a 
selectivity of dropout can be detrimental to the generalization of the results 
of the study. For example, the conclusion that a genetic test does not have 
serious harmful psychological effects cannot be generalised to the whole 
group of tested individuals when it is based on individuals who are less 
likely to develop a depression. Indeed, in our study22 the group of 
individuals that could develop adverse consequences is selectively expelled 
from the study. Several studies have demonstrated that pre-test scores are 
highly predictive for post-test levels.23 24 This indicates that this group is 
vulnerable to psychological problems. Hence, this group that has lost all 
contact with the counsellors is probably in need of extra attention and 
support. In only one other study25 such a selective dropout was reported. All 
other studies have not reported on selective drop out. Nearly half of the 
studies (18) did not report anything on dropout. 
 Chapter 5 focuses on the uptake of a more than 99% accurate test. In 
1987 the linkage test for HD was introduced in the Netherlands.26 27 This 
test had a residual risk of 1-10% and the cooperation of relatives was 
needed. In the Netherlands, 245 individuals were tested with linkage 
analysis. Due to a lack of informative markers, 12 did not receive a test 
outcome, and 23 did not receive an outcome because of an uninformative 
family structure. Eighty-eight individuals were identified as carriers and 122 
as noncarriers. Six years later, the gene mutation for HD was identified and 
testing became possible with a reliability of more than 99%,7 without the 
need for testing of multiple family members. In 1997, the new mutation 
retest was offered to the 210 individuals who had received a linkage test 
result for HD. Eighty-one individuals could not participate in the study. The 
most important reasons were that they had been offered the mutation test 
previously in combination with prenatal testing or had already developed 
symptoms. Others were deceased, had moved and were not traceable any 
more, or did not react. This resulted in a study group of 129 individuals. 
Three groups were compared: (1) 18 individuals who were retested 
between 1993 and 1997, before the study had started, (2) 29 individuals 
who were retested after information was provided, and (3) 82 individuals 
who refrained from retesting. Nearly half of the linkage-tested individuals 
choose to be retested, with the exception of noncarriers who previously 
received a residual risk of 2% or lower. Of the latter group, less than 20% 
choose to be retested. Carriers who were more confident in the future 
(BHS)21 and had a better sense of well being (GHQ)28 were more likely to 
opt for a confirmatory test. Noncarriers who were retested were more 
anxious (HADS)29 than noncarriers who refrained from retesting. Female 
carriers were also more likely to have the retest before the information 
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campaign had started. Retestees were younger at the time of testing. No 
risk reversals were revealed by this study. 
 In the Netherlands, a minority of the individuals at risk (24%), who have 
opted for predictive testing since 1987, received precise information about 
their risk status. The study reported in chapter 6 focuses on the residual 
risk status of those who have not (yet) undergone the predictive test. This 
residual risk is often lower then the a priori risk of 50% (children) or 25% 
(grandchildren). A model for calculating the reduced residual risk was 
developed on basis of a data set with CAG repeat lengths and ages of 
onset (AO) of HD patients, and a subset with CAG repeat lengths of parents 
and their children. In this model, the parents' CAG repeat length is 
estimated from the AO in a first step. Secondly, the parents' CAG repeat 
length is used for estimating the CAG repeat length of the proband, 
considering the parents' gender. Thirdly, the probability that the proband 
has not yet symptoms given that he or she is a carrier is estimated. Finally, 
after inclusion of information on favourably tested siblings (non-mutation 
carriers), the residual risk of the proband is calculated. One application is 
that genetic counsellors can offer residual risks as part of the pre-test 
procedure. The provision of a spreadsheet allows genetic counsellors to 
calculate the residual risk relatively easy. In this spreadsheet the age of the 
applicant, the AO, or CAG repeat length of the relative and number of 
favourably tested children can be entered, and estimates of CAG repeat 
length and RRS percentage will be provided. The spreadsheet is available 
on request. 
 HD is a disabling disease that progresses over time, and no curative 
treatment is available yet. One of the main cited reasons to have a 
predictive test was preparing for the future. Individuals, who receive 
unfavourable test results, face new uncertainties with regard to the onset of 
the disease, and to the way the disease will manifest itself. Identified 
carriers may be able to anticipate better their future perspectives when they 
are informed more specifically about the course and progress of the 
disease. The management of HD, the caring, and nursing options have 
been improved by the increasing knowledge about HD. The neurological 
outpatient clinics, the special Huntington Support Centre (Huntington 
Steunpunt), and the special wards for HD-patients in the Netherlands and 
Belgium have developed much experience with HD-patients in the different 
stages of the disease. The perspective of good care in the later stages may 
comfort people, and may help them to distract from the appalling 
experiences with caring and nursing of relatives in the past. However, to 
better tailor the care and nursing of HD-patients, more insight is needed into 
the course and progress of the disorder at different stages of the disease. In 
chapter 7, the development of the Behaviour Observation Scale Huntington 
(BOSH) is reported. In 1996 the Unified Huntington's Disease Rating Scale 
(UHDRS)18 was introduced to assess clinical performance and capacities in 
HD. However, due to ceiling effects, the UHDRS does not differentiate in 
later stages of HD. The BOSH was developed to obtain a detailed 
description of the patients' behaviour in the final phases of the disease. The 
scale contains 32 four-answer category items. From principal component 
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analysis three subscales emerged: (1) degeneration of activities of daily 
living (ADL), (2) social-cognitive degeneration and (3) mental rigidity and 
aggression. The scale was validated in four nursing homes with a 
specialised ward for HD-patients. For 91 patients nursing personnel 
administered the BOSH twice independently. Internal reliabilities of the 
three subscales were between .83 and .94 and inter-rater reliabilities were 
between .85 and .95. A linear relation was found between disease duration 
and deterioration of ADL. Non-linear relations were found between (1) 
degeneration of ADL and rigidity-aggression, and (2) degeneration of ADL 
and of social-cognitive capabilities. Rigidity and aggression become more 
frequent as the disease progresses, later on this behaviour diminishes. 
Social-cognitive capabilities deteriorate more rapidly in later stages of the 
disease 
8a.5. DISCUSSION 
8a.5.1. Psychological adaptation to the test outcome 
It was generally accepted that, when outweighing the psychological 
ramifications of testing for HD, there were more positive than negative 
consequences.15-17 This has led to the suggestion that tested individuals 
have benefited from testing.30 However, such a conclusion must be made 
with caution. Up to 2003, there were no studies reported that encompassed 
a period longer than 3 years after the test. In the study 7-10 years after the 
test outcome, feelings of hopelessness rose again for carriers. Feelings of 
hopelessness or depression, as the first symptoms of HD, could cause this 
effect for the carriers. However, this cannot hold for their partners, who 
reported similar levels of hopelessness. For this reason, it is likely that the 
test outcome, the approaching age of onset, the onset of HD in relatives, 
loss experiences, and HD-related life events are responsible for their 
enhanced feelings of hopelessness. Because the mean age of carriers at 
the last measurement was 45 years (range 27-73), for many of them the 
first symptoms of HD will probably become apparent in the very near future. 
 These results are based on a selection of individuals who had the 
predictive test performed. The study did not include a control group with 
individuals who were not tested. Van der Steenstraten et al.31 noted 
differences between tested and not tested individuals. Untested individuals 
felt more vulnerable and saw themselves as less able to cope with an 
unfavourable test outcome. It should be noted too, that the study group of 
Van der Steenstraten was recruited from volunteer members of the Dutch 
Huntington Association. It is conceivable that even these volunteers belong 
to a selective group of psychologically more stable individuals. For 
conclusions that are more decisive, it would be interesting to study 
individuals at risk at the age of about forty, who were not tested. 
8a.5.2. Dropout analysis 
The dropout problem in longitudinal research is inevitable. There are 
various reasons for persons to be lost to follow-up. People can move and 
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their addresses become unknown. They can decease from a cause 
unrelated to HD. They can develop symptoms and hence be excluded from 
further analysis. Alternatively, they may just not want to cooperate any 
more. In general, when there is no response to the request to complete 
questionnaires, the reasons for non-response remain unknown. It should be 
noticed that non-response is generally not random. Dropouts often have 
special characteristics that can invalidate a longitudinal study.32 Therefore, 
longitudinal research requires the inclusion of dropout analyses. Dropouts 
need to be compared with persons who remained in the study on every 
biographic and outcome measure. Generally, it is reasoned that if no 
differences are found, there is no need to conclude that selective dropout 
has invalidated the study. Although selective dropout is often considered as 
a threat to the validity of a study, a thorough dropout analysis can reveal 
very interesting insights. In Tibben et al.33 no significant differences between 
dropouts and the remaining participants in the study were found. A 
significant difference was present however, and was observed many years 
later, when the effects after 7-10 years were analysed. The key to the 
problem was the insight that individuals who had received an unfavourable 
test outcome will have to adjust to the test outcome completely different 
from individuals who received a negative outcome. When dropout analyses 
were performed on these groups separately, it emerged that dropout 
carriers had a much worse view on the future at pre-test, had much more 
intrusive thoughts, reported more avoidant behaviour and had worse 
general well-being scores. These differences were highly significant and the 
effect sizes ranged from above medium to very large (0.6 to 1.0). Thus, it 
was not only found that carriers had a worse view on the future than 
noncarriers in the long term, but this finding was also based on a selection 
of carriers who were less anxious and distressed. When we add this 
observation to the issue of selectivity of the study group at baseline, it is 
likely that the effects of an unfavourable test outcome are even worse than 
was implied from the longitudinal analyses alone. Geneticists and 
psychosocial workers estimate whether the applicant can adapt adequately 
to an unfavourable result. Nevertheless, individuals, who are very anxious, 
depressed or who have pessimistic views on a future after an unfavourable 
test result should be given professional attention in the long term. Follow up 
appointments should be scheduled, and if needed referral to appropriate 
additional caregivers should be arranged. Yet, we must account for the 
possibility that the offer of further support is rejected because the 
confrontation with the future perspectives is unbearable. 
8a.5.3. Importance of an adequate statistical technique 
Analyses for the study 7-10 years after the test were carried out with 
General Linear Mixed Models (GLMM) that can handle cases with missing 
measurements at one or more time points. This allowed the optimal use of 
data, subjects, and waves. A rather incomplete time-point, 1½ year after the 
test, could also be used. The collection of data of this time-point was 
stopped because the project had been called of at the time. If the technique 
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of GLMM had been used at the time of the 3-year follow-up study, it could 
have been observed by then that carriers were already losing their prospect 
on the future. 
 Another consequence of using an inadequate technique may be that it 
will fail to notice narrowly significant differences. This may happen, for 
example, when a non-parametric test is used instead of a parametric test. 
Often this does not lead to a dramatic loss of power efficiency. Generally, 
the power of a non-parametric test is about 95% compared with an F-test 
when conditions for the latter are met. In some circumstances however, 
such as dichotomising distributions before analysing, the power can drop 
dramatically. When a technique for dichotomous data is used for continuous 
data, efficiency for finding significant results can drop to 63%.34 
8a.5.4. Presenting a more accurate DNA test 
The uptake of the test has been considerably higher in the Netherlands than 
in other countries.14 The main reason to have the test was relief from 
unbearable uncertainty, reflecting the strong need for reassurance. Yet, it 
was debated whether individuals tested by linkage analysis should be 
informed on the mutation test. The Clinical Genetics Centre Leiden had the 
opinion that the new test should be offered to everyone who had taken the 
old linkage test, in order to allow obtaining optimal certainty. However, the 
Leiden Medical Ethical Committee questioned whether individuals should be 
approached after so many years with the chance that they are burdened 
unasked. The committee reasoned that tested individuals may have 
adjusted to their test outcome and have found a new balance in their life. 
This balance could be distorted by the perception of the message that the 
linkage test outcome was uncertain or even wrong. People may conclude 
that the old test was not good at all. 
 On the other hand, people had applied for the test to receive optimal 
certainty in order to make life arrangements in accordance with the test 
outcome, with the inclusion of planning a family. In addition, from a non-
directive and non-paternalistic point of view, it was considered important to 
leave the decision to have a mutation test to the tested individual. Moreover, 
the patient organisation had published information on the direct mutation 
test in its quarterly magazine. After some years of debate and outweighing 
the pros and cons, it was concluded that the test could be offered to those 
who had received the linkage test. 
 Before the >99% reliable mutation test was introduced, Babul et al.35 
questioned linkage-tested individuals whether they were interested in a 
hypothetical 100% certain test. They reported that 72% would be interested 
in such a test. Actually, the uptake of the test was much lower after the 
introduction (42%).36 A similar observation was made before the 
introduction of the linkage test. Than, 40% to 84% individuals at risk 
reported an intention to be tested,16 37-39 but since its introduction in 1987 
the uptake (2-24%), has fallen considerably below expectation.14 40-43 It is 
obvious that there is a discrepancy between the intention to be tested and 
actual behaviour. As was expected, the residual risk of the linkage test was 
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of influence, but only for individuals who had received a decreased risk test 
outcome. Noncarrriers with a low residual risk seemed to feel no need to 
reduce that risk any further. To our knowledge, informing tested individuals 
on the mutation test has not led to adverse effects. 
8a.5.5. Additional risk information for counsellors and counselees 
Generally, persons at risk are considered to be at 50% risk, as he or she 
has a probability of 50% of having inherited the disease. This probability, 
however, decreases with increasing age. The increased number of data on 
CAG-repeats and ages at onset within families allowed us to develop a 
model that estimates the reduced risk for HD regarding an individual's age, 
the parent's repeat length or age of onset, and other favourably tested 
family members. This model can be offered to individuals at risk who have 
not (yet) been tested and who do not have any symptoms. The model can 
only lead to a decreased risk estimation, while the mutation test can yield 
the irreversible outcome that one certainly will get HD. Nevertheless, this 
model is not primarily aimed at persons who do not whish to be tested for a 
variety of reasons. Generally, we speculate that these persons are not 
interested in their precise risk estimation. Our model and the accompanying 
spreadsheet are meant to broaden the range of information that clinical 
geneticists and genetic counsellors will be able to provide to persons who 
come for a genetic test and have no symptoms. They can offer them a best 
estimation of the residual risk in their specific circumstances. 
 All calculations are based on the best possible estimates of parameters 
and consequently all values of the CAG of a proband and Residual Risk 
Status (RRS) must be considered as best possible estimates too. A certain 
amount of uncertainty exists in this model, which will be reduced in the 
future when more data on CAG repeat lengths of parents and offspring, and 
more data on ages of onset will become available.  
 Counselees will generally be interested to learn whether their prior risk 
has substantially changed with increasing age, and what the best possible 
estimate of the RRS would be, given their situation. This might help in the 
decision to be tested and to be better prepared for the test result. This 
decision can depend on the actual RRS and the RRS in the near future. 
From the CAG repeat length estimated with our model and the tables 
published by Langbehn et al.44 it can be determined whether the individual 
is at a critical age regarding onset. During this critical period, the decrease 
of the RRS is most substantial, which can influence the decision to be 
tested soon or to postpone the test for a few years. 
 Persons at risk have encountered problems with insurance companies 
and employment.45-48 As it is ethically disputed to require a genetic test 
when persons apply for a job or a health or life insurance, a refinement of 
the actual risk for HD without actually performing a test can be a benefit for 
third parties such as insurance companies and employers. If we assume 
that third parties apply an estimation of 50% for offspring of HD patients, 
this model is also beneficial for individuals at risk, as the actual risk is 
virtually always lower. 
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8a.5.6. Structure of the Behaviour Observation Scale Huntington (BOSH) 
In the development of the BOSH, three principal components were found: 
deterioration of activities of daily living (ADL), deterioration of social and 
cognitive abilities, and mental rigidity and aggression. A good indicator for 
disease duration was not available because the age at onset was often 
determined retrospectively. In some cases, for instance, the age at onset 
was estimated by the date of admittance to a psychiatric hospital. If this 
admittance was indeed the result of disturbances caused by HD, then the 
age at onset was estimated too late. If not, then the age at onset was 
estimated too early. This resulted in a weak though significant relation 
between disease duration and deterioration of social-cognitive abilities. The 
institutional care period did not serve as a better indicator for disease 
duration either. On the one hand, impairment of motor functioning is 
important in the decision for placement in a nursing home. Patients can also 
have obsessions, compulsions, delusions, and auditory hallucinations. 
These behaviours may have been the compelling reason for admission in 
an institution.49 On the other hand, the decision to be placed in a nursing 
home is principally dependent on the presence of a caring spouse or other 
person, and less dependent on the capabilities of the patient and severity of 
HD. In the Belgian nursing home in this study, the absence of a caretaker is 
even a prerequisite for admission. Nevertheless, a significant linear relation 
between the care period and ADL was found. 
 A strong significant quadratic relation between rigidity-aggression and 
the ADL level was found. This can be interpreted as rigid and aggressive 
behaviour becoming more frequent at first, and less frequent later. It must 
be noted that the level of aggression is moderated, as the nursing homes try 
to reduce the aggression by psychological and pharmacological 
interventions. Future research should take into account sedative medicines. 
A similar relation, between inflexibility and disease duration was observed in 
the study of Craufurd et al.50 51 
 A second significant quadratic relation was found between social-
cognitive functioning and ADL level. Again, applying ADL level as an 
operationalization of disease progression, this indicates that the 
deterioration of social-cognitive capabilities progresses in later stages of the 
disease, when rigid and aggressive behaviour is decreasing. In other words, 
the decline of ADL and rigid and aggressive behaviour precedes the decline 
of social-cognitive behaviour. This is consistent with the observation of 
Bamford et al.52 that memory did not deteriorate until patients reached 
advanced stages of the disease. 
 The external validity of the BOSH needs to be assessed more 
extensively. In a subsequent study the BOSH in combination with the 
Unified Huntington Disease Rating Scale (UHDRS) will be administered. 
The UHDRS was developed by the US-based Huntington Study Group in 
199418 to provide a comprehensive assessment of motor performance, 
cognitive functioning, behavioural and psychiatric problems, and functional 
status of an individual. The UHDRS was not intended to provide an all-
encompassing description of every possible manifestation of HD.1 Though 
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the UHDRS does not differentiate in later stages of HD, a comparison of the 
BOSH with the UHDRS is needed. 
 The BOSH was developed in order to gain detailed insight into the 
progress of the disease and to distinguish individual differences between 
patients. A more detailed insight into these differences will facilitate a study 
of the relation of the phenotypic expression of HD with the pre-morbid 
personality and social support system. Finally, a better insight into this 
relation can be of help in better tailoring treatment to individual patients. 
 To date, there still is no cure for HD, and treatment for patients is limited 
to palliative aspects. The specific manifestations of HD justify nursing in 
specialised wards that have been established in many countries. There is 
an increasing knowledge of the clinical expressions of the disease in the 
mid-stages.50 53 To enable the development of tailored support programmes 
in the final stages, there is a need for a detailed description of the course of 
the disease that can help to improve the care of patients. 
8a.5.7. Concluding remarks 
The future perspectives of HD patients, mutation-carriers and individuals at 
risk are extremely difficult to cope with. Yet, compared with their affected 
parents they can perceive slight rays of hope. Thanks to the co-operation of 
patients, family members, and patient associations with scientific 
investigations, a lot of insight has been gained. Predictive tests have been 
developed, psychological counselling is offered, much has been revealed of 
psychological and psychosocial effects of testing. Genetic predictive testing 
have allowed studies on the onset of symptoms and improvement of the 
diagnostic process at an earlier stage. Nursing homes with specialised 
wards for HD patients have been established. Palliative treatment is 
available, and the first hints to the direction of finding a cure for HD emerge. 
 HD is a rather rare disease. For this reason, much more progression can 
be made when information and studies are brought together. An 
interventional trial, testing Riluzole in 450 patients in early stages of HD in 9 
countries throughout Europe, demonstrated that large scale studies on HD 
can be done in Europe. To allow a long-term observation period of HD-
patients and to create an appropriate infrastructure for clinical trials on HD 
in Europe, the Euro-HD Network was established in 2003. The Predict 
Study, one of the activities of the network, aims to assess the early clinical 
changes paralleling the onset of HD, using sophisticated and standardised 
measures of cognitive performance and volumetric assessment of serial 
brain magnetic resonance imaging.54 The database can be used to get 
more insight into the onset of symptoms in unaffected identified mutation 
carriers, to study the course of the disease after onset, and to investigate 
therapies meant to influence the course of HD or to delay the onset. 
 The Euro-HD Network provides a platform for professionals, people 
affected by HD and their relatives to facilitate working together throughout 
Europe. The Euro-HD Network facilitates natural history studies and 
interventional trials meeting high standards ('Good Clinical Practice' = GCP) 
thus helping on the road towards a cure of HD (http://www.euro-hd.net). The 
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Euro-HD Network aims to be a true network in that all participants involved 
can take a lead and propose, conduct and publish studies. The network 
provides an infrastructure for large-scale clinical trials on HD throughout 
Europe (database, IT-tools, monitoring personal etc.). An IT platform for 
communication tools (in the respective native languages) and e-trials. A 
forum for close cooperation of basic scientists and clinicians. Low threshold 
(native language!) support for study sites by language group coordinators. 
 The Euro-HD network encourages long-term investigations and 
stimulates the development of instruments that are used in the studies of 
HD. These instruments -tests, questionnaires, rating scales - are unified and 
translated in the languages of the participating countries. 
 There is no cure for HD yet. It is promising that the joint efforts and 
collaborations of the patients, their families, the Huntington associations, the 
physicians and the scientific researchers have contributed to make the 
burden of the disease and the future perspective more bearable for all 
individuals involved.  
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8b.1. ALGEMENE INLEIDING 
De ziekte van Huntington is een autosomaal dominante erfelijke ziekte die 
wordt gekenmerkt door onwillekeurige bewegingen, cognitieve 
achteruitgang, en psychiatrische problemen. De eerste verschijnselen 
openbaren zich meestal op middelbare leeftijd. Gemiddeld begint de ziekte 
tussen 43,7 en 55,8 jaar,1-3 met standaardafwijkingen van respectievelijk 
10,9 en 13,5 jaar.2 3 De mediaan van de ziekteduur is ongeveer 16,2 jaar3 
en uiteindelijk overlijdt de patiënt door complicaties ten gevolge van de 
ziekte.1 De ziekte komt naar schatting voor bij 5 - 10 per 100.000 personen 
van West-Europese afkomst,4 hoewel er aanwijzingen zijn dat het er meer 
zijn.5 De specifieke symptomen en beloop van de ziekte kunnen in verband 
worden gebracht met de neuropathologie, die gekenmerkt wordt door een 
verlies van bepaalde neuronengroepen, in het bijzonder in de basale 
ganglia van de hersenen.6 De ziekte wordt veroorzaakt door een CAG 
herhaling op de korte arm van het vierde chromosoom.7-10 Aangedane 
personen hebben herhalingen van 36 tot meer dan 100.8-10 De grenzen van 
deze herhalingen zijn als volgt vastgesteld: een normaal allel heeft ten 
hoogste 26 herhalingen, een intermediair allel heeft 27-35 herhalingen, 
ziekte met beperkte penetrantie heeft 36-39 herhalingen en een ziekte allel 
heeft tenminste 40 herhalingen.11 De aanvangsleeftijd is omgekeerd 
evenredig met het aantal CAG's,12 terwijl er geen samenhang is met de 
ziekteduur.13 
 Personen die één ouder met de ziekte van Huntington hebben, hebben 
50% kans om de ziekte te hebben geërfd. Aan het eind van de tachtiger 
jaren van de vorige eeuw kwam de voorspellende test beschikbaar. Deze 
test werd met enige terughoudendheid geïntroduceerd omdat een 
ongunstige uitslag verstrekkende gevolgen zou kunnen hebben. In 
Nederland heeft 24% van de risicodragers zich laten testen.14 
8b.2. ACHTERGROND VAN HET ONDERZOEK 
De introductie van de voorspellende test heeft een aantal psychologische 
vragen opgeroepen die een bijzondere aandacht verdienden. Het bleek dat 
de schok na een ongunstige testuitslag slechts van tijdelijke aard was. Zes 
maanden tot een paar jaar na de test was de stress weer tot pre-test niveau 
gedaald. Personen die een gunstige testuitslag kregen voelden een 
kortstondige opluchting na de test, maar ook zij keerden naar pre-test 
niveaus terug.15-17 Het Nederlandse onderzoeksprogramma richtte zich op 
de psychologische effecten op de lange termijn. 
 Aanvankelijk werd de test met koppelingsonderzoek uitgevoerd en had 
een betrouwbaarheid van 90-99%. In 1993 maakte de ontdekking van de 
CAG herhaling een directe mutatietest met een zekerheid van meer dan 
99% mogelijk. Er volgde in Nederland een uitgebreide discussie over de 
wenselijkheid om personen, die eerder waren getest met DNA-
koppelingsonderzoek, te informeren over de mutatietest. In 1997 werd hen 
aangeboden om zich opnieuw te laten testen. De belangstelling voor de 
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nieuwe zekere test en de lange termijn psychologische effecten werden 
toen systematisch onderzocht. 
 De bevindingen van de vervolgstudies hebben een diepgaande invloed 
gehad op de psychosociale ondersteuning en de kwaliteit van de 
voorspellende testprogramma's voor diverse erfelijke aandoeningen die op 
latere leeftijd optreden. Deze psychologische vervolgstudies dienen 
betrouwbare en effectieve methodologie te gebruiken. De methodologie van 
alle gepubliceerde vervolgstudies op het gebied van psychosociale effecten 
van voorspellend genetisch testen tussen 1988 en 2003 zijn onderzocht. 
 Erfelijkheidsadvisering heeft onder meer als doel een precieze 
risicoschatting te geven. De op DNA-koppelingsonderzoek gebaseerde 
voorspellende test gaf een schatting van het verhoogde of verlaagde risico, 
terwijl de mutatietest optimale zekerheid bood. De toenemende kennis over 
de aanvangsleeftijd en de relatie met het aantal CAG's, alsmede het aantal 
CAG's in nabije familieleden laten, voorafgaand aan de mutatietest, meer 
precieze risicoschattingen toe. 
 De voorbereiding op de toekomst is een van de belangrijkste redenen 
om zich te laten testen. Personen die een ongunstige testuitslag ontvangen, 
zullen naast nieuwe onzekerheden met betrekking tot de aanvang van de 
ziekte, ook de manier waarop de ziekte zich precies zal uiten onder ogen 
moeten zien. Hoe meer specifieke informatie beschikbaar is, hoe meer 
bewezen gendragers in staat zullen zijn om rekening te houden met hun 
toekomstperspectieven. De ontwikkeling van de ziekte is momenteel niet te 
vertragen, noch te stoppen. En hoewel er nog geen genezing mogelijk is, 
heeft de toegenomen kennis over de ziekte de verzorging en verpleging 
aanzienlijk verbeterd. Speciale Huntington afdelingen in verpleeghuizen in 
Nederland en België hebben veel ervaring opgedaan in de latere stadia van 
de ziekte. Het vooruitzicht van een goede verzorging in de latere stadia kan 
een geruststelling zijn en kan er aan bijdragen dat de negatieve ervaringen 
met de zorg voor familieleden in het verleden niet langer het eigen 
toekomstperspectief bepalen. Om de verzorging van de patiënten nog beter 
op maat te maken, is nog meer inzicht nodig in het beloop en voortgang van 
de ziekte in de verschillende stadia. De Unified Huntington's Disease Rating 
Scale (UHDRS) is een beschrijvende schaal, waarmee het motorisch 
functioneren, en de cognitieve-, gedrags- en functionele capaciteiten 
vastgelegd kunnen worden.18 De UHDRS maakt het mogelijk het beloop 
van de ziekte in de tijd te volgen, hoewel het instrument niet erg gevoelig is 
in de latere stadia van de ziekte. Er was behoefte aan een schaal waarmee 
de beperkingen van de ziekte in de latere stadia konden worden 
vastgesteld. Bovendien was er behoefte aan een betere indicator van de 
cognitieve en psychiatrische aspecten van de patiënt.19 De Gedrags 
Observatie Schaal Huntington (GOSH) is ontwikkeld als observatie 
instrument om de gedragsaspecten in de latere stadia te volgen. 
8b.3. DOEL VAN HET ONDERZOEK 
In dit proefschrift worden de volgende aspecten behandeld die met het 
voorspellend genetisch testen voor de ziekte van Huntington samenhangen: 
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− de lange termijn psychologische aanpassing na de testuitslag bij 
risicodragers en hun partners, 
− de gebruikte methodologie in vervolgonderzoek naar aanpassing aan 
genetische testuitslagen in het algemeen, 
− de kenmerken van personen die zich opnieuw hebben laten testen, 
− de berekening van het risico van personen die zich niet hebben laten 
testen. 
Daarnaast is een instrument ontwikkeld om het beloop van de ziekte vast te 
stellen, dat gemakkelijk en snel door verplegend personeel is in te vullen. 
8b.4. RESULTATEN 
In hoofdstuk 2 zijn de psychologische effecten 3 jaar na de test op geteste 
personen en hun partners beschreven. De intrusie- en 
vermijdingssubschalen van de Impact of Event Scale (IES)20 die 
ziektespecifieke stress meet, en de Beck Hopelessness Scale (BHS),21 die 
iemands toekomstverwachtingen meet, zijn voorafgaand aan de test, 1 
week, 6 maanden en 3 jaar na de test afgenomen. Variantie analyse met 
herhaalde metingen toonde gelijksoortige intrusiepatronen voor gendragers 
en niet-dragers, maar tegenovergestelde patronen voor vermijdingsgedrag 
na 6 maanden. Een week na de testuitslag rapporteerden gendragers een 
slechter toekomstperspectief en niet-dragers een beter 
toekomstperspectief. Deze effecten waren 6 maanden na de test 
verminderd en bleven daarna op hetzelfde niveau. Partners van de 
gendragers volgden hetzelfde beloop. Partners met kinderen waren 
psychisch meer aangedaan dan partners zonder kinderen. 
 In hoofdstuk 3 worden de effecten 7 tot 10 jaar na de test op geteste 
personen en hun partners gepresenteerd. Dit onderzoek omvat wereldwijd 
gezien de langste periode waarover psychologische effecten van genetisch 
testen van op latere leeftijd optredende erfelijke ziekten zijn onderzocht. 
Gendragers en hun partners waren direct na de test tijdelijk geschokt en 
meer aangeslagen, daarna, in de periode van 2 tot 3 jaar na de test werd 
hun toekomstvisie enigszins beter. Zij werden echter op de langere termijn, 
bij het naderen van de aanvangsleeftijd, weer pessimistischer. Niet-dragers 
rapporteerden grote opluchting na de testuitslag, maar keerden op termijn 
weer naar pre-test niveaus terug. Gendragers die na de uitslag geen 
vragenlijsten meer invulden, rapporteerden pre-test meer stress dan 
gendragers die de vragenlijsten wel invulden en terugkwamen voor 
vervolggesprekken. Gegeven dat de beste voorspeller voor psychologische 
stress na de testuitslag de stress voor de test is, verdient het aanbeveling 
na te denken hoe in de toekomst hulpverleners contact kunnen blijven 
houden met personen met hoge stress. Het lijkt erop dat onderzoeken, die 
weinig nadelige effecten rapporteren over personen met een ongunstig 
testresultaat, de werkelijke invloed onderschat hebben. 
 In het onderzoek naar de lange termijn effecten van testen kwam het 
belang van een adequate statistische techniek en de aandacht voor uitval 
van deelnemers naar voren. Dit leidde tot een onderzoek naar rapportage 
over uitval en de adequaatheid van technieken die in psychologische 
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vervolgstudies naar effecten van voorspellend testen werden gebruikt. De 
resultaten worden in hoofdstuk 4 beschreven. Het doel van dit 
systematische literatuuronderzoek is om de in dit soort vervolgonderzoek 
gebruikte statistische methoden te beschrijven en te beoordelen. Een 
literatuurzoektocht resulteerde in 40 longitudinale kwantitatieve 
onderzoeken, die aan de selectiecriteria voor dit literatuuronderzoek 
voldeden. Vijftien onderzoeken (38%) pasten adequate statistische 
technieken toe. De meerderheid, 25 onderzoeken, gebruikten minder 
geschikte of minder efficiënte statistische technieken. Negen onderzoeken 
(23%) rapporteerden in het geheel niet over uitval van respondenten, en 18 
(45%) onderzoeken deden geen mededelingen over de kenmerken van 
uitvallers. Dertien van de 22 onderzoeken met tenminste 3 meetmomenten, 
die over missende waarden gerapporteerd zouden behoren te hebben, 
deden dat daadwerkelijk. De conclusie is dat veel onderzoeken meer en 
betere resultaten zouden kunnen hebben als een meer adequate techniek 
was gebruikt. De meest voorkomende zwakheid was dat een statistische 
methode, geschikt voor hoogstens twee meetmomenten, werd gebruikt voor 
een onderzoek met meer meetmomenten. Dit was het geval in 14 van de 28 
betroffen studies. In veel van deze onderzoeken werden de analyses in 
deelanalyses uitgevoerd, met daardoor een minder compleet overzicht en 
minder inzicht in het totale beloop. 
 Uitval van deelnemers is een ernstig probleem in longitudinale 
onderzoeken. Hoewel zoveel mogelijk voorkomen moet worden dat 
personen zich aan het onderzoek onttrekken, zal er altijd om diverse 
redenen uitval zijn. Bij een onbekend adres of bij overlijden is het effect in 
het algemeen niet erg verstorend. Als de uitval echter wordt veroorzaakt 
door ongeïnteresseerdheid van de respondent, of door psychische 
problemen, dan kan dat het onderzoek wel ernstig verstoren. Selectieve 
uitval is met name beperkend voor de generalisatie van de 
onderzoeksresultaten. De conclusie bijvoorbeeld, dat een voorspellende 
test geen ernstige ongewenste psychologische gevolgen heeft, geldt niet 
voor de hele groep geteste personen als die conclusie gebaseerd is op 
personen die minder depressief zijn. In ons onderzoek22 is de groep, die 
gemakkelijker nadelige gevolgen kan ondervinden, inderdaad selectief uit 
het onderzoek verdwenen. Diverse onderzoeken hebben uitgewezen dat 
pre-test scores goede voorspellers zijn voor post-test scores.23 24 De groep 
met een pessimistischer toekomstperspectief en met hoge 
vermijdingsscores vóór de test is dus vatbaarder voor psychologische 
problemen na de test. In de toekomst moet door extra aandacht en steun 
voorkomen worden dat er een groep ontstaat die alle contact met de 
hulpverleners verliest. In slechts één ander onderzoek25 werd ook een 
selectieve uitval gemeld. Geen enkel ander onderzoek rapporteerde een 
selectieve uitval en bijna de helft (18) van de onderzoeken beschreef in het 
geheel niets over uitval. 
 Hoofdstuk 5 is gericht op de interesse voor een meer dan 99% zekere 
voorspellende test. In 1987 kwam de koppelingstest in Nederland 
beschikbaar.26 27 Deze test had een restrisico van 1-10% waarbij de 
medewerking van familieleden vereist was. In Nederland hebben 245 
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personen de koppelingstest laten uitvoeren. Twaalf van hen kregen geen 
testuitslag omdat de markeerpunten niet voldoende informatief waren, en 
23 personen kregen geen uitslag omdat de familiestructuur niet voldoende 
informatief was. Van de anderen bleken 88 personen gendragers en 122 
niet-dragers te zijn. Zes jaar later werd de genmutatie van de ziekte van 
Huntington gevonden en werd voorspellend testen met een zekerheid van 
meer dan 99% mogelijk.7 De medewerking van familieleden was toen niet 
meer nodig. In 1997 werd deze nieuwe mutatietest aangeboden aan de 210 
personen die een koppelingstestuitslag hadden ontvangen. Eenentachtig 
personen konden niet aan het onderzoek deelnemen. De belangrijkste 
redenen waren dat de mutatietest al eerder was uitgevoerd in combinatie 
met prenatale diagnostiek of dat inmiddels de diagnose Huntington was 
vastgesteld. Anderen waren overleden, waren verhuisd, waren om andere 
redenen niet meer te achterhalen of zij reageerden niet. Een 
onderzoeksgroep van 129 personen bleef over. Drie groepen werden 
vergeleken: (1) 18 personen die met mutatieanalyse waren getest tussen 
1993 en 1997 voor dit onderzoek was begonnen, (2) 29 personen die 
opnieuw getest werden nadat wij hun hadden geïnformeerd en (3) 82 
personen die de niet opnieuw wilden worden getest. Bijna de helft van de 
personen, die met koppelinganalyse waren getest, wilde opnieuw worden 
getest, met als uitzondering de personen die eerder een gunstige testuitslag 
hadden gekregen met een restrisico van 2% of minder. In deze laatste 
groep heeft minder dan 20% zich opnieuw laten testen. Gendragers die 
meer vertrouwen hadden in de toekomst (BHS)21 en een betere algemene 
gezondheid (GHQ)28 aangaven, kozen vaker voor de nieuwe, meer 
betrouwbare test. Niet-dragers, die hun eerdere uitslag lieten bevestigen, 
waren angstiger (HADS)29 dan niet-dragers die dat niet lieten doen. 
Vrouwelijke gendragers hadden vaker de voorspellende test laten 
bevestigen voordat onze informatiecampagne begon. Personen, die zich 
opnieuw lieten testen, waren jonger dan personen die dat niet lieten doen. 
Er zijn geen foutieve koppelingstestuitslagen aan het licht gekomen bij dit 
onderzoek. 
 In Nederland heeft een minderheid van de risicodragers (24%), zich 
sinds 1987 laten testen. Zij hebben daarmee precieze informatie over hun 
risicostatus. Het onderzoek in hoofdstuk 6 is gericht op het restrisico van 
risicodragers die zich (nog) niet hebben laten testen. Dit restrisico is vaak 
lager dan het a priori risico van 50% voor kinderen, of 25% voor 
kleinkinderen van gendragers. Wij hebben een model ontwikkeld om het 
verminderde risico te berekenen. Daarvoor hebben wij een gegevensset 
met aantallen CAG's en aanvangsleeftijden gebruikt, deze bevatte ook een 
deelgegevensset met CAG's van ouders en hun kinderen. In dit model 
wordt eerst de CAG van de ouder uit zijn of haar aanvangsleeftijd geschat. 
In een tweede stap wordt de CAG van de adviesvrager uit de CAG van de 
aangedane ouder geschat, waarbij rekening met het geslacht van die ouder 
wordt gehouden. Als derde stap wordt de kans bepaald dat de adviesvrager 
nog geen symptomen heeft, gegeven dat hij of zij gendrager zou zijn. 
Tenslotte wordt daaruit het restrisico berekend, waarbij ook rekening wordt 
gehouden met eventuele gunstige geteste kinderen. Dit model kan door 
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klinisch genetici worden gebruikt om het restrisico van een adviesvrager te 
bepalen. Doordat een spreadsheet beschikbaar is gesteld, is het voor de 
adviesgever betrekkelijk eenvoudig om dit restrisico te berekenen. In deze 
spreadsheet kan de leeftijd van de adviesvrager, de aanvangsleeftijd of de 
CAG van het aangedane familielid en het aantal gunstig geteste kinderen 
worden ingevoerd. Schattingen van de CAG en het restrisico worden dan 
als uitkomst gegeven. 
 De achteruitgang bij de ziekte van Huntington is niet te stoppen en ook 
niet te vertragen. Genezing is niet mogelijk. Een van de meest genoemde 
motieven om zich te laten testen was een betere voorbereiding op de 
toekomst. Personen met een ongunstige uitslag moeten nieuwe 
onzekerheden onder ogen zien. Daarbij gaat het om het begin van de ziekte 
en hoe deze zich zal openbaren. Bewezen gendragers zullen zich beter op 
hun toekomst kunnen voorbereiden als zij adequater over de 
bijzonderheden van het beloop van de ziekte worden ingelicht. De 
behandeling, de verzorging en de zorgmogelijkheden zijn verbeterd door 
meer kennis over de ziekte. De neurologische poliklinieken, het Huntington 
Steunpunt, en de speciale verpleegafdelingen voor Huntington patiënten in 
Nederland en België hebben veel ervaring opgedaan met Huntington 
patiënten in de verschillende stadia van de ziekte. Het vooruitzicht op een 
goede verzorging in de latere stadia kan een geruststelling zijn en kan er 
aan bijdragen dat de negatieve ervaringen met de zorg voor familieleden in 
het verleden niet langer het eigen toekomstperspectief bepalen. Om deze 
zorg verder te verbeteren is nog meer inzicht nodig in het beloop van de 
ziekte. In hoofdstuk 7 wordt de ontwikkeling van de Gedrags Observatie 
Schaal Huntington (GOSH) beschreven. In 1996 werd de UHDRS18 
geïntroduceerd om het klinisch beeld en functionele beperkingen bij de 
ziekte van Huntington te bepalen. Door plafondeffecten onderscheidt de 
UHDRS echter niet in latere stadia van de ziekte. De GOSH werd 
ontwikkeld om een gedetailleerde beschrijving van het gedrag van de 
patiënten in de laatste fasen van de ziekte te geven. De schaal bevat 32 
vragen met ieder vier antwoordcategorieën. Principale componenten 
analyse leverde drie subschalen op: (1) achteruitgang van activiteiten van 
het dagelijks leven (ADL), (2) sociaal-cognitieve achteruitgang en (3) 
mentale rigiditeit en agressie. De schaal is gevalideerd in vier 
verzorgingshuizen met een speciale Huntington afdeling. Verpleegkundigen 
hebben voor 91 patiënten de GOSH twee maal onafhankelijk van elkaar 
ingevuld. Interne betrouwbaarheden van de drie subschalen lagen tussen 
.83 en .94 en tussen-beoordelaar betrouwbaarheden lagen tussen .85 en 
.95. Er werden zwak significante verhoudingen gevonden tussen ziekteduur 
en vermindering van sociaal-cognitieve vermogens en rigide en agressief 
gedrag. Tussen componenten onderling werden sterkere significante 
verhoudingen gevonden. Non-lineaire verhoudingen bestonden tussen (1) 
achteruitgang van ADL en rigiditeit-agressie en (2) achteruitgang van ADL 
en sociaal-cognitieve achteruitgang. Rigide en agressief gedrag kwam bij 
de ontwikkeling van de ziekte steeds vaker voor, later verminderde dit 
gedrag weer. Sociaal-cognitieve vermogens gingen vooral in de laatste 
stadia van de ziekte achteruit. 
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8b.5. DISCUSSIE  
8b.5.1. Psychologische aanpassing aan de testuitslag 
De algemeen heersende opvatting was dat de gevolgen van voorspellend 
testen voor de ziekte van Huntington meer positief dan negatief waren.15-17 
Aangenomen werd dat men baat had bij het testen.30 Deze conclusie kan 
echter niet zonder meer worden getrokken. Tot 2003 waren er geen 
publicaties over een periode langer dan drie jaar na de test. In het 
onderzoek zeven tot tien jaar na de test gaven de gendragers aan slechtere 
toekomstperspectieven te hebben gekregen. Depressieve gevoelens en 
pessimistische toekomstverwachtingen kunnen eerste symptomen van de 
ziekte van Huntington zijn en derhalve de hogere scores verklaren. Echter, 
bij hun partners werd een zelfde verandering in toekomstperspectief 
waargenomen. Waarschijnlijker is dat de testuitslag, de naderende 
aanvangsleeftijd, het begin van de ziekte bij familieleden, verlieservaringen 
en andere Huntington gerelateerde levensgebeurtenissen deze 
verslechtering van het toekomstperspectief veroorzaakt hebben. Omdat de 
gemiddelde leeftijd op het laatste meetmoment 45 jaar was, uiteenlopend 
van 27 tot 73, zullen de eerste verschijnselen zich in de nabije toekomst 
gaan voordoen. 
 Deze resultaten zijn gebaseerd op een selectie van personen die zich 
hebben laten testen. Er was geen controlegroep van personen die dat niet 
hebben laten doen. Van der Steenstraten et al.31 bemerkten verschillen 
tussen wel en niet geteste personen. Personen die zich niet hebben laten 
testen voelden zich kwetsbaarder en minder goed in staat een slechte 
testuitslag te verwerken. Maar ook bij dat onderzoek moet worden 
opgemerkt, dat de onderzoeksgroep een selectie was, geworven uit leden 
van de Vereniging van Huntington. Het is denkbaar dat ook deze personen 
psychologisch stabieler waren. Voor meer definitieve conclusies is het 
aangewezen om niet-geteste risicodragers van rond de veertig jaar in een 
onderzoek te betrekken. 
8b.5.2. Uitvalanalyse 
Uitvallers in longitudinaal onderzoek zijn onvermijdelijk. Er bestaan diverse 
redenen waarom men niet meer aan het vervolgonderzoek deelneemt. Dit 
kunnen verhuizingen of niet te achterhalen adressen zijn. Men kan 
overlijden aan een ziekte of oorzaak die geen verband met de ziekte van 
Huntington heeft. Men kan voor de ziekte kenmerkende symptomen krijgen 
en daardoor van verdere analyses uitgesloten worden. In een aantal 
gevallen is de reden niet bekend. Één van die redenen kan zijn dat men niet 
meer wìl meewerken. Non-response is meestal niet toevallig. Uitvallers 
hebben vaak bepaalde kenmerken die een longitudinaal onderzoek kunnen 
ontkrachten.32 Bij longitudinaal onderzoek moet daarom een uitvalanalyse 
uitgevoerd worden. Uitvallers behoren vergeleken te worden met personen 
die in de studie behouden blijven op alle aanwezige biografische en 
psychologische uitkomstmaten. Daarbij kan geredeneerd worden dat als 
zulke verschillen niet worden gevonden, dat er dan ook geen reden is om 
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aan te nemen dat het onderzoek door selectieve uitval ontkracht wordt. 
Selectieve uitval wordt vaak gezien als een bedreiging voor de validiteit van 
het onderzoek. Een goede uitvalanalyse kan daarentegen juist zeer 
interessante inzichten bieden. In Tibben et al.33 werden geen significante 
verschillen tussen uitvallers en de andere deelnemers aan het onderzoek 
gevonden. Er bleek echter wel degelijk een significant verschil aanwezig. 
Dit werd pas vele jaren later gevonden, toen de effecten zeven tot tien jaar 
na de test geanalyseerd werden. De sleutel tot het probleem was het inzicht 
dat een gunstige testuitslag geheel anders verwerkt wordt dan een 
ongunstige uitslag. Toen uitvalanalyses op deze groepen afzonderlijk 
uitgevoerd werden, kwam naar voren dat uitgevallen gendragers, 
voorafgaand aan de test, meer vermijdend gedrag vertoonden, aanmerkelijk 
slechtere toekomstverwachtingen, meer intrusieve gedachten, en slechtere 
algemene gezondheidsscores hadden. Deze verschillen waren hoogst 
significant en effectgrootten varieerden van middelgroot tot zeer groot (0.6 - 
1.0). Daarmee werd dus niet alleen gevonden dat gendragers op lange 
termijn een slechter toekomstperspectief aangaven dan niet-dragers, maar 
deze bevinding was bovendien gebaseerd op een selectie van gendragers 
die psychologisch stabieler waren. Het is dus waarschijnlijk dat de effecten 
van een ongunstige testuitslag nog sterker zijn dan uit de longitudinale 
analyses alleen was af te leiden. 
 Genetici en psychosociale medewerkers schatten in of iemand een 
ongunstig testresultaat goed zal kunnen verwerken. Niettemin zouden meer 
angstige, depressieve of pessimistische personen, die een ongunstige 
testuitslag krijgen, op lange termijn extra professionele aandacht verdienen. 
Er zouden lange termijn vervolgafspraken geregeld moeten worden en 
zonodig zou naar additionele hulpverleners moeten worden verwezen. 
Ondanks al dit soort inspanningen moeten we er rekening mee blijven 
houden dat het aanbod van verdere steun wordt geweigerd, omdat elke 
confrontatie met de ziekte en de toekomst uit de weg wordt gegaan. 
8b.5.3. Het belang van een adequate statistische techniek 
Voor de analyse van het lange termijn onderzoek zeven tot tien jaar na de 
voorspellende test werd General Linear Mixed Modeling (GLMM) gebruikt. 
Deze methode is geschikt voor longitudinaal onderzoek met ontbrekende 
waarnemingen. Dit maakt een optimaal gebruik van de gegevens, 
deelnemers en meetmomenten mogelijk. Zo konden de vragenlijsten, die 
anderhalf jaar na de test afgenomen waren, ook verwerkt worden. Van dat 
meetmoment waren weinig gegevens, omdat het project toen tijdelijk 
onderbroken was. Als GLMM voor het onderzoek drie jaar na de test was 
gebruikt, en daarbij het anderhalf jaar meetmoment was geïncludeerd, dan 
had toen al aan het licht kunnen komen dat het toekomstperspectief van de 
gendragers zich minder gunstig ontwikkelde. 
 Een minder adequate techniek kan er ook toe leiden dat zwak 
significante verschillen niet worden opgemerkt. Dit kan optreden als een 
non-parametrische test gebruikt wordt waar een parametrische op zijn 
plaats is. Meestal leidt dit niet tot een ernstig powerverlies, want gewoonlijk 
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is de power van een non-parametrische test ongeveer 95% vergeleken met 
bijvoorbeeld die van een F-test. Soms kan de power echter wel drastisch 
verminderen. Als een analyse voor dichotome gegevens gebruikt wordt voor 
continue gegevens kan de efficiëntie dalen tot 63%.34 
8b.5.4. De introductie van een meer accurate DNA test 
In Nederland hebben aanzienlijk meer risicodragers zich laten testen dan in 
andere landen.14 De voornaamste reden om zich te laten testen was om 
verlost te worden van de ondragelijke onzekerheid. De grote noodzaak om 
zekerheid en geruststelling te krijgen wordt hiermee duidelijk. Toen de 
nieuwe, zekere mutatietest beschikbaar werd, ontstond er niettemin toch 
een discussie of de personen die met koppelingsanalyse getest waren, wel 
ingelicht moesten worden. Het Klinisch Genetisch Centrum Leiden wilde de 
nieuwe test aan iedereen aanbieden, die met koppelingsanalyse was 
getest. De Leidse Commissie Medische Ethiek (CME) vroeg zich echter af 
of men wel na zoveel jaar nog benaderd zou mogen worden, met het risico 
dat men daarmee ongevraagd problemen zou oprakelen. De CME 
redeneerde dat geteste personen zich aan hun testuitslag zouden hebben 
aangepast en een nieuwe balans in hun leven zouden hebben gevonden. 
Deze balans zou kunnen worden verstoord. Men zou de indruk kunnen 
krijgen dat de koppelingstestuitslag onzeker of misschien zelfs onjuist was. 
Zelfs de conclusie dat de test in het geheel niet goed geweest zou zijn, zou 
kunnen worden getrokken. 
 Aan de andere kant had men zich laten testen om optimale zekerheid te 
krijgen en daarmee het leven in te richten. Als een nieuwe techniek meer 
zekerheid geeft, dan moet die techniek ook worden aangeboden. 
Bovendien, vanuit een niet-directief en niet-paternalistisch oogpunt zou de 
beslissing voor een zekere test aan het geteste individu moeten worden 
overgelaten. Daar komt nog bij dat de Vereniging van Huntington al 
informatie over de directe test in hun kwartaalblad had gepubliceerd. Na 
enige jaren discussie, waarin de argumenten voor en tegen werden 
afgewogen, werd de conclusie getrokken dat de test mocht worden 
aangeboden aan allen die met koppelingsanalyse waren getest. 
 Voordat de mutatietest, die een betrouwbaarheid van praktisch 100% 
heeft, beschikbaar kwam, enquêteerden Babul et al.35 personen, die met 
koppelinganalyse getest waren. Er werd hun gevraagd of zij in een, toen 
nog hypothetische, 100% zekere test geïnteresseerd waren. Het bleek dat 
72% aangaf zich dan opnieuw te willen laten testen. Toen de test 
daadwerkelijk uitkwam, bleek in het Nederlandse onderzoek, dat het 
percentage personen dat zich opnieuw liet testen slechts 42% was.36 Een 
soortgelijke waarneming werd gedaan voorafgaand aan de koppelingstest 
in de jaren 1984-1987. Toen gaf 40% tot 84% van de risicodragers aan 
getest te willen worden.16 37-39 Het percentage dat zich sinds de introductie 
van de test daadwerkelijk heeft laten testen (2%-24%) viel echter beduidend 
lager uit.14 40-43 Het is duidelijk dat er een discrepantie bestaat tussen het 
voornemen om getest te worden en het daadwerkelijk laten uitvoeren ervan. 
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 Zoals verwacht, was het restrisico van de koppelingstest van invloed op 
de beslissing om zich opnieuw te laten testen, maar dat gold alleen voor 
personen die een gunstige uitslag hadden gekregen. Niet-dragers met een 
laag restrisico schenen minder noodzaak te voelen om dat risico nog verder 
te verlagen. Voor zover wij weten heeft het informeren van geteste 
personen over de mutatietest niet tot nadelige effecten geleid. 
8b.5.5. Additionele risico informatie voor hulpvragers en hulpverleners 
Algemeen wordt een risicodrager voor de ziekte van Huntington beschouwd 
als iemand met 50% kans om de ziekte te krijgen. Hij heeft immers een 
kans van 50% om de erfelijke eigenschap van de aangedane ouder bij zich 
te dragen. De kans neemt echter af bij het toenemen van de leeftijd.44 De 
hoeveelheid gegevens over CAG en aanvangsleeftijden binnen families 
maakte het mogelijk een model te ontwikkelen waarmee het risico 
nauwkeuriger kan worden ingeschat van iemand die (nog) niet getest is en 
symptoomvrij is. Dit gebeurt aan de hand van iemands leeftijd, de CAG of 
de aanvangsleeftijd van de ouder en van eventuele geteste familieleden 
met een gunstige testuitslag. Het model leidt alleen tot een lagere 
risicoschatting, terwijl de mutatietest tot een onomkeerbare uitkomst leidt. 
Het model is niet in de eerste plaats gericht op personen voor wie, om 
welke reden dan ook, de test geen optie is. Ons model en bijbehorende 
spreadsheet kunnen het repertoire van klinisch genetici uitbreiden. Klinisch 
genetici kunnen hiermee een meer precieze actuele risicoschatting van de 
adviesvrager bepalen. Een risico lager dan 50% kan de beleving van het 
persoonlijke risico beïnvloeden en een ander licht werpen op de motieven 
om meer zekerheid te wensen. 
 Alle berekeningen zijn gebaseerd op de best mogelijke 
parameterschattingen en zodoende dienen ook de restrisico's en CAG's van 
de adviesvrager als de beste schattingen beschouwd te worden. Deze 
schattingen hebben een zekere betrouwbaarheidsmarge. Als in de 
toekomst meer gegevens over CAG's, aanvangsleeftijden en de betreffende 
relaties tussen ouders en hun kinderen beschikbaar komen, kunnen deze 
marges kleiner worden en zullen de schattingen preciezer worden. 
 Adviesvragers willen vaak weten hoe groot hun risico is en hoe dat risico 
in de toekomst zal veranderen. Dit kan hen van dienst zijn bij de keuze om 
zich te laten testen en om zich beter op de uitslag voor te bereiden. Deze 
beslissing kan afhankelijk zijn van het actuele restrisico en het restrisico in 
de nabije toekomst. Aan de hand van ons model en de tabellen die door 
Langbehn et al.44 zijn gepubliceerd, kan worden bepaald of de adviesvrager 
betreffende de aanvangsleeftijd in een kritische periode is. In deze kritische 
periode is de afname van het restrisico het grootst en dat kan van invloed 
zijn op de beslissing om in korte termijn getest te willen worden of de test 
enige jaren uit te stellen. 
 Risicodragers kunnen problemen met verzekeringsmaatschappijen en 
het verkrijgen van werk ondervinden.45-48 Voor derden kan een nadere 
nuancering van het actuele risico nuttig zijn, zonder dat een genetische test 
wordt uitgevoerd. Aangenomen dat deze derden meestal een 
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risicoschatting van 50% voor kinderen van Huntington patiënten hanteren, 
biedt dit model ook voordelen voor de risicodragers, want het actuele risico 
is altijd lager dan het a priori risico. 
8b.5.6. Structuur van de Gedrags Observatie Schaal Huntington (GOSH) 
Bij de ontwikkeling van de GOSH werden drie principale componenten 
gevonden: achteruitgang van activiteiten van het dagelijks leven (ADL), 
achteruitgang van sociale en cognitieve vermogens, en mentale rigiditeit en 
agressie. Er was geen goede indicator voor ziekteduur beschikbaar omdat 
de aanvangsleeftijd vaak retrospectief bepaald was. Zo was in een aantal 
gevallen de aanvangsleeftijd bepaald aan de hand van de opname in een 
psychiatrisch ziekenhuis. Indien deze opname inderdaad het gevolg was 
van een stoornis die door de ziekte van Huntington was veroorzaakt, dan 
was de aanvangsleeftijd te laat ingeschat. Als dat niet het geval was, dan 
was de aanvangsleeftijd juist te vroeg ingeschat. Dit leidde tot een slechts 
zwak significante samenhang tussen ziekteduur en sociaal-cognitieve 
achteruitgang. De verplegingsduur was geen betere indicatie van de 
ziekteduur. De achteruitgang van motorische functies kan doorslaggevend 
geweest zijn in de beslissing tot plaatsing in een verpleeghuis. Bij andere 
patiënten kon de psychiatrische problematiek op de voorgrond staan 
waardoor opname in een verpleeginrichting noodzakelijk werd.49 De 
beslissing om opgenomen te worden kon ook afhankelijk zijn van de 
aanwezigheid van een verzorgende partner of een andere verzorger en in 
mindere mate van de beperkingen van de patiënt en ernst van de ziekte. In 
het Belgische verzorgingstehuis is het ontbreken van een verzorger zelfs de 
belangrijkste indicatie voor opname. Niettemin is er een zwak significante 
lineaire samenhang tussen de verzorgingsperiode en achteruitgang van 
ADL gevonden. 
 Er wel is een hoogst significante kwadratische relatie tussen rigiditeit-
agressie en ADL gevonden. Een verklaring is dat rigide en agressief gedrag 
aanvankelijk toeneemt en later weer afneemt. Een soortgelijke relatie 
tussen rigide gedrag en ziekteduur is beschreven in het onderzoek van 
Craufurd et al.50 51 Opgemerkt moet worden dat het agressieniveau beperkt 
wordt. In verpleeginrichtingen wordt agressie met psychologische 
behandeling en farmacotherapie bestreden. Toekomstig onderzoek zou 
rekening moeten houden met de aard en effecten van deze interventies. 
 Een tweede significante kwadratische relatie is gevonden tussen sociaal-
cognitief functioneren en ADL niveau. Als wederom het ADL niveau als 
operationalisatie van ziektevoortgang genomen wordt, dan duidt dit erop dat 
de achteruitgang van sociaal-cognitieve vermogens vooral in de latere 
stadia van de ziekte toeneemt, als rigide en agressief gedrag afnemen. Met 
andere woorden: de achteruitgang van ADL en rigide en agressief gedrag 
gaat vooraf aan de achteruitgang van sociaal-cognitief gedrag. Dit is in 
overeenstemming met de waarneming van Bamford et al.52 dat het 
geheugen pas in de laatste stadia van de ziekte verslechtert. 
 De externe validiteit van de GOSH kan nog beter bepaald worden. In 
een vervolgonderzoek zal de GOSH tezamen met de UHDRS afgenomen 
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worden. De UHDRS is door de Amerikaanse Huntington Study Group in 
1994 ontwikkeld voor een ruimere bepaling van iemands motorische, 
cognitieve en functionele vaardigheden, alsmede van de gedrags en 
psychiatrische problemen.18 Het was niet de bedoeling dat de UHDRS een 
alomvattende beschrijving van elke mogelijke uiting van de ziekte van 
Huntington zou geven.1 Hoewel de UHDRS niet goed in latere stadia van de 
ziekte differentieert, is een vergelijking tussen de GOSH en de UHDRS wel 
gewenst. 
 De GOSH is ontwikkeld om een gedetailleerd inzicht in het beloop van 
de ziekte te krijgen, en om individuele verschillen tussen patiënten te 
onderscheiden. Een meer gedetailleerd inzicht in deze verschillen is van 
belang voor een lopende studie naar de relatie tussen de fenotypische 
expressie van de ziekte van Huntington en de pre-morbide persoonlijkheid 
en het sociale ondersteuningssysteem. Uiteindelijk kan een beter inzicht in 
deze verhouding de begeleiding van patiënten verbeteren.  
 Tot op heden bestaat er geen genezing voor de ziekte van Huntington, 
de behandeling blijft beperkt tot palliatieve ondersteuning. De kenmerken 
van de ziekte rechtvaardigen verzorging in speciale verpleegafdelingen die 
in een toenemend aantal landen zijn ingericht. Er is een groeiende 
hoeveelheid kennis over de klinische expressie van de ziekte in de 
middenstadia.50 53 Om de ontwikkeling van toegespitste 
begeleidingsprogramma's in de laatste stadia mogelijk te maken, is er een 
nauwkeurige beschrijving van het ziektebeloop nodig. Daarmee kan de zorg 
voor de patiënten toegesneden en verbeterd worden. 
8b.5.7. Slotopmerkingen 
Het toekomstperspectief van patiënten met de ziekte van Huntington, 
gendragers en risicodragers is moeilijk in te schatten. Toch lijkt voor hen 
meer hoop gerechtvaardigd in vergelijking met hun aangedane ouders en 
voorouders. Dankzij de medewerking van patiënten, familieleden en de 
Vereniging van Huntington aan wetenschappelijk onderzoek naar de 
effecten van de voorspellende test is in de afgelopen 15 jaar veel inzicht 
verkregen in de beleving van de ziekte bij alle betrokkenen. Psychologische 
ondersteuning kan steeds beter toegesneden worden aangeboden. Met de 
mutatietest kan de ziekte in een eerder stadium worden vastgesteld of 
bevestigd. De mutatietest maakt ook wetenschappelijk onderzoek naar de 
eerste symptomen in een vroeger stadium mogelijk. Verpleeghuizen 
hebben speciale afdelingen opgericht waar goede verzorging op basis van 
kennis en ervaring met deze bijzondere ziekte kan worden aangeboden. De 
eerste aanwijzingen in de richting van het vinden van genezing dienen zich 
aan. 
 De ziekte van Huntington is een zeldzame ziekte. Er kan veel meer 
vooruitgang geboekt worden als kennis, informatie, en wetenschappelijk 
onderzoek gebundeld worden. Zo heeft er een interventiestudie 
plaatsgevonden met 450 patiënten in negen Europese landen waarin 
Riluzole in vroege stadia van de ziekte getest werd. Dit toonde aan dat 
grootschalig onderzoek in Europa mogelijk is. In 2003 werd het Euro-HD 
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netwerk opgericht. Dit netwerk beoogt een lange termijn observatieperiode 
van patiënten met de ziekte van Huntington, en het creëren van een 
passende infrastructuur voor klinisch onderzoek in Europa (http://www.euro-
hd.net). Met het Predict onderzoek, een van de activiteiten van het netwerk, 
wil men de klinische veranderingen bij het eerste begin van de ziekte 
vaststellen. Daarbij gebruikt men verfijnde en gestandaardiseerde 
cognitieve prestatiematen en wordt met seriële MRI (Magnetic Resonance 
Imaging) scans de omvang van de hersenen bepaald.54 Het 
gegevensbestand kan ook gebruikt worden om meer inzicht te krijgen in de 
allereerste symptomen bij nog niet aangedane gendragers. Ook kan het 
beloop van de ziekte na het begin worden bestudeerd en kunnen 
therapieën worden onderzocht die bedoeld zijn om het beloop van de ziekte 
te beïnvloeden. Het Euro-HD netwerk dient als een spreekbuis voor 
professionals, aangedane personen en hun familie om de samenwerking in 
Europa gemakkelijker te maken. Het Euro-HD netwerk bevordert ook 
biologisch en interventie onderzoek dat aan hoge standaarden voldoet, 
waarmee de weg naar genezing voor de ziekte van Huntington wordt 
vrijgemaakt. Het netwerk is erop gericht een echt netwerk te zijn, in die zin 
dat iedereen die zich met de ziekte van Huntington bezig houdt kan 
participeren in de ontwikkeling van onderzoeksvoorstellen en de uitvoering 
van onderzoek.  
 Het Euro-HD netwerk stimuleert de ontwikkeling van instrumenten die in 
de Huntington studies gebruikt worden. Deze instrumenten (testen, 
vragenlijsten en beoordelingsschalen) worden gestandaardiseerd en 
vertaald in de talen van de deelnemende landen. 
 De ziekte van Huntington is nog niet te genezen. Maar door de 
gezamenlijke inspanningen van patiënten en hun families, de Vereniging 
van Huntington, de bij de ziekte betrokken (para)medici, en de 
wetenschappelijk onderzoekers kunnen patiënten en hun families geholpen 
worden allerlei aspecten van de ziekte, hun leven en hun levensperspectief 
beter te leren verdragen.  
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8c.1. ALLGEMEINE EINLEITUNG 
Die Huntingtonsche Krankheit ist eine autosomal dominante Erbkrankheit, 
die durch unwillkürliche Bewegungen, kognitive Degeneration und 
psychiatrische Probleme charakterisiert wird. Die ersten Anzeichen treten 
normalerweise im mittleren Lebensalter auf. Durchschnittlich beginnt die 
Krankheit zwischen dem 43,7 und dem 55,8 Lebensjahr,1-3 
(Standardabweichungen 10,9 beziehungsweise 13,5 Jahre).2 3 Die 
Krankheit dauert im Median etwa 16,2 Jahre3; der Patient stirbt schließlich 
an Ursachen, die mit der Krankheit in Verbindung stehen.1 Die Prävalenz 
bei Menschen westeuropäischer Herkunft wird auf 5 - 10 pro 100.000 
Einwohner geschätzt,4 obwohl es Hinweise gibt, dass die Häufigkeit höher 
ist.5 Die kennzeichnenden Symptome und der Fortschritt der Krankheit 
beziehen sich auf die Neuropathologie, die von einem Verlust spezifischer 
Neuronen, insbesondere in den Oberschlundganglien, gekennzeichnet ist.6 
Die Krankheit wird von einer CAG-Wiederholung auf dem kurzen Arm des 
vierten Chromosoms verursacht.7-10 Erkrankte Personen haben 
Wiederholungen von 36 bis über 100.8-10 Die Grenzen dieser 
Wiederholungen sind folgendermaßen bestimmt: ein normales Allel hat 
höchstens 26 Wiederholungen, ein intermediäres Allel hat 27-35 
Wiederholungen, eine Erkrankung mit eingeschränkter Penetranz hat 36-39 
Wiederholungen und ein krankes Allel hat mindestens 40 
Wiederholungen.11 Das Anfangsalter steht in einem umgekehrten 
Zusammenhang mit der Wiederholungslänge,12 während es keinen 
Zusammenhang mit der Krankheitsdauer gibt.13
 Kinder eines Huntingtonpatienten haben eine 50% Chance, die 
Erkrankung selbst geerbt zu haben. Seit dem Ende der Achtziger Jahre des 
letzten Jahrhunderts steht ein prädiktiver DNA-Test zur Verfügung. Die 
Einführung des Tests wurde behutsam vorgenommen, da schwerwiegende 
Konsequenzen, insbesondere für Personen mit einem erhöhten Risiko, 
erwartet wurden. In den Niederlanden sind bereits 24% der Risikoträger 
getestet.14
8c.2. HINTERGUND DER FORSCHUNG 
Die Einführung des prädiktiven Tests warf eine Vielzahl psychologischer 
Fragen auf, die besonderer Aufmerksamkeit bedürfen. Es zeigte sich, dass 
ein ungünstiges Testergebnis vorübergehend psychische Beschwerden 
verursachte, welche sich sechs Monate bis ein paar Jahre nach dem Test 
wieder auf Prä-Test Niveau verringerten. Teilnehmer, die ein günstiges 
Ergebnis erhielten, erlebten eine kurzfristige Erleichterung, kehrten aber 
mittelfristig ebenfalls auf das Prä-Test Niveau zurück.15-17 Das 
Niederländische Forschungsprogramm hatte die Untersuchung der 
langfristigen psychologischen Effekte zum Ziel. 
 1993 ermöglichte die Entdeckung der CAG-Wiederholung einen direkten 
Mutationstest mit einer Sicherheit von über 99%. Nach einer ausführlichen 
Diskussion, ob zuvor getestete Personen über den Mutationstest informiert 
und diesen angeboten bekommen sollten, wurde dieser Test 1997 
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angeboten. Dies ermöglichte die Untersuchung des Interesses am neuen 
Test und die langfristigen psychologischen Effekte. 
 Die Ergebnisse der Follow-up Studien hatten einen starken Einfluss auf 
die psychosoziale Unterstützung und die Qualität des prädiktiven 
Testprogramms bei mehreren Erbkrankheiten, die in fortgeschrittenem 
Lebensalter auftreten. Es wird angenommen, dass diese Studien 
zuverlässige und effektive Methoden anwenden. Die Methodologie nahezu 
aller zwischen 1988 und 2003 publizierten Follow-up Studien über die 
psychosozialen Effekte von Gentests wurde von uns untersucht. 
 Genetische Beratung zielt unter anderem auf eine genaue 
Risikobewertung. Der auf Kopplungsanalyse basierende prädiktive Test 
resultiert in der Einschätzung eines erhöhten oder verminderten Risikos, 
während der Mutationstest eine optimale Sicherheit gibt. Die zunehmende 
Kenntnis über das Erkrankungsalter, dessen Beziehung zur CAG-
Wiederholungslänge, und die CAG-Wiederholungslänge bei nahen 
Verwandten ermöglichen genauere Risikoabschätzungen vor dem 
Mutationstest. 
 Die Vorbereitung auf die Zukunft ist einer der wichtigsten Gründe, einen 
prädiktiven Test durchführen zu lassen. Personen, die ein ungünstiges 
Testresultat empfangen, werden neuen Unsicherheiten bezüglich des 
Ausbruchs der Krankheit und der Weise, wie die Krankheit sich 
manifestieren wird, gegenübertreten müssen. Je mehr spezifische 
Information verfügbar sein wird, desto mehr identifizierte Genträger werden 
imstande sein, ihren Zukunftsaussichten entgegenzusehen. Die 
Huntingtonsche Krankheit schreitet über die Zeit hinweg fort. Obwohl 
Heilung noch unmöglich ist, hat die zunehmende Kenntnis über die 
Krankheit die Versorgung und die Pflege bedeutend verbessert. 
Spezialabteilungen in den Niederlanden und Belgien haben umfangreiche 
Erfahrung mit Huntingtonpatienten in späteren Erkrankungsphasen 
gesammelt. Die Aussicht auf eine gute Versorgung in späteren Phasen 
kann beruhigend wirken und einen Beitrag leisten, die entsetzlichen 
Erlebnisse mit der Pflege von Verwandten in der Vergangenheit zu 
vergessen. Jedoch ist mehr Einblick in den Verlauf und den Fortschritt der 
Krankheit in verschiedenen Phasen nötig, um die Versorgung besser 
anzupassen. Die Unified Huntington's Disease Rating Scale (UHDRS) 
wurde als eine klinische Beurteilungsskala entwickelt, um die vier 
Leistungsbereiche, die von der Krankheit betroffen sind, zu bestimmen: das 
motorische Funktionsniveau, das kognitive Funktionsniveau, 
Verhaltensstörungen und die funktionale Kapazität.18 Die UHDRS 
ermöglicht die Beobachtung des Krankheitsverlaufes, obwohl das 
Instrument in späteren Phasen der Krankheit nicht sehr sensitiv ist. Daher 
fehlte eine Skala, die stärker auf spätere Phasen der Krankheit gerichtet ist. 
Darüber hinaus war ein besserer Indikator für die kognitiven und 
psychischen Aspekte des Patienten nötig.19 Die Behaviour Observation 
Scale Huntington (BOSH) wurde als Beobachtungsinstrument entwickelt, 
um die Verhaltensaspekte in späteren Phasen der Erkrankung zu 
betrachten. 
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8c.3. ZIEL DER FORSCHUNG 
In dieser Arbeit werden folgende, mit dem Gentest bei der Hungtington-
Erkrankung zusammenhängende psychologische Aspekte behandelt: 
- langfristige psychologische Anpassung von Risikoträgern und ihren 
Partnern an das Testresultat 
- in der Forschung angewendete Methoden zur Untersuchung der 
Anpassung an die Ergebnisse von Gentests im Allgemeinen 
- die Merkmale getesteter Personen mit einem sicheren Testergebnis  
- die Risikoberechnung nicht getesteter Personen 
Zudem wurde ein Instrument zur Erfassung des Fortschreitens der 
Krankheit entwickelt, das einfach und schnell vom Pflegepersonal 
angewendet werden kann. 
8c.4. ERGEBNISSE 
In Kapitel 2 werden die psychologischen Effekte des prädiktiven Tests bei 
Getesteten und ihren Partnern nach drei Jahren beschrieben. Die 
Intrusions- und Vermeidungssubskalen der Impact of Event Scale (IES)20, 
die krankheitsspezifisches Verhalten misst, und die Beck Hopelessness 
Scale (BHS),21 die Zukunftserwartungen erfasst, wurden vor dem Test 
sowie eine Woche, sechs Monate und drei Jahre nach dem Test erhoben. 
Varianzanalysen mit wiederholten Messungen zeigten gleichartige 
Intrusionspatterns für Genträger und Nichtträger, jedoch entgegengesetzte 
Vermeidungsmuster nach sechs Monaten. Eine Woche nach dem Test 
berichteten Genträger schlechtere und Nichtträger bessere 
Zukunftserwartungen. Diese Effekte verminderten sich sechs Monate nach 
dem Test und blieben danach stabil. Die Partner von Genträgern hatten 
denselben Verlauf. Partner mit Kindern waren psychisch stärker 
beeinträchtigt als Partner ohne Kinder. 
 In Kapitel 3 werden die Effekte, die sieben bis acht Jahre nach dem 
Test auftreten, dargestellt. Diese Studie untersucht mit der weltweit 
längsten Zeitspanne die psychologischen Effekte von Gentests für im 
mittleren Erwachsenenalter auftretende Erbkrankheiten. Genträger und ihre 
Partner waren unmittelbar nach dem Test vorübergehend beeinträchtigt, 
jedoch verbesserten sich ihre Erwartungen zwei bis drei Jahre nach dem 
Test. Sie wurden aber langfristig, mit Näherrücken des prognostizierten 
Krankheitsbeginns, wieder pessimistischer. Nichtträger berichteten große 
Erleichterung nach dem Testergebnis, kehrten aber langfristig wieder auf 
das Prä-Test Niveau zurück. Genträger, die nach dem Testergebnis keine 
Fragebögen mehr ausfüllten, berichteten vor dem Test mehr 
psychologischen Stress als solche, die die folgenden Fragebögen ausgefüllt 
hatten und weitere Beratungen in Anspruch nahmen. Für den Fall, dass 
sich die Prä-Test Beeinträchtigung als der beste Prädiktor für Post-Test 
Beeinträchtigung erweisen sollte, ist den zuständigen Beratern zu 
empfehlen, zukünftig Kontakt mit stärker beeinträchtigten Testpersonen zu 
halten. Studien, die bei Testpersonen mit einem ungünstigen Testergebnis 
kaum schädliche Effekte berichten, scheinen den wirklichen Einfluss des 
Testergebisses unterschätzt zu haben. 
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 Bei der Untersuchung langfristiger Effekte des Gentests sind adäquate 
statistische Methoden von großer Bedeutung. Daher wurden die 
statistischen Methoden, die in anderen Langzeitstudien über die 
psychologischen Folgen des prädiktiven Testens angewendet werden, auf 
ihre Angemessenheit hin untersucht. Die Ergebnisse werden in Kapitel 4 
beschrieben. Das Ziel dieses systematischen Literatur-Reviews ist die 
Beschreibung und Beurteilung der statistischen Methoden, die in den 
Follow-up Studien verwendet werden. Eine Literaturrecherche ergab 40 
longitudinale quantitative Studien, die den gestellten Selektionskriterien 
entsprachen. Fünfzehn Studien (38%) wendeten adäquate statistische 
Methoden an. Die Mehrheit (25 Studien) verwendeten weniger geeignete 
oder weniger effiziente Methoden. Neun Studien (23%) berichteten keine 
Dropout-Rate und in 18 Studien (45%) wurden keine Merkmale der 
Dropouts beschrieben In dreizehn der 22 Studien mit mindestens drei 
Messzeitpunkten wurden wie erwartet die fehlenden Werte über die Zeit 
hinweg beschrieben. Daraus ist zu schließen, dass viele Studien mehr und 
bessere Ergebnisse gebracht hätten, wenn angemessenere Methoden 
angewendet worden wären. Die häufigste methodische Schwäche war die 
Anwendung von statistischen Methoden, die für höchstens zwei Zeitpunkte 
geeignet sind, in Studien mit mehr als zwei Zeitpunkten. Dies war bei 14 
von 28 Studien der Fall. In vielen dieser Studien wurden die Analysen in 
Teilanalysen unterteilt, was zu einem weniger vollständigen Überblick und 
einem geringeren Einblick in den Gesamtverlauf führt. 
 Dropout ist ein wichtiges Problem in longitudinalen Follow-up-Studien. 
Obwohl jede Möglichkeit, den Dropout von Teilnehmern zu vermeiden, 
ausgeschöpft werden muss, ist Dropout nicht vollständig zu verhindern. 
Dropout kann mehrere Ursachen haben. Falls eine unbekannte Adresse 
oder ein Todesfall vorliegt, ist der Einfluss auf die Forschungsergebnisse in 
der Regel weniger bedeutsam. Falls Dropout jedoch auf mangelndes 
Interesse oder psychische Probleme des Teilnehmers zurückzuführen ist, 
kann das Ergebnis erheblich verzerrt werden. Selektiver Dropout kann 
insbesondere die Generalisierung der Forschungsergebnisse verhindern. 
Beispielsweise kann die Folgerung, dass Gentests keine bedeutsamen 
schädlichen psychologischen Konsequenzen haben, nicht auf die 
Gesamtgruppe getesteter Personen verallgemeinert werden, wenn das 
Ergebnis nur für Personen mit einem geringen Risiko, eine Depression zu 
entwickeln, gilt. In unsere Studie22 ist die Personengruppe, die mit höherer 
Wahrscheinlichkeit schädliche Konsequenzen erleben könnte, tatsächlich 
selektiv aus der Studie ausgeschieden. Mehrere Studien haben gezeigt, 
dass Prä-Test Werte sehr gute Prädiktoren für Post-Test Werte sind.23 24 
Personen mit negativen Zukunftserwartungen und hohen 
Vermeidungsscores leiden also mit höherer Wahrscheinlichkeit nach dem 
Test unter psychologischen Problemen. Deswegen benötigt diese Gruppe, 
die jeden Kontakt mit den Beratern verloren hat, besondere Aufmerksamkeit 
und Unterstützung. Nur in einer anderen Studie25 wurde ein selektiver 
Dropout berichtet. Keine andere Studie berichtet einen selektiven Dropout 
und in fast der Hälfte (18) der Studien wurde kein Dropout beschrieben. 
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 In Kapitel 5 wird die Akzeptanz eines zu mehr als 99% sicheren 
prädiktiven Tests dargestellt. 1987 wurde der prädiktive Kopplungstest 
verfügbar.26 27 Dieser Test, bei dem die Mithilfe von Verwandten erforderlich 
ist, hat ein Restrisiko von 1-10%. In den Niederlande hatten sich 245 
Personen dem Kopplungstest unterzogen. Zwölf von ihnen hatten kein 
Testergebnis bekommen, weil die Marker nicht genügend Informationen 
enthielten. Weitere 23 Personen hatten wegen ungenügender Information 
zu ihrer Familienstruktur kein Testergebnis erhalten. 88 der übrigen 
Personen waren Genträger und 122 waren Nichtträger. Sechs Jahre später 
wurde die Genmutation der Huntington-Krankheit identifiziert und damit ein 
Test mit einer Sicherheit von mehr als 99% möglich. Das Testen von 
Verwandten war nicht mehr erforderlich.7 1997 wurde dieser neue 
Mutationstest den 210 Personen, die das Ergebnis des Kopplungstests 
erhalten hatten, angeboten. 81 Personen konnten nicht an der Studie 
teilnehmen. Die Hauptgründe dafür waren, dass bereits ein Mutationstest 
durchgeführt worden war oder bereits die ersten Krankheitsanzeichen 
vorlagen. Andere Personen waren gestorben, umgezogen, wegen anderer 
Gründe nicht auffindbar oder reagierten nicht. Daraus resultierte ein 
Untersuchungssample von 129 Personen. Es wurden drei Gruppen 
miteinander verglichen: (1) 18 Personen, die sich zwischen 1993 und 1997, 
vor dem Beginn dieser Studie, mit der Mutationsanalyse hatten testen 
lassen, (2) 29 Personen, die wieder getestet wurden, nachdem wir sie 
informiert hatten und (3) 82 Personen, die sich nicht noch einmal testen 
lassen wollten. Fast die Hälfte der Personen, die mit der Kopplungsanalyse 
getestet worden waren, ließ sich wieder testen. Eine Ausnahme bildeten 
Personen mit einem günstigen Ergebnis (Nichtträger) und einem sehr 
geringen Restrisiko im Kopplungstest, von denen sich weniger als 20% 
wieder testen ließ. Optimistischere Genträger (BHS)21 mit besserem 
Wohlbefinden (GHQ)28 ließen häufiger den neuen Test durchführen. 
Nichtträger, die ihr früheres Testergebnis durch den neuen Test bestätigen 
lassen wollten, waren ängstlicher (HADS)29 als Nichtträger, die sich nicht 
wieder testen ließen. Weibliche Genträger hatten sich häufiger erneut 
testen lassen, noch bevor unsere Informationskampagne gestartet war. 
Personen, die sich erneut testen ließen, waren zum Testzeitpunkt jünger. In 
dieser Studie konnten alle Ergebnisse des Kopplungstests bestätigt werden. 
 In den Niederlanden hat sich eine Minderheit (24%) der Risikoträger seit 
1987 testen lassen. Damit sind sie genau über ihr Risiko informiert. Die 
Studie, die in Kapitel 6 dargestellt wird, beschäftigt sich mit dem Restrisiko 
von Personen, die sich (noch) nicht haben testen lassen. Dieses Restrisiko 
ist oft niedriger als das a priori Risiko für Kinder (50%) oder für Enkelkinder 
(25%) von Genträgern. Wir haben ein Modell zur Berechnung des 
verminderten Restrisikos entwickelt. Dafür verwendeten wir eine Datenbank 
mit CAG-Zahlen und dem Alter bei Krankheitsbeginn und eine 
Teildatenbank mit CAG-Zahlen von Eltern und ihren Kindern. Im ersten 
Schritt dieses Modells wird die CAG-Wiederholungslänge des Elternteils 
aus dem Alter bei Krankheitsbeginn geschätzt. Im zweiten Schritt wird 
hieraus die CAG-Länge des Probanden geschätzt, wobei das Geschlecht 
des betroffenen Elternteils berücksichtigt wird. Im dritten Schritt wird die 
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Wahrscheinlichkeit, dass der Proband – vorausgesetzt, er oder sie sei 
Genträger - noch keine Krankheitssymptome aufweist, bestimmt. 
Schließlich wird daraus das Restrisiko des Probanden berechnet, wobei die 
Information über eventuell getestete Geschwister (Nichtträger) 
berücksichtigt wird. Dieses Modell kann von Mitarbeitern in der genetischen 
Beratung angewendet werden, um das Restrisiko eines Probanden zu 
bestimmen. Dank einer dafür zur Verfügung gestellten Kalkulationstabelle 
ist die Berechnung dieses Restrisiko relativ einfach. In diese 
Kalkulationstabelle wird das Alter des Probanden, das Alter bei 
Krankheitsbeginn oder die CAG-Wiederholungslänge des erkrankten 
Verwandten und die Anzahl eventueller als Nichtträger getesteter Kinder 
eingetragen. Als Ergebnis erhält man die Schätzung der CAG-
Wiederholungslänge und des reduzierten Restrisikos. 
 Chorea Huntington ist eine Krankheit mit progressivem Verlauf, für die 
es bisher keine Heilung gibt. Einer der meist genannten Beweggründe, sich 
testen zu lassen, ist eine bessere Vorbereitung auf die Zukunft. Als 
Genträger getestete Personen sehen sich neuen Unsicherheiten in bezug 
auf den Krankheitsbeginn und die Art der Krankheitsmanifestation 
gegenüber. Als Genträger identifizierte Personen werden sich besser auf 
die Zukunft vorbereiten können, wenn sie besser über die Besonderheiten 
des Krankheitsverlaufs informiert werden. Die Behandlung der Krankheit 
und die Versorgung der Erkrankten haben sich mit zunehmender Kenntnis 
über die Huntingtonsche Krankheit verbessert. Die neurologischen 
Tageskliniken, das Spezialzentrum für Huntington (Huntington Steunpunt) 
und die Spezialabteilungen für Huntington-Patienten in den Niederlanden 
und in Belgien haben viel Erfahrung mit Huntington-Patienten in 
verschiedenen Krankheitsphasen gesammelt. Die Aussicht auf eine gute 
Versorgung in späteren Krankheitsphasen kann beruhigend wirken und 
dazu beitragen, die negativen Erfahrungen mit der Pflege erkrankter 
Verwandter in der Vergangenheit zu vergessen. Um die Versorgung und 
Pflege besser den Bedürfnissen der Hungtinton-Patienten anzupassen, ist 
jedoch mehr Einblick in den Verlauf der Krankheit notwendig. In Kapitel 7 
wird die Entwicklung der BOSH (Behaviour Observation Scale Huntington - 
Verhaltensbeobachtungsskala bei Huntington) beschrieben. 1996 war die 
UHDRS18 (Unified Huntingtons Disease Rating Scale) eingeführt worden, 
um klinische Leistungs- und Kapazitätsparameter der Huntingtonschen 
Krankheit zu bestimmen. Aufgrund von Deckeneffekten differenzierte die 
UHDRS jedoch nicht in späteren Krankheitsphasen. Die BOSH wurde 
entwickelt, um eine detaillierte Beschreibung des Verhaltens in späteren 
Phasen der Krankheit zu erhalten. Der Fragebogen enthält 32 Items mit vier 
Antwortmöglichkeiten. Eine Hauptkomponentenanalyse führte zu drei 
Subskalen: (1) Abnahme von Aktivitäten des täglichen Lebens (Activities of 
Daily Living, ADL), (2) Abnahme des sozial-kognitiven Funktionsniveaus 
und (3) mentale Rigidität und Aggression. Der Fragebogen wurde in vier 
Pflegeheimen mit Spezialabteilungen für Huntington-Patienten validiert. Bei 
91 Patienten wurde die BOSH von zwei Krankenpflegern unabhängig 
voneinander ausgefüllt. Die internen Konsistenzen der drei Subskalen lagen 
zwischen .83 und .94, die Interrater-Übereinstimmungen zwischen .85 und 
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.95. Es wurde eine lineare Beziehung zwischen der Krankheitsdauer und 
der Abnahme der ADL gefunden. Nicht-lineare Beziehungen wurden 
gefunden zwischen (1) Abnahme der ADL und Rigidität-Aggression und (2) 
Abnahme der ADL und sozial-kognitiver Fähigkeiten. Rigides und 
aggressives Verhalten trat zunächst mit zunehmendem Krankheitsverlauf 
häufiger auf, nahm aber in späten Krankheitsphasen wieder ab. Sozial-
kognitive Fähigkeiten verschlechterten sich vor allem in den letzten 
Krankheitsphasen. 
8c.5. DISKUSSION 
8c.5.1. Psychologische Adaptation infolge des Testergebnisses 
Es war allgemein herrschende Meinung, dass der prädiktive Gentest bei 
Chorea Huntington mehr positive als negative Konsequenzen nach sich 
zieht.15-17 Dies führte zu der Annahme, dass getestete Personen vom Test 
profitierten.30 Diese Schlussfolgerung kann allerdings nicht ohne 
Einschränkungen getroffen werden. Bis 2003 wurden keine Studien 
veröffentlicht, die eine Zeitspanne von mehr als drei Jahren nach dem Test 
eingeschlossen hatten. In der Studie verschlimmerten sich sieben bis zehn 
Jahre nach dem Testergebnis die Hoffnungslosigkeitsgefühle bei den 
Genträgern. Die ersten Krankheitssymptome können Gefühle von 
Hoffnungslosigkeit oder Depression sein, was die höheren Werte bei 
Genträgern verursacht haben könnte. Dies gilt jedoch nicht für die Partner 
der Genträger, die ähnlich starke Hoffnungslosigkeitsgefühle berichteten. 
Daher ist anzunehmen, dass das Testergebnis, das nahende Alter des 
Krankheitsbeginns, der Ausbruch der Krankheit bei Verwandten, 
Verlusterfahrungen und Huntington-spezifische Lebenserfahrungen die 
Verschlechterung der Zukunftserwartungen verursachten. Da das 
Durchschnittsalter der Genträger beim letzten Messzeitpunkt 45 Jahre 
betrug (Range: 27 bis 73 Jahre), werden bei vielen von ihnen die ersten 
Symptome der Krankheit in naher Zukunft auftreten. 
 Diese Ergebnisse beziehen sich auf eine Auswahl von Personen, die 
den prädiktiven Test durchführen ließen. Es gab keine Kontrollgruppe mit 
nicht getesteten Personen. Van der Steenstraten et al.31 berichten 
Unterschiede zwischen getesteten und nicht getesteten Personen. Nicht 
getestete Personen fühlten sich verletzbarer und weniger gut in der Lage, 
ein ungünstiges Testergebnis zu bewältigen. Allerdings muss berücksichtigt 
werden, dass bei dieser Studie das Untersuchungssample aus Freiwilligen 
der Niederländischen Huntington Vereinigung rekrutiert worden war. Diese 
Freiwilligen könnten einer selektiven Gruppe von psychisch stabileren 
Personen angehören. Für definitive Schlussfolgerungen wäre es 
interessant, nicht getestete Risikoträger im Alter von etwa 40 Jahren zu 
untersuchen. 
8c.5.2. Dropout-Analyse 
Das Dropout-Problem ist in longitudinalen Studien unvermeidbar. Es gibt 
verschiedene Gründe, warum Probanden nicht mehr an der Studie 
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teilnehmen. Manche ziehen um und ihre Adresse ist nicht mehr auffindbar. 
Manche sterben an einer Krankheit, die nichts mit Huntington zu tun hat, 
oder entwickeln die ersten Symptome der Huntington-Krankheit und sind 
daher von weiteren Analysen ausgeschlossen. Auf der anderen Seite gibt 
es Personen, die einfach nicht mehr teilnehmen möchten. Wenn auf die 
Bitte hin, Fragebögen auszufüllen, gar nicht reagiert wird, bleiben die 
Gründe für den Non-Response im allgemeinen unbekannt. Dabei ist 
anzumerken, dass Non-Response in der Regel nicht zufällig auftritt. 
Dropouts weisen oft bestimmte Charakteristika auf, die die Validität einer 
Langzeitstudie infrage stellen können.32 Bei longitudinalen Studien sollte 
deshalb eine Dropout-Analyse durchgeführt werden. Dropouts sollten mit 
Personen, die die Studie beenden, bezüglich aller biografischen und 
ergebnisbezogenen Variablen verglichen werden. Falls keine Unterschiede 
gefunden werden, gibt es keinen Grund anzunehmen, die Validität der 
Studie sei durch selektiven Dropout geschwächt. Selektiver Dropout wird oft 
als eine Bedrohung der Validität der Studie angesehen. Eine gründliche 
Dropout-Analyse kann allerdings sehr interessante Einblicke bieten. Tibben 
et al.33 fanden keine signifikanten Unterschiede zwischen Dropouts und 
Personen, die in der Studie verblieben waren. Jedoch wurde Jahre später, 
als die Effekte sieben bis zehn Jahre nach dem Test analysiert wurden, ein 
Unterschied gefunden. Der Schüssel für dieses Problem war die Erkenntnis, 
dass sich Personen mit einem positiven Testergebnis ganz anders an das 
Ergebnis anpassen als Personen mit einem negativen Ergebnis. Als für 
diese Gruppen getrennte Dropout-Analysen durchgeführt wurden, wiesen 
Genträger, die die Studie abgebrochen hatten, vor dem Test bedeutend 
schlechtere Zukunftserwartungen, ein schlechteres allgemeines 
Wohlbefinden, mehr Intrusionsgedanken und mehr Vermeidungsverhalten 
auf. Diese Unterschiede waren hoch signifikant und die Effektgrößen 
variierten von mittelgroß bis sehr groß (0.6 - 1.0). Demnach wurde nicht nur 
gefunden, dass Genträger langfristig schlechtere Zukunftserwartungen 
zeigten als Nichtträger, sondern auch, dass dieses Ergebnis auf einer 
selektiven Gruppe von Genträgern, die weniger psychologisch 
beeinträchtigt waren, basierte. Vermutlich sind die Effekte eines 
ungünstigen Testergebnisses noch schlimmer als aus den longitudinalen 
Analysen allein hervorgegangen war. 
 Genetiker und Mitarbeiter im psychosozialen Bereich schätzen ab, ob 
eine Person ein ungünstiges Testergebnis adäquat verarbeiten kann. 
Dennoch sollten besonders ängstliche, depressive oder pessimistische 
Personen die ein ungünstiges Testergebnis bekommen, langfristig 
besondere Aufmerksamkeit von professioneller Seite erhalten. Es sollten 
Follow-up Termine angesetzt werden und bei Bedarf zu anderen Personen 
oder Einrichtungen im Gesundheitssystem überwiesen werden. Dennoch 
müssen wir damit rechnen, dass das Angebot weiterer Unterstützung 
zurückgewiesen wird, da die Konfrontation mit der Zukunft vermieden 
werden soll. 
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8c.5.3. Die Bedeutung adäquater statistischer Methoden 
Für die Analyse der longitudinalen Daten sieben bis zehn Jahre nach dem 
prädiktiven Test wurden allgemeine gemischt-lineare Modelle (General 
Linear Mixed Modeling, GLMM) angewendet. Diese Methode ist für 
Langzeitstudien mit fehlenden Werten zu einem oder mehreren 
Erhebungszeitpunkten geeignet und ermöglicht den optimalen Umgang mit 
Daten, Probanden und Messzeitpunkten. Daher konnten auch die Daten, 
die 1½ Jahre nach dem Test erhoben worden waren, verwendet werden. Zu 
diesem Messzeitpunkt liegen unvollständige Daten vor, da das Projekt 
damals vorübergehend unterbrochen worden war. Mit Hilfe von GLMM hätte 
sich, bei Berücksichtigung des Messzeitpunkts nach 1½ Jahren, bereits drei 
Jahre nach dem Test gezeigt, dass sich die Zukunftserwartungen von 
Genträgern verschlechtern.  
 Auch können als Folge einer weniger geeigneten Methode kleine, aber 
signifikante Unterschiede unbemerkt bleiben. Dies kann z.B. auftreten, 
wenn ein nicht parametrischer Test angewendet wird, obwohl ein 
parametrischer Test geeignet wäre. Häufig führt dies nicht zu einem 
folgenreichen Verlust an Power, da die Power eines nicht parametrischen 
Tests ungefähr 95% im Vergleich zu einem F-Test beträgt – vorausgesetzt, 
die Bedingungen für den parametrischen Test sind erfüllt. Unter bestimmten 
Umständen kann die Power aber drastisch absinken. Wenn eine Methode, 
die für dichotome Daten bestimmt ist, auf kontinuierliche Daten angewendet 
wird, kann die Effizienz bis auf 63% fallen.34
8c.5.4. Die Einführung eines präziseren DNA-Tests 
In den Niederlanden wurden bedeutend mehr Risikoträger getestet als in 
anderen Ländern.14 Der wichtigste Grund, sich testen zu lassen, ist das 
Ende der unerträglichen Ungewissheit, was ein starkes Bedürfnis nach 
Sicherheit ausdrückt. Dennoch wurde darüber diskutiert, ob der zu über 
99% sichere Mutationstest Personen, die mit der Kopplungsanalyse 
getestet worden waren, angeboten werden soll. Das Zentrum für Klinische 
Genetik in Leiden wollte den neuen Test jedem anbieten, der mit der 
Kopplungsanalyse getestet worden war. Allerdings stellte die Medizinische 
Ethik-Kommission in Leiden (MEK) infrage, ob nach so vielen Jahren noch 
an Personen herangetreten werden dürfe mit dem Risiko, dass sie damit 
ungefragt belastet werden könnten. Das MEK war der Meinung, dass sich 
die getesteten Personen mit ihrem Testergebnis abgefunden und ein neues 
Gleichgewicht in ihrem Leben gefunden hätten. Dieses Gleichgewicht 
könnte durch den Eindruck, das Ergebnis des Kopplungstests sei unsicher 
oder sogar falsch, gestört werden. Es könnte die Schlussfolgerung, der alte 
Test sei ganz und gar nutzlos gewesen, gezogen werden. 
 Andererseits hatten sich die Personen testen lassen, um die 
bestmögliche Gewissheit zu erhalten und damit ihre Lebensplanung, 
einschließlich der Familienplanung, zu gestalten. Wenn eine neue Methode 
mehr Sicherheit bietet, dann sollte diese auch angeboten werden. Von 
einem nicht-direktiven und nicht-paternalistischen Standpunkt aus ist es 
außerdem wichtig, die Entscheidung über die Durchführung des sicheren 
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Mutationstests den Betroffenen selbst zu überlassen. Darüber hinaus hatte 
die Niederländische Huntington Vereinigung bereits Informationen über den 
Mutationstest in ihrer vierteljährlich erscheinenden Zeitschrift veröffentlicht. 
Nachdem einige Jahre über die Vor- und Nachteile diskutiert worden war, 
wurde beschlossen, den Test allen anzubieten, die mit der 
Kopplungsanalyse getestet worden waren. 
 Bevor der Mutationstest entwickelt wurde, fragten Babul et al.35 mit 
Kopplungsanalyse getestete Personen, ob sie sich einem, damals 
hypothetischen, zu 100% sicheren Test unterziehen würden. 72% gaben 
an, sich unter diesen Umständen testen zu lassen. Als der Test tatsächlich 
eingeführt wurde, ließen sich allerdings nur 42% der Betroffenen testen.36 
Vor der Einführung des Kopplungstests war eine ähnliche Beobachtung 
gemacht worden. Damals gaben 40% bis 84% der Risikoträger an, sich 
testen lassen zu wollen.16 37-39 Der Prozentsatz an Personen, die sich seit 
der Verfügbarkeit des Tests tatsächlich haben testen lassen, ist mit 2% bis 
24% aber deutlich geringer.14 40-43 Es herrscht eine offensichtliche 
Diskrepanz zwischen der Intention und dem tatsächlichen Verhalten. 
 Wie erwartet, beeinflusste das Restrisiko die Entscheidung, sich wieder 
testen zu lassen - allerdings nur bei Personen mit einem günstigen 
Testergebnis. Genträger mit einem niedrigen Restrisiko hatten bei einem 
neuen Test offenbar nichts zu verlieren und ließen sich häufiger testen als 
Nichtträger mit einem niedrigen Restrisiko. Nichtträger mit niedrigem 
Restrisiko sahen es wohl nicht als notwendig an, das Risiko noch weiter zu 
reduzieren. Unseres Wissens hatte es keinerlei nachteilige Konsequenzen, 
bereits getestete Personen über den Mutationstest zu informieren. 
8c.5.5. Zusätzliche Risikoaufklärung für Berater und ihre Klienten 
Die Datenmenge zu CAG-Wiederholungen und dem Alter bei 
Krankheitsbeginn innerhalb von Familien ermöglichte es uns, ein Modell zur 
Einschätzung des reduzierten Restrisikos zu entwickeln. Dafür wird das 
Alter der Person selbst, die CAG-Länge oder das Auftrittsalter des 
erkrankten Elternteils und eventuell Verwandte, die als Nichtträger getestet 
wurden, berücksichtigt. Dieses Modell richtet sich an (noch) nicht getestete 
Risikopersonen, die noch keine Symptome haben. Das Modell kann nur 
eine Abnahme der Risikoeinschätzung zur Folge haben, während der 
Mutationstest zu dem unwiderruflichen Ergebnis führen kann, dass man 
erkranken wird. Dennoch richtet sich das Modell nicht in erster Linie an 
Personen, die sich, aus welchen Gründen auch immer, nicht testen lassen 
wollen. Wir nehmen an, dass diese Personen nicht an einer präzisen 
Risikoeinschätzung interessiert sind. Unser Modell und die von uns 
entwickelte Kalkulationstabelle sollen das Repertoire von klinischen 
Genetikern und Beratern erweitern. Damit können sie bei Personen, die 
wegen eines Gentests kommen und keine Symptome haben, das Restrisiko 
am besten einschätzen. Mit Hilfe dieses Modells kann auch die Abnahme 
des Restrisikos in den Folgejahren bestimmt werden. Diese Information 
kann die Entscheidung, den Test sofort durchführen zu lassen oder zu 
verschieben, unterstützen. 
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Alle Berechnungen basieren auf den bestmöglichen Parameterschätzungen 
und deshalb sollen auch die Werte des Restrisikos und der CAG-
Wiederholungslängen des Probanden als bestmögliche Schätzungen 
betrachtet werden. Wenn zukünftig mehr Daten über das Onset-Alter der 
Krankheit und über die CAG-Wiederholungslängen von Eltern und ihren 
Kindern verfügbar sein werden, werden die Schätzungen genauer werden. 
 Probanden fragen sich oft, wie groß ihr Risiko ist und wie sich das Risiko 
in Zukunft ändern wird. Das kann hilfreich sein für die Entscheidung, sich 
testen zu lassen und um sich besser auf den Test vorzubereiten. Diese 
Entscheidung kann vom aktuellen Restrisiko und dem Risiko in der nahen 
Zukunft abhängen. Anhand unseres Modells und der Tabellen, die von 
Langbehn et al.44 publiziert wurden, kann festgestellt werden, ob sich der 
Proband in einem für den Ausbruch der Krankheit kritischen Alter befindet. 
In diesem kritischen Zeitraum ist die Reduktion des Restrisikos von 
besonderer Bedeutung und kann die Entscheidung beeinflussen, sich 
kurzfristig testen zu lassen, oder noch einige Jahre zu warten. 
 Risikoträger können Probleme mit Versicherungsgesellschaften und 
Arbeitgebern bekommen.45-48 Da es vom ethischen Standpunkt aus 
umstritten ist, bei der Bewerbung um eine Arbeitsstelle oder dem Antrag auf 
eine Lebensversicherung einen Gentest zu verlangen, kann eine genauere 
Risikoeinschätzung, ohne dass ein Test durchgeführt wird, für diese dritten 
Parteien sinnvoll sein. Angenommen, dritte Parteien geben bei Kindern von 
Huntingtonpatienten eine Risikoeinschätzung von 50% an, dann ist die 
Anwendung dieses Modells auch für die Risikoträger selbst vorteilhaft, da 
das tatsächliche Risiko nahezu immer niedriger ist als das a priori Risiko. 
8c.5.6. Struktur der Verhaltensbeobachtungsskala Huntington (Behaviour 
Observation Scale Huntington - BOSH) 
Bei der Entwicklung der BOSH wurden drei Hauptkomponenten gefunden: 
Abnahme der Aktivitäten des täglichen Lebens (ADL), Rückgang sozialer 
und kognitiver Fähigkeiten, mentale Rigidität und Aggression. Es ergab sich 
kein guter Indikator für die Krankheitsdauer, da das Auftrittsalter der 
Krankheit oft retrospektiv bestimmt wurde. In einigen Fällen wurde das 
Auftrittsalter aus dem Aufnahmedatum in ein psychiatrisches Krankenhaus 
geschätzt. Falls die Aufnahme tatsächlich aufgrund einer von Huntington 
verursachten Störung erfolgte, wurde das Auftrittsalter zu spät eingeschätzt. 
Falls dies nicht der Fall war, wurde das Auftrittsalter zu früh geschätzt. Dies 
führte zu einem nur schwachen, aber signifikanten Zusammenhang 
zwischen der Krankheitsdauer und der Abnahme sozial-kognitiver 
Fähigkeiten. Die Zeitspanne, seit der sich eine Person in stationärer 
Betreuung befindet, erwies sich ebenfalls als kein guter Indikator für die 
Krankheitsdauer. Einerseits ist der Rückgang motorischer Funktionen für 
die Entscheidung, jemanden in ein Pflegeheim einzuweisen, von 
Bedeutung. Patienten können auch unter Zwangsgedanken, 
Wahnvorstellungen oder akustischen Halluzinationen leiden, die zur 
Aufnahme in ein Pflegeheim führen.49 Andererseits hängt die Entscheidung, 
den Betroffenen in einem Pflegeheim unterzubringen, weniger von dessen 
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Fähigkeiten und dem Schweregrad der Erkrankung ab, als vielmehr davon, 
ob Ehepartner oder Angehörige die Pflege übernehmen. Für die Aufnahme 
in belgischen Pflegeheimen ist es sogar Voraussetzung, dass im 
persönlichen Umfeld niemand die Pflege übernehmen kann. Dennoch 
wurde ein schwacher linearer Zusammenhang zwischen der Pflegedauer 
und dem Rückgang der Aktivitäten des täglichen Lebens festgestellt. 
 Demgegenüber wurde ein hochsignifikanter Zusammenhang zwischen 
Rigidität/Aggression und dem ADL-Index festgestellt. Dies kann als eine 
Zunahme von rigidem und aggressivem Verhalten, das später wieder 
abnimmt, interpretiert werden. Ein ähnlicher Zusammenhang zwischen 
unflexiblem Verhalten und Krankheitsdauer wird in der Studie von Craufurd 
et al.50 51 beschrieben. Allerdings muss angemerkt werden, dass in 
Pflegeheimen das Aggressionsniveau durch psychologische und 
pharmakologische Maßnahmen eingeschränkt wird. Zukünftige Studien 
sollten daher die Wirkung von Sedativa berücksichtigen. 
Ein weiterer signifikanter Zusammenhang wurde zwischen dem sozial-
kognitiven Funktionsniveau und dem ADL-Index festgestellt. Wenn der 
ADL-Index als Indikator für die Entwicklung der Krankheit herangezogen 
wird, dann weist dies darauf hin, dass sich die sozial-kognitiven Fähigkeiten 
besonders in späteren Phasen der Krankheit, wenn rigides und aggressives 
Verhalten abnimmt, verschlechtern. In anderen Worten: der Rückgang des 
rigiden und aggressiven Verhaltens und die Abnahme der Aktivitäten des 
täglichen Lebens gehen dem Rückgang sozial-kognitiver Fähigkeiten 
voraus. Dies stimmt mit der Beobachtung von Bamford et al.52 überein, dass 
sich das Erinnerungsvermögen erst in den letzten Phasen der Krankheit 
verschlechtert. 
 Die externe Validität der BOSH bedarf noch intensiverer Untersuchung. 
In einer künftigen Studie wird die BOSH zusammen mit der UHDRS (Unified 
Huntington Disease Rating Scale) verwendet werden. Die UHDRS wurde 
von der amerikanischen Huntington Study Group 1994 entwickelt, um 
motorische und kognitive Fähigkeiten, Verhaltensauffälligkeiten, 
psychiatrische Probleme sowie das allgemeine Funktionsnivau 
umfangreicher zu erfassen.18 Die UHDRS sollte keine allumfassende 
Beschreibung aller denkbaren Ausprägungen der Huntington-Erkrankung 
enthalten.1 Da die UHDRS in späteren Phasen der Krankheit nicht gut 
differenziert, ist ein Vergleich zwischen der BOSH und der UHDRS nötig. 
 Die BOSH wurde entwickelt, um einen detaillierten Einblick in den 
Fortschritt der Krankheit und die individuellen Differenzen zwischen 
Patienten zu gewinnen. Ein besserer Einblick in diese Unterschiede wird die 
Untersuchung des Zusammenhangs zwischen dem phänotypischen 
Ausdruck der Erkrankung einerseits und der prämorbiden Persönlichkeit 
und dem Netzwerk an sozialer Unterstützung andererseits erleichtern. 
Schließlich kann eine genauere Kenntnis dieses Zusammenhangs dazu 
beitragen, die Behandlung besser auf die Bedürfnisse der Patienten 
abzustimmen. 
 Bis jetzt ist die Huntingtonsche Krankheit nicht heilbar; die Behandlung 
beschränkt sich auf palliative Maßnahmen. Die spezifischen 
Krankheitssymptome rechtfertigen die Behandlung in Spezialabteilungen, 
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die in vielen Ländern eingerichtet wurden. Die Kenntnis der klinischen 
Erscheinungsformen in den mittleren Krankheitsphasen hat zugenommen.50 
53 Um die Entwicklung spezieller Unterstützungsprogramme für die letzten 
Krankheitsphasen und damit eine Verbesserung der Pflege zu ermöglichen, 
ist eine genauere Beschreibung des Krankheitsverlaufs nötig.  
8c.5.7. Abschließende Bemerkungen 
Für Huntington-Patienten, Genträger und Risikoträger ist es außerordentlich 
schwierig, mit den Zukunftsperspektiven zurecht zu kommen. Dennoch gibt 
es für sie verglichen mit ihren erkrankten Elternteilen einen Funken 
Hoffnung Dank der Mitarbeit von Patienten, Verwandten und 
Patientenvereinen an wissenschaftlichen Untersuchungen wurden viele 
Einsichten gewonnen. Prädiktive Test wurden entwickelt, psychologische 
Unterstützung wird angeboten und psychologische und psychosoziale 
Effekte des Tests wurden erforscht. Prädiktive Gentests bieten frühzeitige 
Diagnosemöglichkeiten und ermöglichten Studien über die 
Erstmanifestation von Symptomen in frühen Phasen. Pflegeheime mit 
Spezialabteilungen für Huntington-Patienten wurden eingerichtet. Es stehen 
palliative Behandlungsmöglichkeiten zur Verfügung und erste Hinweise, 
dass in Zukunft eine Heilung möglich sein könnte, werden sichtbar. 
 Chorea Huntington ist eine ziemlich seltene Krankheit. Daher kann mehr 
Fortschritt erzielt werden, wenn Information und Forschung Hand in Hand 
gehen. Beispielsweise wurde eine Interventionsstudie mit 450 Patienten in 
neun europäischen Ländern durchgeführt, in der Riluzol in den frühen 
Phasen der Krankheit getestet wurde. Dies zeigt, dass bedeutende 
Huntington-Forschung in Europa möglich ist. Um Langzeitbeobachtungen 
von Huntington-Patienten zu ermöglichen und eine angemessene 
Infrastruktur für klinische Forschung in Europa zu schaffen, wurde 2003 das 
Euro-HD Netzwerk eingerichtet (http://www.euro-hd.net). Mit der "Predict"-
Studie, einer der Aktivitäten des Netzwerks, sollen die ersten klinischen 
Veränderungen in der frühen Krankheitsphase festgestellt werden. Dazu 
werden verbesserte Standardinstrumente zur Erfassung der kognitiven 
Leistung und serielles MRI (Magnetic Resonance Imaging) zur Bestimmung 
des Gehirnvolumens eingesetzt.54 Die Datenbank kann auch verwendet 
werden, um die Erstmanifestation von Symptomen bei noch nicht 
erkrankten Genträgern und den Krankheitsverlauf zu untersuchen. Auch 
können Therapien untersucht werden, die den Krankheitsverlauf 
beeinflussen oder den Beginn der Krankheit verzögern sollen. Das Euro-HD 
Netzwerk stellt eine gemeinsame Plattform für Professionals, Huntington-
Erkrankte und ihre Angehörigen dar, um die Zusammenarbeit über ganz 
Europa hinweg zu erleichtern. Das Netzwerk fördert auch biologische 
Studien und Interventionsstudien, die hohen Maßstäben entsprechen (good 
clinical practice, GCP), womit die Suche nach Heilungsmöglichkeiten 
vorangebracht wird. In diesem Netzwerk kann sich jeder Teilnehmer zu 
Wort melden, Forschungsthemen vorschlagen, Studien durchführen und 
publizieren. Das Netzwerk stellt eine Infrastruktur für groß angelegte 
klinische Studien über Huntington in ganz Europa zur Verfügung: Eine IT-
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Plattform für Kommunikations-Tools und e-trials in der jeweiligen 
Muttersprache und ein Forum, das die enge Zusammenarbeit von 
Grundlagenforschern und Klinikern ermöglicht. 
 Das Euro-HD Netzwerk unterstützt Langzeitstudien und fördert die 
Entwicklung von Instrumenten die in der Huntington-Forschung verwendet 
werden. Diese Instrumente (Tests, Fragebögen und Beurteilungsskalen) 
werden standardisiert und in die Sprachen der teilnehmenden Länder 
übersetzt. 
8c.6. LITERATURHINWEISE 
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